<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3-mathml3.dtd">
<article xml:lang="EN" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" dtd-version="1.3" article-type="review-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Microbiol.</journal-id>
<journal-title-group>
<journal-title>Frontiers in Microbiology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Microbiol.</abbrev-journal-title>
</journal-title-group>
<issn pub-type="epub">1664-302X</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fmicb.2026.1757551</article-id>
<article-version article-version-type="Version of Record" vocab="NISO-RP-8-2008"/>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Interactions of bile acids and gut microbiota modulate neurological health: a comprehensive review on mechanisms and therapeutic potential of dietary phytochemicals</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Wang</surname> <given-names>Jie</given-names></name>
<xref ref-type="aff" rid="aff1"/>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
<uri xlink:href="https://loop.frontiersin.org/people/3299501"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Zhang</surname> <given-names>Ying</given-names></name>
<xref ref-type="aff" rid="aff1"/>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
</contrib>
<contrib contrib-type="author">
<name><surname>Wu</surname> <given-names>Quan</given-names></name>
<xref ref-type="aff" rid="aff1"/>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
</contrib>
<contrib contrib-type="author">
<name><surname>Zhong</surname> <given-names>Yingfu</given-names></name>
<xref ref-type="aff" rid="aff1"/>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
<uri xlink:href="https://loop.frontiersin.org/people/3065394"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Xu</surname> <given-names>Ze</given-names></name>
<xref ref-type="aff" rid="aff1"/>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &#x00026; editing</role>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Yang</surname> <given-names>Juan</given-names></name>
<xref ref-type="aff" rid="aff1"/>
<xref ref-type="corresp" rid="c001"><sup>&#x0002A;</sup></xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &#x00026; editing</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role>
</contrib>
</contrib-group>
<aff id="aff1"><institution>Tea Research Institute, Chongqing Academy of Agricultural Sciences</institution>, <city>Chongqing</city>, <country country="cn">China</country></aff>
<author-notes>
<corresp id="c001"><label>&#x0002A;</label>Correspondence: Juan Yang, <email xlink:href="mailto:yj20041539@163.com">yj20041539@163.com</email></corresp>
</author-notes>
<pub-date publication-format="electronic" date-type="pub" iso-8601-date="2026-02-04">
<day>04</day>
<month>02</month>
<year>2026</year>
</pub-date>
<pub-date publication-format="electronic" date-type="collection">
<year>2026</year>
</pub-date>
<volume>17</volume>
<elocation-id>1757551</elocation-id>
<history>
<date date-type="received">
<day>30</day>
<month>11</month>
<year>2025</year>
</date>
<date date-type="rev-recd">
<day>06</day>
<month>01</month>
<year>2026</year>
</date>
<date date-type="accepted">
<day>13</day>
<month>01</month>
<year>2026</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#x000A9; 2026 Wang, Zhang, Wu, Zhong, Xu and Yang.</copyright-statement>
<copyright-year>2026</copyright-year>
<copyright-holder>Wang, Zhang, Wu, Zhong, Xu and Yang</copyright-holder>
<license>
<ali:license_ref start_date="2026-02-04">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
<license-p>This is an open-access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License (CC BY)</ext-link>. The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p>
</license>
</permissions>
<abstract>
<p>Bile acids (BAs), classically regarded as detergents for dietary lipid absorption, have emerged as pivotal signaling molecules with systemic endocrine functions. The discovery of the Farnesoid X Receptor (FXR) and Takeda G protein-coupled receptor 5 (TGR5) as BAs-activated receptors unveiled their profound influences on glucose, lipid, and energy metabolism. BAs are first synthesized in hepatocytes and further metabolized by gut microbes, can either circulate in enterohepatic system or be found in circulations to exert various effects. More recently, the gut-brain axis has been identified as a critical pathway through which BAs exert significant effects on central nervous system (CNS) function and health. Based on research progresses mentioned above, this review systematically delineates the synthesis, metabolism, and classification of BAs, with a focus on the intricate crosstalk between the hepatic-gut BA axis and the brain. In addition, we explore the compelling evidences linking BAs dysregulation to a spectrum of neurological disorders, including neurodegenerative diseases (Alzheimer&#x00027;s and Parkinson&#x00027;s disease), depression, and hepatic encephalopathy. Besides, the potential mechanisms, such as alleviating neuroinflammation, maintaining the integrity of blood-brain barrier, increasing the neuronal survival, and modulating neurotransmitter systems are further elucidated. Finally, strategies of dietary intervention through phytochemicals to modulate the BAs pool for improved neurological outcomes are summarized and discussed. By integrating pre-clinical and clinical findings, this review aims to establish a foundation for understanding BAs as novel therapeutic targets in neurology and nutritional neuroscience.</p></abstract>
<kwd-group>
<kwd>bile acids</kwd>
<kwd>gut-brain axis</kwd>
<kwd>microbiome</kwd>
<kwd>neuroinflammation</kwd>
<kwd>neurological health</kwd>
<kwd>phytochemicals</kwd>
</kwd-group>
<funding-group>
<funding-statement>The author(s) declared that financial support was received for this work and/or its publication. This work was supported by Chongqing Modern Agricultural Industry Technology System Innovation Team, CQMAITS202508; Chongqing Natural Science Foundation General Project (cstc2021jcyj-msxmX0997); Chongqing Municipal Commission of Agriculture and Rural Affairs Project (YuNongFa [2022] No. 87).</funding-statement>
</funding-group>
<counts>
<fig-count count="1"/>
<table-count count="2"/>
<equation-count count="0"/>
<ref-count count="171"/>
<page-count count="16"/>
<word-count count="14476"/>
</counts>
<custom-meta-group>
<custom-meta>
<meta-name>section-at-acceptance</meta-name>
<meta-value>Microorganisms in Vertebrate Digestive Systems</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec sec-type="intro" id="s1">
<label>1</label>
<title>Introduction</title>
<p>For centuries, bile has been recognized for its role in digestion. However, the molecular constituents of bile, the bile acids (BAs), have recently been elevated from their humble status as biological detergents to critical signaling molecules with far-reaching systemic effects (<xref ref-type="bibr" rid="B54">Houten et al., 2006</xref>). The synthesis of BAs from cholesterol in the liver represents the major pathway for cholesterol catabolism, a process that is not only crucial for lipid homeostasis but also for generating a diverse family of signaling molecules (<xref ref-type="bibr" rid="B19">Chiang, 2013</xref>; <xref ref-type="bibr" rid="B83">Liu et al., 2025</xref>). Upon meal ingestion, they are released into the duodenum to facilitate the emulsification and absorption of dietary fats and fat-soluble vitamins (<xref ref-type="bibr" rid="B52">Hofmann and Hagey, 2008</xref>). The majority (&#x0007E;95%) of BAs are efficiently reabsorbed in the ileum and returned to the liver, a process known as enterohepatic circulation, which ensures their efficient reuse but also creates a dynamic pool that can be influenced by dietary and microbial factors (<xref ref-type="bibr" rid="B26">Dawson and Karpen, 2015</xref>). The small fraction that escapes this recycling enters the colon, where the gut microbiota extensively modifies them, generating a diverse secondary BAs pool that possesses distinct biological activities from their primary precursors (<xref ref-type="bibr" rid="B117">Ridlon et al., 2006</xref>).</p>
<p>The paradigm shifts in BAs biology began with the identification of specific receptors that recognize BAs as their ligands. The nuclear receptor FXR (Farnesoid X Receptor) and the membrane-bound G protein-coupled receptor TGR5 (Takeda G protein-coupled receptor 5, also known as GPBAR1) are now established as the primary mediators of BA signaling (<xref ref-type="bibr" rid="B90">Makishima et al., 1999</xref>; <xref ref-type="bibr" rid="B94">Maruyama et al., 2002</xref>). Through these receptors, BAs regulate their own synthesis and enterohepatic circulation, control glucose and lipid homeostasis, modulate energy expenditure, and exert potent anti-inflammatory and metabolic effects across various tissues (<xref ref-type="bibr" rid="B142">Thomas et al., 2008</xref>; <xref ref-type="bibr" rid="B111">Pols et al., 2011</xref>). The discovery of this &#x0201C;endocrine&#x0201D; dimension of BAs action fundamentally altered our understanding of their physiological roles (<xref ref-type="bibr" rid="B77">Lefebvre et al., 2009</xref>).</p>
<p>The influence of BAs extends beyond peripheral tissues to the central nervous system (CNS). The gut-brain axis, a bidirectional communication network linking the gastrointestinal tract and the brain via neural, endocrine, and immune pathways, serves as a critical channel for this crosstalk (<xref ref-type="bibr" rid="B24">Cryan et al., 2019</xref>; <xref ref-type="bibr" rid="B133">Sharon et al., 2016</xref>). BAs can influence the brain via distinct, though potentially overlapping, pathways: (i) indirect endocrine pathways (e.g., TGR5-mediated GLP-1 secretion, FXR-mediated FGF19 release); (ii) indirect neural pathways (vagal afferent signaling); (iii) modulation of systemic and neuroimmune responses; and (iv) potential direct effects after crossing the BBB (<xref ref-type="bibr" rid="B95">McMillin and DeMorrow, 2016</xref>; <xref ref-type="bibr" rid="B42">Grant and DeMorrow, 2020</xref>). Dysregulation of BAs homeostasis, often characterized by shifts in the ratio of primary to secondary BAs or in the hydrophobicity profile, has been implicated in a growing list of neurological and psychiatric conditions, suggesting a core disruption of gut-brain communication (<xref ref-type="bibr" rid="B74">Kiriyama and Nochi, 2019</xref>; <xref ref-type="bibr" rid="B65">Jia et al., 2018</xref>). Conversely, neurological states, particularly those involving stress, can influence gut permeability and motility, thereby shaping the BA metabolism, creating a complex, dynamic feedback loop (<xref ref-type="bibr" rid="B37">Foster et al., 2017</xref>; <xref ref-type="bibr" rid="B21">Collins et al., 2023</xref>).</p>
<p>This review aims to synthesize the current knowledge on the classification, synthesis, and metabolism of BAs, and to critically evaluate their emerging role as key modulators of brain health and disease. To identify relevant literature, we performed searches in PubMed, Web of Science, and Google Scholar databases from inception until October 2025, using keywords and their combinations including: &#x0201C;bile acid,&#x0201D; &#x0201C;FXR,&#x0201D; &#x0201C;TGR5,&#x0201D; &#x0201C;gut-brain axis,&#x0201D; &#x0201C;neurodegeneration,&#x0201D; &#x0201C;depression,&#x0201D; &#x0201C;hepatic encephalopathy,&#x0201D; &#x0201C;microbiome,&#x0201D; and &#x0201C;phytochemical.&#x0201D; Given the interdisciplinary and emerging nature of the topic, we prioritized inclusion of high-impact original research, authoritative reviews, and seminal clinical studies. We will delve into the molecular mechanisms connecting specific BA alterations to the pathogenesis of neurodevelopmental, neurodegenerative, and neuropsychiatric disorders. Finally, we will conclude by exploring the exciting potential of targeted dietary interventions, particularly through the use of plant-derived phytochemicals, as a strategic means to modulate BAs for the prevention and adjunct treatment of neurological conditions, thereby opening a new frontier in nutritional neuroscience.</p>
</sec>
<sec id="s2">
<label>2</label>
<title>Classification and sources of BAs</title>
<p>The BAs pool in humans is a complex mixture of different steroid molecules, primarily classified based on their origin and structure. This diversity is fundamental to their varied signaling functions and their impact on host physiology, including neurology (<xref ref-type="bibr" rid="B18">Chiang, 2009</xref>). The classification and properties of major human BAs are shown in <xref ref-type="table" rid="T1">Table 1</xref>. The enterohepatic circulation and gut-brain axis of BAs are presented in <xref ref-type="fig" rid="F1">Figure 1</xref>.</p>
<table-wrap position="float" id="T1">
<label>Table 1</label>
<caption><p>Major human bile acids: classification and properties.</p></caption>
<table frame="box" rules="all">
<thead>
<tr>
<th valign="top" align="left"><bold>Bile acid</bold></th>
<th valign="top" align="left"><bold>Abbreviation</bold></th>
<th valign="top" align="left"><bold>Type</bold></th>
<th valign="top" align="left"><bold>Origin</bold></th>
<th valign="top" align="center"><bold>Hydrophobicity index</bold></th>
<th valign="top" align="left"><bold>Primary receptor affinity</bold></th>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" align="left">Cholic acid</td>
<td valign="top" align="left">CA</td>
<td valign="top" align="left">Primary</td>
<td valign="top" align="left">Hepatic synthesis</td>
<td valign="top" align="center">0.00</td>
<td valign="top" align="left">FXR (weak)</td>
</tr>
<tr>
<td valign="top" align="left">Chenodeoxycholic acid</td>
<td valign="top" align="left">CDCA</td>
<td valign="top" align="left">Primary</td>
<td valign="top" align="left">Hepatic synthesis</td>
<td valign="top" align="center">0.59</td>
<td valign="top" align="left">FXR (potent)</td>
</tr>
<tr>
<td valign="top" align="left">Deoxycholic acid</td>
<td valign="top" align="left">DCA</td>
<td valign="top" align="left">Secondary</td>
<td valign="top" align="left">Bacterial 7&#x003B1;-dehydroxylation of CA</td>
<td valign="top" align="center">0.79</td>
<td valign="top" align="left">FXR, TGR5</td>
</tr>
<tr>
<td valign="top" align="left">Lithocholic acid</td>
<td valign="top" align="left">LCA</td>
<td valign="top" align="left">Secondary</td>
<td valign="top" align="left">Bacterial 7&#x003B1;-dehydroxylation of CDCA</td>
<td valign="top" align="center">0.96</td>
<td valign="top" align="left">PXR, VDR, TGR5</td>
</tr>
<tr>
<td valign="top" align="left">Ursodeoxycholic acid</td>
<td valign="top" align="left">UDCA</td>
<td valign="top" align="left">Secondary</td>
<td valign="top" align="left">Bacterial epimerization of CDCA</td>
<td valign="top" align="center">0.08</td>
<td valign="top" align="left">Antagonizes FXR, TGR5</td>
</tr>
<tr>
<td valign="top" align="left">Glycocholic acid</td>
<td valign="top" align="left">GCA</td>
<td valign="top" align="left">Primary (conjugated)</td>
<td valign="top" align="left">Conjugation of CA with glycine</td>
<td valign="top" align="center">&#x02212;0.13</td>
<td valign="top" align="left">TGR5</td>
</tr>
<tr>
<td valign="top" align="left">Taurochenodeoxycholic acid</td>
<td valign="top" align="left">TCDCA</td>
<td valign="top" align="left">Primary (conjugated)</td>
<td valign="top" align="left">Conjugation of CDCA with taurine</td>
<td valign="top" align="center">&#x02212;0.22</td>
<td valign="top" align="left">TGR5?</td>
</tr></tbody>
</table>
<table-wrap-foot>
<p>FXR: Farnesoid X Receptor; TGR5: Takeda G protein-coupled receptor 5; PXR: Pregnane X Receptor; VDR: Vitamin D Receptor.</p>
</table-wrap-foot>
</table-wrap>
<fig position="float" id="F1">
<label>Figure 1</label>
<caption><p>The enterohepatic circulation and gut-brain axis of BAs. The enterohepatic circulation include: (1) Hepatocyte: primary BAs (Cholic Acid, CA; Chenodeoxycholic Acid, CDCA) are synthesized from cholesterol via the classical pathway (CYP7A1) and the alternative pathway (CYP27A1/CYP7B1). (2) Conjugation: primary BAs are conjugated with glycine or taurine (via BAAT) to form conjugated BAs (e.g., TCA, GCA). (3) Gallbladder &#x00026; secretion: conjugated BAs are stored in the gallbladder and released into the duodenum upon meal ingestion. (4) Emulsification: BAs facilitate the emulsification and absorption of dietary lipids and fat-soluble vitamins in the small intestine. (5) Ileal reabsorption: &#x0007E;95% of BAs are actively reabsorbed in the ileum via the Apical Sodium-dependent Bile Acid Transporter (ASBT) and returned to the liver via the portal vein. (6) Colonic biotransformation: the remaining BAs reach the colon, where gut microbiota performs deconjugation (Bile Salt Hydrolase, BSH) and 7&#x003B1;-dehydroxylation to form secondary BAs (Deoxycholic acid, DCA; Lithocholic acid, LCA). A portion of these are passively absorbed and returned to the liver. The gut-brain signaling pathways include: (1) Systemic circulation &#x00026; BBB: BAs can enter systemic circulation and some may cross the blood-brain barrier to act directly on neurons and glial cells (e.g., via FXR, TGR5). (2) Neural &#x00026; immune pathways: BAs can signal via the vagus nerve or by modulating the activity of systemic and perivascular immune cells. (3) Endocrine pathways: ileal FXR Activation by BAs induces the release of Fibroblast Growth Factor 19 (FGF19), which can signal to the brain. TGR5 Activation on intestinal L-cells stimulates the secretion of Glucagon-Like Peptide-1 (GLP-1), which has central effects.</p></caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fmicb-17-1757551-g0001.tif">
<alt-text content-type="machine-generated">Flowchart illustrating the enterohepatic circulation of bile acids. It includes microbial biotransformation processes, portal vein return to the liver, primary bile acid synthesis, conjugation, secretion, reabsorption, and systemic circulation effects. Key elements are deconjugation, 7&#x003B1;-dehydroxylation, lipid emulsification, and endocrine signaling.</alt-text>
</graphic>
</fig>
<sec>
<label>2.1</label>
<title>Primary and secondary bile acids</title>
<p>Primary BAs are synthesized <italic>de novo</italic> from cholesterol in the hepatocytes of the liver. The two main primary BAs in humans are cholic acid (CA) and chenodeoxycholic acid (CDCA; <xref ref-type="bibr" rid="B129">Sayin et al., 2013</xref>). A critical interspecies difference exists; mice and rats produce significant amounts of muricholic acids (MCAs), particularly &#x003B2;-muricholic acid (&#x003B2;-MCA), which acts as a natural FXR antagonist. This distinction is crucial when extrapolating findings from animal models to human physiology and therapeutic development (<xref ref-type="bibr" rid="B81">Li-Hawkins et al., 2002</xref>). Before secretion into bile, primary BAs are almost always conjugated at the C-24 carboxyl group with either the amino acids glycine or taurine, forming conjugated BAs such as glycocholic acid (GCA), taurocholic acid (TCA), glycochenodeoxycholic acid (GCDCA), and taurochenodeoxycholic acid (TCDCA; <xref ref-type="bibr" rid="B51">Hofmann, 1999</xref>). Conjugation, catalyzed by the enzyme bile acid-CoA: amino acid N-acyltransferase (BAAT), can increase the hydrophilicity and acidity of BAs, and therefore reduce their passive absorption in the biliary tract and small intestine. This ensures their efficient delivery to the distal gut where they are needed for both lipid digestion and microbial transformation, thereby linking hepatic synthesis with gut microbial ecology (<xref ref-type="bibr" rid="B27">Dawson et al., 2009</xref>; <xref ref-type="bibr" rid="B137">Stieger, 2010</xref>).</p>
<p>Secondary BAs are derived from primary BAs through the enzymatic activities of the gut microbiota in the colon, a process known as biotransformation that significantly expands the functional repertoire of the BAs pool (<xref ref-type="bibr" rid="B150">Wahlstr&#x000F6;m et al., 2016</xref>). This process involves two key steps (<xref ref-type="bibr" rid="B116">Ridlon et al., 2016a</xref>). The first step is deconjugation in which bacterial bile salt hydrolases (BSH) cleave the glycine/taurine conjugate, releasing free, unconjugated primary BAs (CA and CDCA). BSH enzymes are widely distributed across many bacterial phyla, including <italic>Firmicutes</italic> (e.g., <italic>Lactobacillus, Clostridium</italic>), <italic>Bacteroidetes</italic>, and <italic>Actinobacteria</italic> (e.g., <italic>Bifidobacterium</italic>), making this a common microbial function (<xref ref-type="bibr" rid="B68">Jones et al., 2008</xref>; <xref ref-type="bibr" rid="B36">Foley et al., 2019</xref>). The second step is 7&#x003B1;-dehydroxylation. This is a more specialized subset of anaerobic bacteria, notably from the genera <italic>Clostridium</italic> (e.g., <italic>C. scindens</italic>) and <italic>Eubacterium</italic>, performs 7&#x003B1;-dehydroxylation. This complex enzymatic process removes the 7&#x003B1;-hydroxyl group, converting CA into deoxycholic acid (DCA) and CDCA into lithocholic acid (LCA; <xref ref-type="bibr" rid="B82">Little et al., 2020</xref>; <xref ref-type="bibr" rid="B157">Winston and Theriot, 2020</xref>). LCA is highly hydrophobic and relatively insoluble with a significant portion excreted into feces, while some is absorbed and sulfated in the liver for renal excretion (<xref ref-type="bibr" rid="B138">Stiehl et al., 1980</xref>). DCA is more efficiently absorbed and becomes a major component of the circulating BA pool, contributing significantly to BA signaling (<xref ref-type="bibr" rid="B46">Hamilton et al., 2007</xref>). Other bacterial modifications include oxidation and epimerization of hydroxyl groups, leading to the formation of minor but physiologically important BAs like ursodeoxycholic acid (UDCA; the 7&#x003B2;-epimer of CDCA) and various iso-BAs, which can have unique receptor affinities (<xref ref-type="bibr" rid="B7">Batta et al., 1990</xref>; <xref ref-type="bibr" rid="B118">Ridlon et al., 2014</xref>).</p>
<p>A third category, sometimes termed tertiary BAs, includes BAs that undergo further hepatic modification after intestinal absorption, such as the re-conjugation of secondary BAs (e.g., glycodeoxycholic acid, GDCA) or the sulfation of LCA to increase its solubility for renal excretion, representing the liver&#x00027;s role in &#x0201C;editing&#x0201D; the microbiome-modified BA pool (<xref ref-type="bibr" rid="B171">Zollner and Trauner, 2008</xref>; <xref ref-type="bibr" rid="B62">Jansen et al., 2017</xref>).</p>
</sec>
<sec>
<label>2.2</label>
<title>Synthesis of primary bile acids</title>
<p>The <italic>de novo</italic> synthesis of primary BAs from cholesterol is a complex, multi-step process that occurs in the hepatocyte and is tightly regulated to maintain BA homeostasis and overall cholesterol balance. It can be divided into two major pathways that operate in parallel (<xref ref-type="bibr" rid="B17">Chiang, 2002</xref>).</p>
<list list-type="order">
<list-item><p><bold>The classical (neutral) pathway:</bold> This is the predominant pathway in humans, responsible for about 75% of the total BAs synthesis. It is initiated by the rate-limiting enzyme cholesterol 7&#x003B1;-hydroxylase (CYP7A1), which hydroxylates cholesterol at the 7&#x003B1; position (<xref ref-type="bibr" rid="B127">Russell and Setchell, 1992</xref>). The subsequent activity of sterol 12&#x003B1;-hydroxylase (CYP8B1) is a key branch point, determining the ratio of CA to CDCA produced. The high CYP8B1 activity is beneficial for producing CA with stronger hydrophilicity, while low activity shifts production toward CDCA (<xref ref-type="bibr" rid="B107">Pandak and Kakiyama, 2019</xref>).</p></list-item>
<list-item><p><bold>The alternative (acidic) pathway:</bold> This pathway contributes to the remaining 25% of BA production and is initiated by mitochondrial sterol 27-hydroxylase (CYP27A1), followed by oxidation by oxysterol 7&#x003B1;-hydroxylase (CYP7B1). This pathway primarily leads to the formation of CDCA and becomes relatively more important when the classical pathway is impaired (<xref ref-type="bibr" rid="B80">Li and Chiang, 2012</xref>).</p></list-item>
</list>
<p>The synthesis of BAs is under exquisite negative feedback regulation, primarily mediated by the FXR-SHP (Small Heterodimer Partner) axis. When intrahepatic BA levels rise, particularly of potent agonists like CDCA, they activate FXR (<xref ref-type="bibr" rid="B86">Lu et al., 2000</xref>). Activated FXR induces the expression of SHP, which in turn represses the transcription of the genes encoding <italic>CYP7A1</italic> and <italic>CYP8B1</italic>, thus reducing the amount and altering the composition of BA produced (<xref ref-type="bibr" rid="B40">Goodwin et al., 2000</xref>; <xref ref-type="bibr" rid="B151">Wang et al., 2002</xref>). An additional endocrine loop involves the ileum: upon BA absorption, intestinal FXR is activated, leading to the secretion of fibroblast growth factor 19 (FGF19; FGF15 in mice) into the portal circulation (<xref ref-type="bibr" rid="B59">Inagaki et al., 2005</xref>). FGF19 travels to the liver and binds to its receptor FGFR4/&#x003B2;-Klotho complex, initiating a signaling cascade that potently represses <italic>CYP7A1</italic> transcription, providing a refined, meal-responsive layer of regulation (<xref ref-type="bibr" rid="B112">Potthoff et al., 2013</xref>; <xref ref-type="bibr" rid="B135">Song and Chiang, 2006</xref>).</p>
</sec>
<sec>
<label>2.3</label>
<title>Synthesis of secondary bile acids</title>
<p>The synthesis of secondary BAs is entirely dependent on the metabolic activity of the gut microbiome, making it a key point of interaction between host physiology and microbial ecology (<xref ref-type="bibr" rid="B141">Theriot and Young, 2015</xref>). As conjugated primary BAs traverse the small intestine and reach the colon, they encounter a dense and diverse microbial community equipped with a repertoire of BA-transforming enzymes (<xref ref-type="bibr" rid="B30">Devkota et al., 2012</xref>). The key enzymes involved are bile salt hydrolases (BSH) and 7&#x003B1;-dehydroxylase (<xref ref-type="bibr" rid="B36">Foley et al., 2019</xref>).</p>
<p>BSH present in many commensal bacteria (e.g., <italic>Lactobacillus, Bifidobacterium, Clostridium, Bacteroides</italic>), are the gatekeepers of secondary BAs formation (<xref ref-type="bibr" rid="B69">Joyce and Gahan, 2014</xref>). Deconjugation is a prerequisite for most subsequent bacterial modifications, particularly 7&#x003B1;-dehydroxylation. BSH activity is thought to provide a fitness advantage to bacteria by reducing BA toxicity in the gut environment and by providing a source of glycine and taurine, which can be used as nutrients or for sulfur metabolism (<xref ref-type="bibr" rid="B36">Foley et al., 2019</xref>).</p>
<p>7&#x003B1;-Dehydroxylase is a multi-enzyme complex found in a more restricted, specialized group of Gram-positive anaerobes (e.g., <italic>Clostridium scindens</italic>). It catalyzes the removal of the 7&#x003B1;-hydroxyl group, converting CA to DCA and CDCA to LCA (<xref ref-type="bibr" rid="B29">Dean et al., 2020</xref>). This pathway is highly sensitive to the colonic environment, particularly pH. A lower pH resulting from bacterial fermentation of dietary fiber to short-chain fatty acids can inhibit 7&#x003B1;-dehydroxylase activity, thereby providing a direct link between diet, microbial metabolism, and the secondary BAs profile (<xref ref-type="bibr" rid="B61">Islam et al., 2011</xref>; <xref ref-type="bibr" rid="B119">Ridlon et al., 2016b</xref>).</p>
<p>The composition and metabolic capacity of the gut microbiome therefore directly shapes the secondary BAs metabolome. Factors such as diet (high-fat, high-fiber), antibiotics, age, and various disease states can dramatically alter the microbial community structure, particularly the abundance of 7&#x003B1;-dehydroxylating bacteria, and consequently, the profile of secondary BAs (<xref ref-type="bibr" rid="B67">Jiao et al., 2018</xref>; <xref ref-type="bibr" rid="B101">Mouzaki et al., 2016</xref>). This has profound implications for systemic health, including immune function, metabolic homeostasis, and, as discussed in subsequent sections, brain function and disease susceptibility (<xref ref-type="bibr" rid="B130">Schaap et al., 2014</xref>; <xref ref-type="bibr" rid="B28">de Aguiar Vallim et al., 2013</xref>).</p>
</sec>
</sec>
<sec id="s3">
<label>3</label>
<title>The crosstalk between metabolism of BAs and gut microbiota</title>
<sec>
<label>3.1</label>
<title>BAs affect the gut microbiota and its composition</title>
<p>Various BAs in the intestine can directly or indirectly inhibit the growth of gut microbiota especially when primary BAs (CA) is converted into secondary BAs (DCA) through dehydroxylation, its antibacterial ability can be increased by more than 10 times. Low doses of various BAs can affect the fluidity and permeability of bacterial cell membranes. In contrast, high doses can directly bind to membrane phospholipids and disrupt internal protein structures. This disruption causes cellular enzymes and contents to leak out, thereby inhibiting excessive intestinal microbiota growth (<xref ref-type="bibr" rid="B91">Malhi and Camilleri, 2017</xref>). The increase in BAs secretion and changes in BAs composition caused by high-fat diet can significantly affect the types and quantities of gut microbiota, and different gut microbiota members have varying sensitivities to different BAs components (<xref ref-type="bibr" rid="B63">Janssen et al., 2017</xref>).</p>
<p>Feeding BAs to rats can increase the abundance of <italic>Firmicutes</italic> and decrease the abundance of <italic>Bacteroidetes</italic>, ultimately leading to an increase in the ratio between <italic>Firmicutes</italic> and <italic>Bacteroidetes</italic>. Feeding milk derived fat to mice leads to an increased level of TCA. And the abundance of opportunistic pathogens such as <italic>Bilophila wadsworth</italic> is also increased (<xref ref-type="bibr" rid="B132">Schneider et al., 2018</xref>). <xref ref-type="bibr" rid="B63">Janssen et al. (2017)</xref> found that feeding mice with TCA not only causes changes in gut microbiota structure, but also exacerbates liver inflammation and fibrosis, indicating that BAs metabolism can indirectly affect gut microbiota structure by inducing immune responses in the liver to inhibit the growth of certain specific microorganisms. After binding to FXR, BAs can regulate the gene expression of antibacterial substances in the intestine, and prevent the overgrowth of bacterial by activating the defense system of the small intestine (<xref ref-type="bibr" rid="B14">Buzzetti et al., 2016</xref>). After binding to FXR, CDCA can cause intestinal epithelial cells to secrete antimicrobial peptides with broad-spectrum antibacterial activity (such as cathelicidin), further exerting antibacterial effects (<xref ref-type="bibr" rid="B125">Rodrigues et al., 2014</xref>). In addition, a high-fat diet causes the accumulation of liver cell fat and insulin resistance. These changes lead to BAs accumulation and compositional shifts, which in turn cause an imbalance in the gut microbiota. This microbiota imbalance further exacerbates BAs metabolism disorders and liver inflammatory reactions (<xref ref-type="bibr" rid="B60">Inagaki et al., 2006</xref>).</p>
</sec>
<sec>
<label>3.2</label>
<title>Gut microbiota influences and participates in the metabolism of BAs</title>
<p>The synthesis of BAs in the liver begins with a cytochrome P450-mediated oxidation of cholesterol. This reaction primarily generates CA and CDCA through classical and alternative pathways. These acids then conjugate with taurine or glycine to form conjugated BAs (<xref ref-type="bibr" rid="B150">Wahlstr&#x000F6;m et al., 2016</xref>). The synthesized primary BAs are stored in the gallbladder through a bile salt export pump, and the contraction of the gallbladder caused by eating can promote the secretion of BAs into the intestine. The BSH enzymes produced by <italic>Bacteroides, Clostridium, Lactobacillus, Bifidobacterium</italic>, and <italic>Listeria</italic> in the gut microbiota can cause the dissociation of bound BAs to form free BAs. <italic>Clostridium, Fusobacterium, Peptococcus</italic>, and <italic>Pseudomonas</italic> can catalyze the desulfurization of BAs. <italic>Bacteroides, Eubacteria, Clostridium, Escherichia, Eggerthella, Peptostreptococcus</italic>, and <italic>Ruminococcus</italic> can remove hydroxyl groups on C3, C7, and C12 to form secondary BAs such as DCA and LCA (<xref ref-type="bibr" rid="B49">He et al., 2016</xref>). About 95% of primary and secondary BAs can be reabsorbed in the intestine and transported back to the liver through the portal vein, but LCAin secondary BAs is mostly excreted with feces. The BAs lost in the enterohepatic circulation are replenished by the synthesis of new BAs by liver. After BAs reabsorption, it binds to FXR and TGR-5 in ileal, promoting the secretion of FGF-19 by intestinal. The latter then binds to FGFR-4 and activates the c-Jun N-terminal kinase and extracellular signal regulated kinase signaling pathways, respectively, to reduce the gene expression of <italic>CYP7A1</italic> enzyme. Thus, it inhibits the synthesis of BAs in a negatively feedback way (<xref ref-type="bibr" rid="B20">Chiang, 2017</xref>).</p>
</sec>
</sec>
<sec id="s4">
<label>4</label>
<title>BAs and brain disorders</title>
<p>The connection between BAs metabolism and neurological health is supported by a rapidly expanding body of evidences from metabolomic studies, animal models, and clinical observations. Alterations in the BAs pool, either in overall composition, concentration, or the relative abundance of specific species, can disrupt central homeostatic mechanisms and contribute to disease pathogenesis through multiple interconnected pathways.</p>
<sec>
<label>4.1</label>
<title>BAs and neurodegenerative diseases</title>
<sec>
<label>4.1.1</label>
<title>Alzheimer&#x00027;s disease (AD)</title>
<p>AD is characterized by the accumulation of amyloid-&#x003B2; (A&#x003B2;) plaques and neurofibrillary tangles of hyperphosphorylated tau, accompanied by chronic neuroinflammation and synaptic loss. Recent metabolomic studies have consistently identified significantly altered BAs profiles in the serum, plasma, and cerebrospinal fluid of AD patients and those with mild cognitive impairment (<xref ref-type="bibr" rid="B5">Baloni et al., 2020</xref>; <xref ref-type="bibr" rid="B88">MahmoudianDehkordi et al., 2019</xref>). A common finding is a relative increase in conjugated primary BAs (e.g., TCA, GCA) and a decrease in secondary BAs, particularly DCA and its conjugates (<xref ref-type="bibr" rid="B103">Nho et al., 2019</xref>; <xref ref-type="bibr" rid="B92">Marksteiner et al., 2018</xref>). This pattern suggests a potential shift toward reduced microbial 7&#x003B1;-dehydroxylation activity, possibly reflecting the gut dysbiosis reported in AD patients. While causal relationships remain to be firmly established, several mechanistic pathways, primarily elucidated in preclinical models, provide plausible links between these BA alterations and AD pathophysiology TGR5 Signaling in Neuroinflammation: The TGR5 receptor is expressed on key CNS cell types, including microglia, the brain&#x00027;s resident immune cells (<xref ref-type="bibr" rid="B72">Keitel et al., 2010</xref>). Preclinical studies indicate that activation of TGR5 by BA ligands like TUDCA, LCA, or DCA has been shown to induce a potent anti-inflammatory response. It shifts microglia from a pro-inflammatory (M1) state, characterized by the production of neurotoxic cytokines like TNF-&#x003B1;, IL-1&#x003B2;, and IL-6, to an anti-inflammatory (M2) phenotype that promotes tissue repair and resolution of inflammation (<xref ref-type="bibr" rid="B164">Yoneno et al., 2013</xref>; <xref ref-type="bibr" rid="B44">Guo et al., 2016</xref>). This TGR5-mediated suppression of neuroinflammation is hypothesized to be a key mechanism through which BAs could potentially mitigate AD progression. Furthermore, TGR5 activation in astrocytes and neurons promotes mitochondrial function and reduces oxidative stress, both of which are compromised in AD (<xref ref-type="bibr" rid="B96">McMillin et al., 2015</xref>; <xref ref-type="bibr" rid="B73">Keitel and H&#x000E4;ussinger, 2011</xref>).</p>
<p>FXR Signaling in Amyloid and Tau Pathology: FXR is also expressed in the brain, with notable presence in neurons (<xref ref-type="bibr" rid="B56">Huang et al., 2016</xref>). FXR activation has been demonstrated to influence amyloid precursor protein (APP) processing, potentially reducing the production of pathogenic A&#x003B2; peptides by downregulating the expression and activity of &#x003B2;-secretase (BACE1; <xref ref-type="bibr" rid="B102">Mulak, 2021</xref>). Furthermore, FXR agonism has been shown to improve cognitive function and reduce A&#x003B2; plaque load in transgenic AD mouse models. Emerging evidence also suggests that FXR signaling can modulate tau phosphorylation, indicating a broader role in attenuating key aspects of AD pathology (<xref ref-type="bibr" rid="B1">Ackerman and Gerhard, 2016</xref>).</p>
<p>Direct Neuroprotection by TUDCA: The taurine-conjugated BA Tauroursodeoxycholic Acid (TUDCA), and its unconjugated form UDCA, have demonstrated particularly potent neuroprotective properties in various models of neurodegeneration (<xref ref-type="bibr" rid="B146">Vang et al., 2014</xref>). TUDCA acts as a chemical chaperone that reduces Endoplasmic Reticulum (ER) stress, a key contributor to neuronal apoptosis in AD (<xref ref-type="bibr" rid="B115">Ramalho et al., 2008</xref>). It also stabilizes the mitochondrial membrane by inhibiting the mitochondrial Permeability Transition Pore (mPTP), thereby preventing the release of pro-apoptotic factors like cytochrome c, and attenuates apoptosis by modulating the balance of Bcl-2 family proteins (<xref ref-type="bibr" rid="B123">Rodrigues et al., 2002</xref>). In preclinical studies, administration of TUDCA reduces both A&#x003B2; and tau pathology, mitigates synaptic loss, and improves memory and learning performance (<xref ref-type="bibr" rid="B104">Nunes et al., 2012</xref>).</p>
<p>Blood-Brain Barrier Integrity: The BBB is increasingly recognized as a critical player in AD pathogenesis. BAs can exert dual effects on the BBB. High concentrations of hydrophobic BAs like CDCA and DCA can be cytotoxic and disrupt tight junction proteins (e.g., occludin, ZO-1), increasing BBB permeability. In contrast, UDCA and TUDCA have been shown to protect BBB integrity by reducing inflammation and oxidative stress in brain endothelial cells, thereby limiting the entry of neurotoxic blood-derived substances into the brain parenchyma (<xref ref-type="bibr" rid="B163">Yanguas-Cas&#x000E1;s et al., 2017</xref>).</p>
</sec>
<sec>
<label>4.1.2</label>
<title>Parkinson&#x00027;s disease (PD)</title>
<p>PD is marked by the progressive loss of dopaminergic neurons in the substantia nigra pars compacta and the presence of intracellular Lewy bodies composed of aggregated &#x003B1;-synuclein. The gut-brain axis is strongly implicated in PD, with Braak&#x00027;s hypothesis proposing that &#x003B1;-synuclein pathology may originate in the enteric nervous system and spread to the CNS via the vagus nerve (<xref ref-type="bibr" rid="B128">Sampson et al., 2016</xref>). BAs alterations increasingly recognized as part of this gut-brain dialogue in PD in several ways are discussed below.</p>
<p>The first one is altered BAs metabolism and dysbiosis. PD patients frequently show altered BA profiles in their feces and serum, often characterized by decreased levels of secondary BAs, particularly DCA and LCA (<xref ref-type="bibr" rid="B48">Hasegawa et al., 2015</xref>; <xref ref-type="bibr" rid="B79">Li et al., 2021</xref>). This is consistent with the well-documented gut dysbiosis in PD, which often includes a reduced abundance of bacterial genera from the <italic>Clostridium</italic> clusters that are capable of 7&#x003B1;-dehydroxylation (e.g., <italic>Clostridium scindens</italic>; <xref ref-type="bibr" rid="B131">Scheperjans et al., 2015</xref>; <xref ref-type="bibr" rid="B50">Hill-Burns et al., 2017</xref>). The reduction in DCA is particularly significant as it is a potent TGR5 agonist, and its deficiency could diminish a key anti-inflammatory signaling pathway in the brain and periphery.</p>
<p>The second one is FXR and TGR5 in glial neuroprotection. Similar to AD, the anti-inflammatory effects of FXR and TGR5 signaling are highly relevant to PD, where neuroinflammation driven by activated microglia contributes to dopaminergic neuron loss (<xref ref-type="bibr" rid="B154">Wang et al., 2008</xref>). Activation of these receptors on glial cells can suppress the production of pro-inflammatory cytokines and reactive oxygen species, creating a more supportive neuronal environment (<xref ref-type="bibr" rid="B97">Mencarelli et al., 2009</xref>). Additionally, TGR5 activation in intestinal L-cells promotes the release of GLP-1, and GLP-1 receptor agonists have shown promising neuroprotective and anti-inflammatory effects in PD models, independently improving motor function and neuronal survival (<xref ref-type="bibr" rid="B53">H&#x000F6;lscher, 2018</xref>; <xref ref-type="bibr" rid="B4">Athauda and Foltynie, 2016</xref>).</p>
<p>Besides, modulation of &#x003B1;-synuclein aggregation may also contribute to the progression of PD. While the direct interaction between BAs and &#x003B1;-synuclein is still an emerging area of research, it is hypothesized that the gut microbial environment and its BAs metabolites could influence &#x003B1;-synuclein aggregation in the enteric nervous system or its propagation to the brain (<xref ref-type="bibr" rid="B31">Devos et al., 2013</xref>). The systemic anti-inflammatory environment fostered by certain BAs might reduce the glial activation that facilitates the spread and toxicity of &#x003B1;-synuclein pathology (<xref ref-type="bibr" rid="B35">Fiorucci et al., 2018</xref>). Furthermore, the ability of BAs like UDCA to act as chemical chaperones could theoretically mitigate &#x003B1;-synuclein misfolding, and reducing oxidative stress and neuroinflammation through mitogen-activated protein kinases pathways in MPTP-induced mouse model of PD (<xref ref-type="bibr" rid="B71">Keene et al., 2001</xref>; <xref ref-type="bibr" rid="B66">Jiang et al., 2022</xref>).</p>
</sec>
</sec>
<sec>
<label>4.2</label>
<title>BAs and depression</title>
<p>Major Depressive Disorder (MDD) is a multifactorial disease characterized by complex interactions between genetic predisposition, chronic stress, neuroinflammation, hypothalamic-pituitary-adrenal (HPA) axis dysregulation, and monoaminergic neurotransmitter dysfunction. The BAs system intersects with these core pathophysiological pathways in several compelling ways summarized below.</p>
<p><bold>HPA Axis Modulation:</bold> The HPA axis, the body&#x00027;s central stress response system, is often hyperactive in depression. BAs can cross the BBB and interact with receptors in key regulatory regions like the hypothalamus and pituitary (<xref ref-type="bibr" rid="B57">Huang et al., 2015</xref>). Certain BAs, notably LCA, are potent agonists of the Pregnane X Receptor (PXR) and Vitamin D Receptor (VDR). Both of them can cross-talk with glucocorticoid receptor signaling and influence HPA axis feedback sensitivity (<xref ref-type="bibr" rid="B136">Staudinger et al., 2001</xref>; <xref ref-type="bibr" rid="B89">Makishima et al., 2002</xref>). An imbalanced BAs profile, particularly one enriched in specific secondary BAs, may therefore contribute to the HPA axis hyperactivity seen in depression. Preclinical evidence supports this; for instance, FXR knockout mice exhibit exacerbated depressive-like behaviors and impaired HPA axis negative feedback in response to chronic stress, suggesting the role of FXR in stress resilience (<xref ref-type="bibr" rid="B55">Hu et al., 2020</xref>; <xref ref-type="bibr" rid="B57">Huang et al., 2015</xref>).</p>
<p><bold>Neurotransmitter Systems:</bold> BAs can directly and indirectly modulate the activity of central neurotransmitter systems. Some BAs have been shown to act as allosteric modulators of neurotransmitter receptors, including the gamma-aminobutyric acid-A (GABA-A) receptor. For example, certain BAs can potentiate GABAergic inhibition, which may influence neural circuit activity underlying anxiety and mood (<xref ref-type="bibr" rid="B114">Quinn et al., 2014</xref>; <xref ref-type="bibr" rid="B2">Ahboucha and Butterworth, 2008</xref>). More indirectly, the TGR5-mediated release of GLP-1 from intestinal L-cells can affect central dopamine and serotonin signaling pathways, both of which are critically implicated in the pathophysiology and treatment of depression (<xref ref-type="bibr" rid="B38">Ghosal et al., 2013</xref>; <xref ref-type="bibr" rid="B47">Harach et al., 2012</xref>).</p>
<p><bold>Inflammation and Neurogenesis:</bold> Depression is now recognized as a neuroinflammatory disorder, with elevated levels of pro-inflammatory cytokines contributing to symptoms and negatively impacting neurogenesis, particularly in the hippocampus (<xref ref-type="bibr" rid="B99">Miller and Raison, 2016</xref>). The anti-inflammatory effects of TGR5 and FXR signaling, as described in neurodegenerative contexts, are therefore highly relevant. By reducing the production of pro-inflammatory cytokines (e.g., IL-6, TNF-&#x003B1;) in both the periphery and the brain, a healthy, balanced BAs profile may help to create an environment conducive to hippocampal neurogenesis, which is often impaired in depression and is thought to be a mechanism of action for some antidepressants (<xref ref-type="bibr" rid="B87">Lucidi et al., 2021</xref>; <xref ref-type="bibr" rid="B99">Miller and Raison, 2016</xref>). Administration of TUDCA has been shown to reduce depressive-like behaviors in rodent models, an effect associated with mitigated neuroinflammation, reduced oxidative stress, and promoted synaptic plasticity and neurogenesis (<xref ref-type="bibr" rid="B1">Ackerman and Gerhard, 2016</xref>; <xref ref-type="bibr" rid="B163">Yanguas-Cas&#x000E1;s et al., 2017</xref>).</p>
<p><bold>Clinical and Metabolomic Evidences:</bold> Metabolomic analyses in human patients consistently report that altered serum and plasma BAs profiles in individuals with MDD compared to healthy controls. While findings can vary, a recurring result is a disturbance in the ratio of primary to secondary BAs. Research has revealed a specific shift in the BAs profile: an increase in primary conjugated forms alongside a decrease in secondary ones like DCA and LCA. This shift mirrors a &#x0201C;dysbiotic&#x0201D; signature seen in neurodegenerative diseases. Furthermore, it strengthens the evidence for a shared gut-brain axis disruption in various neuropsychiatric conditions (<xref ref-type="bibr" rid="B168">Zheng et al., 2016</xref>). A larger-scale study found that specific BAs ratios and concentrations were correlated with depression severity. Importantly, these alterations were partially normalized after successful antidepressant treatment. This suggests the changes are state-dependent and hold potential for monitoring treatment response (<xref ref-type="bibr" rid="B64">Jia et al., 2024</xref>).</p>
</sec>
<sec>
<label>4.3</label>
<title>BAs and hepatic encephalopathy</title>
<p>Hepatic Encephalopathy (HE) is a complex and debilitating neuropsychiatric complication of acute or chronic liver failure, characterized by a wide spectrum of symptoms from subtle cognitive impairment to coma. While hyperammonemia is a central driver, the role of BAs in HE pathogenesis is gaining significant attention, as they are intimately linked to liver function and can directly impact brain function (<xref ref-type="bibr" rid="B3">Ahluwalia et al., 2016</xref>). The neurotoxic mechanism of BAs in HE involves multiple pathways.</p>
<p><bold>The Accumulation and Altered Composition of Peripheral BAs:</bold> In advanced liver cirrhosis and liver failure, the damaged liver fails to synthesize, conjugate, and clear BAs efficiently. This leads to systemic BAs accumulation, a condition known as cholestasis (<xref ref-type="bibr" rid="B62">Jansen et al., 2017</xref>). The composition of the circulating BA pool becomes profoundly altered, typically featuring an increase in the concentrations of toxic, hydrophobic BAs like CDCA and DCA, and a relative decrease in the more hydrophilic and less toxic BAs like CA and UDCA (<xref ref-type="bibr" rid="B70">Kakiyama et al., 2013</xref>; <xref ref-type="bibr" rid="B34">Ferslew et al., 2015</xref>). This shift toward a more hydrophobic and cytotoxic BAs profile is a major contributor to systemic and cerebral toxicity in HE.</p>
<p><bold>Disruption of BBB:</bold> The BBB is a critical interface that becomes compromised in HE. High concentrations of hydrophobic BAs are directly cytotoxic to cerebrovascular endothelial cells. They can disrupt the integrity of tight junctions (e.g., by downregulating occludin and ZO-1 expression and promoting oxidative stress), leading to increased BBB permeability (<xref ref-type="bibr" rid="B41">G&#x000F6;rg et al., 2015</xref>). This &#x0201C;leaky&#x0201D; BBB facilitates the entry of neurotoxins such as ammonia, manganese, and pro-inflammatory cytokines into the brain parenchyma, where they can disrupt astrocyte function (leading to Alzheimer type II astrocytosis) and neuronal excitability (<xref ref-type="bibr" rid="B170">Ziemi&#x00144;ska and Lazarewicz, 2006</xref>; <xref ref-type="bibr" rid="B2">Ahboucha and Butterworth, 2008</xref>).</p>
<p><bold>Direct Neurotransmitter Dysfunction:</bold> BAs can directly interfere with neuronal and synaptic function. They have been shown to alter neuronal membrane fluidity and inhibit key enzymes like Na&#x0002B;/K&#x0002B;-ATPase, which is essential for maintaining the neuronal resting membrane potential and ionic gradients (<xref ref-type="bibr" rid="B170">Ziemi&#x00144;ska and Lazarewicz, 2006</xref>). This inhibition can contribute to the overall neural inhibition and cognitive-motor slowing characteristic of HE. Furthermore, some BAs and their conjugates can potentiate GABAergic neurotransmission by acting on the GABA-A receptor, potentially exacerbating the sedative effects and neural inhibition observed in HE patients (<xref ref-type="bibr" rid="B2">Ahboucha and Butterworth, 2008</xref>; <xref ref-type="bibr" rid="B114">Quinn et al., 2014</xref>).</p>
<p><bold>Therapeutic Applications of UDCA and TUDCA:</bold> Given their well-established cytoprotective, anti-apoptotic, and anti-inflammatory properties, UDCA and its taurine conjugate TUDCA are approved for the treatment of certain cholestatic liver diseases like primary biliary cholangitis (<xref ref-type="bibr" rid="B110">Paumgartner and Beuers, 2002</xref>; <xref ref-type="bibr" rid="B124">Rodrigues and Steer, 2001</xref>). Their mechanism of action in this context is thought to involve, in part, the displacement of toxic endogenous BAs from the circulating pool. In the context of HE, by stabilizing hepatocyte and neuronal membranes, reducing oxidative stress, improving mitochondrial function, and protecting BBB integrity, UDCA/TUDCA have the potential to ameliorate HE symptoms (<xref ref-type="bibr" rid="B10">Beuers et al., 2015</xref>; <xref ref-type="bibr" rid="B45">Halilbasic et al., 2015</xref>). Studies in animal models of acute liver failure and bile duct ligation have shown that TUDCA treatment can significantly reduce brain edema, lower BBB permeability, attenuate neuroinflammation, and improve neurological outcomes (<xref ref-type="bibr" rid="B163">Yanguas-Cas&#x000E1;s et al., 2017</xref>; <xref ref-type="bibr" rid="B122">Rodrigues et al., 2003</xref>).</p>
</sec>
<sec>
<label>4.4</label>
<title>BAs and other neurological conditions</title>
<p>Observational and preclinical studies are exploring the potential neuromodulatory and neuroprotective roles of BAs in a wider spectrum of CNS disorders, revealing a common thread of gut-brain communication.</p>
<sec>
<label>4.4.1</label>
<title>Multiple sclerosis (MS)</title>
<p>As a prototypical autoimmune, neuroinflammatory disease driven by T-cell mediated attack on CNS myelin, MS is strongly influenced by immunomodulatory pathways that BAs can regulate. TGR5 activation on monocytes, macrophages, and microglia can suppress the differentiation and effector functions of pro-inflammatory Th1 and Th17 cells, which are key drivers of MS pathology (<xref ref-type="bibr" rid="B155">Wang et al., 2011</xref>; <xref ref-type="bibr" rid="B35">Fiorucci et al., 2018</xref>). Studies in the experimental autoimmune encephalomyelitis (EAE) mouse model, a classic model of MS, have demonstrated that administration of FXR or TGR5 agonists can ameliorate disease severity, reduce CNS infiltration of inflammatory cells, decrease demyelination, and promote an anti-inflammatory microenvironment (<xref ref-type="bibr" rid="B149">Vidicevic et al., 2024</xref>). Notably, a seminal study found that MS patients had altered serum BA profiles, and that supplementation with taurine-conjugated Ursodeoxycholic Acid (TUDCA) specifically ameliorated neuroinflammation and clinical scores in the EAE model, highlighting a direct therapeutic link (<xref ref-type="bibr" rid="B11">Bhargava et al., 2020</xref>).</p>
</sec>
<sec>
<label>4.4.2</label>
<title>Ischemic and hemorrhagic stroke</title>
<p>The robust neuroprotective properties of TUDCA have been extensively documented in models of cerebral ischemia. In both transient and permanent middle cerebral artery occlusion models, TUDCA administration reduces infarct volume, attenuates neuronal apoptosis, decreases BBB disruption, and promotes long-term functional recovery (<xref ref-type="bibr" rid="B122">Rodrigues et al., 2003</xref>; <xref ref-type="bibr" rid="B148">Viana et al., 2009</xref>). The underlying mechanisms are multifactorial, involving the stabilization of mitochondria via inhibition of the mPTP, reduction of ER stress through its chaperone activity, decreased activation of caspases, and modulation of anti-apoptotic Bcl-2 proteins (<xref ref-type="bibr" rid="B123">Rodrigues et al., 2002</xref>; <xref ref-type="bibr" rid="B146">Vang et al., 2014</xref>). These findings suggest BAs-based therapies as promising candidates for acute neuroprotection in stroke.</p>
</sec>
<sec>
<label>4.4.3</label>
<title>Amyotrophic lateral sclerosis (ALS)</title>
<p>ALS is a devastating neurodegenerative disease characterized by the progressive loss of upper and lower motor neurons. TUDCA has shown significant promise in preclinical models of ALS. In the SOD1-G93A transgenic mouse model, TUDCA treatment delayed disease onset, extended survival, reduced motor neuron loss, and decreased markers of ER stress and apoptosis in the spinal cord (<xref ref-type="bibr" rid="B33">Elia et al., 2016</xref>; <xref ref-type="bibr" rid="B147">Vaz et al., 2015</xref>). This compelling preclinical data propelled TUDCA into clinical trials. A randomized, placebo-controlled trial in ALS patients demonstrated that TUDCA was safe and well-tolerated and showed a encouraging trend toward slowing functional decline, leading to its inclusion in larger, multi-center Phase 3 clinical trials to definitively assess its efficacy (<xref ref-type="bibr" rid="B106">Paganoni et al., 2020</xref>).</p>
</sec>
<sec>
<label>4.4.4</label>
<title>Huntington&#x00027;s disease (HD)</title>
<p>HD is an inherited neurodegenerative disorder caused by a CAG repeat expansion in the huntingtin gene, leading to protein misfolding and selective neuronal loss in the striatum. In models of HD, such as the 3-nitropropionic acid toxin model and genetic models, TUDCA treatment has been shown to improve motor performance, reduce striatal neuron degeneration, and decrease markers of mitochondrial dysfunction and caspase activation (<xref ref-type="bibr" rid="B71">Keene et al., 2001</xref>; <xref ref-type="bibr" rid="B124">Rodrigues and Steer, 2001</xref>). This suggests that the anti-apoptotic and protein-stabilizing properties of BAs like TUDCA may have broad application across a range of protein-misfolding and neurodegenerative disorders. The study conducted by Lombardo et al., despite being carried out during the COVID-19 pandemic, did not reach the primary endpoint; however, TUDCA was associated with an excellent safety profile (<xref ref-type="bibr" rid="B84">Lombardo et al., 2023</xref>).</p>
</sec>
</sec>
</sec>
<sec id="s5">
<label>5</label>
<title>Potential dietary intervention strategies based on BAs regulation</title>
<p>Given the profound impact of diet on both the gut microbiota composition and function, and on host BAs metabolism, dietary intervention represents a promising, accessible, and non-pharmacological approach to modulate the BAs pool in benefiting neurological health. The overarching goal is to shift the BAs pool away from a &#x0201C;dysbiotic&#x0201D; profile and toward a &#x0201C;healthy&#x0201D; one. The dysbiotic profile is characterized by high levels of hydrophobic, cytotoxic BAs (like CDCA and LCA) and a low abundance of beneficial secondary BAs. In contrast, the healthy profile is more balanced, hydrophilic, and enriched with neuroprotective species like UDCA/TUDCA (<xref ref-type="bibr" rid="B150">Wahlstr&#x000F6;m et al., 2016</xref>). Phytochemicals&#x02014;bioactive compounds derived from plants&#x02014;are particularly potent and versatile modulators of this system. Selected dietary components and their proposed mechanisms of BAs modulation and neurological impact are shown in <xref ref-type="table" rid="T2">Table 2</xref>.</p>
<table-wrap position="float" id="T2">
<label>Table 2</label>
<caption><p>Selected dietary components and their proposed mechanisms of bile acid modulation and neurological impact.</p></caption>
<table frame="box" rules="all">
<thead>
<tr>
<th valign="top" align="left"><bold>Dietary component</bold></th>
<th valign="top" align="left"><bold>Example sources</bold></th>
<th valign="top" align="left"><bold>Proposed mechanism on BA system</bold></th>
<th valign="top" align="left"><bold>Potential neurological benefit</bold></th>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" align="left">Resveratrol</td>
<td valign="top" align="left">Grapes, red wine, berries</td>
<td valign="top" align="left">FXR activation; modulates gut microbiota composition and function</td>
<td valign="top" align="left">Neuroprotection in AD/PD models; reduces neuroinflammation and oxidative stress</td>
</tr>
<tr>
<td valign="top" align="left">Curcumin</td>
<td valign="top" align="left">Turmeric</td>
<td valign="top" align="left">Weak FXR agonist; TGR5 modulation; Profoundly shapes microbiome</td>
<td valign="top" align="left">Anti-depressant and anxiolytic effects; ameliorates AD pathology and cognitive decline</td>
</tr>
<tr>
<td valign="top" align="left">Berberine</td>
<td valign="top" align="left">Goldenseal, barberry</td>
<td valign="top" align="left">Inhibits bacterial BSH; alters BA pool composition; Enhances intestinal FXR/FGF19 signaling</td>
<td valign="top" align="left">Anti-depressant; Improves cognition in AD models; metabolic benefits that support brain health</td>
</tr>
<tr>
<td valign="top" align="left">Quercetin</td>
<td valign="top" align="left">Onions, apples, capers</td>
<td valign="top" align="left">TGR5 activation; modulates gut microbiota</td>
<td valign="top" align="left">Neuroprotection in stroke and AD models; anti-inflammatory and antioxidant</td>
</tr>
<tr>
<td valign="top" align="left">Soluble fiber</td>
<td valign="top" align="left">Oats, legumes, apples</td>
<td valign="top" align="left">Promotes SCFA production; lowers colonic pH and inhibits 7&#x003B1;-dehydroxylating bacteria</td>
<td valign="top" align="left">Reduces systemic inflammation; supports gut-brain axis health; lowers risk of cognitive decline</td>
</tr>
<tr>
<td valign="top" align="left">Resistant starch</td>
<td valign="top" align="left">Cooked &#x00026; cooled potatoes, green bananas</td>
<td valign="top" align="left">Promotes growth of non-7&#x003B1;-dehydroxylating bacteria (e.g., <italic>Bifidobacterium</italic>)</td>
<td valign="top" align="left">Improves metabolic health and insulin sensitivity, indirectly benefiting the brain</td>
</tr>
<tr>
<td valign="top" align="left">Taurine</td>
<td valign="top" align="left">Seafood, meat</td>
<td valign="top" align="left">Substrate for taurine conjugation of BAs, promoting formation of forms like TUDCA</td>
<td valign="top" align="left">Supports endogenous neuroprotective BA production; direct neuroprotective effects</td>
</tr></tbody>
</table>
</table-wrap>
<sec>
<label>5.1</label>
<title>Polyphenols and alkaloids</title>
<p><bold>Resveratrol (found in grapes, berries, and peanuts):</bold> This well-studied compound has been shown to act as an FXR agonist, inducing the expression of SHP and thereby contributing to the feedback repression of hepatic BA synthesis (<xref ref-type="bibr" rid="B113">Qiao et al., 2014</xref>). Perhaps more importantly, resveratrol significantly modulates the gut microbiota by promoting beneficial bacteria like Lactobacillus and Bifidobacterium. It may also suppress pathobionts, and these combined effects can indirectly influence the production of secondary Bas (<xref ref-type="bibr" rid="B76">Larrosa et al., 2009</xref>). It has been well-documented that resveratrol has neuroprotective effects in AD and PD models. These effects include reducing A&#x003B2; plaques, attenuating neuroinflammation, and improving cognitive and motor function. These benefits may be partially achieved through the BAs-FXR axis and its subsequent anti-inflammatory and metabolic actions (<xref ref-type="bibr" rid="B6">Bastianetto et al., 2015</xref>; <xref ref-type="bibr" rid="B140">Tellone et al., 2015</xref>).</p>
<p><bold>Curcumin (the primary curcuminoid in turmeric):</bold> Curcumin exhibits a complex relationship with BAs signaling. It is a weak FXR agonist and can also modulate TGR5 signaling, potentially contributing to its metabolic benefits (<xref ref-type="bibr" rid="B161">Yang et al., 2016</xref>). Its most significant impact may be on the gut microbiome. Curcumin consistently alters microbial composition, often promoting the growth of bacteria associated with a healthy BAs metabolism (e.g., <italic>Bifidobacterium, Lactobacillus</italic>) and reducing pro-inflammatory species, thereby shaping a more favorable BAs profile (<xref ref-type="bibr" rid="B134">Shen et al., 2017</xref>; <xref ref-type="bibr" rid="B32">Di Meo et al., 2019</xref>). The well-documented anti-inflammatory, antioxidant, and neuroprotective effects of curcumin in models of depression and AD could be intimately intertwined with its ability to modulate BAs signaling and the gut-brain axis. Curcumin has been shown to ameliorate depressive-like behaviors in rodents, effects associated with normalized HPA axis activity and increased BDNF levels, which may be facilitated by its impact on the gut-BA-brain circuit (<xref ref-type="bibr" rid="B165">Zhang et al., 2012</xref>; <xref ref-type="bibr" rid="B85">Lopresti, 2017</xref>).</p>
<p><bold>Berberine (an isoquinoline alkaloid from plants like</bold> <italic><bold>Coptis chinensis</bold></italic> <bold>and</bold> <italic><bold>Berberis</bold></italic> <italic><bold>vulgaris</bold></italic><bold>):</bold> Berberine is a potent gut microbiome modulator with a unique mechanism. It exerts a primary indirect effect by inhibiting bacterial BSH activity, leading to an accumulation of conjugated BAs in the gut lumen (<xref ref-type="bibr" rid="B43">Gu et al., 2015</xref>; <xref ref-type="bibr" rid="B152">Wang et al., 2022a</xref>). This accumulation of conjugated BAs can enhance FXR signaling specifically in the intestine, leading to a robust increase in FGF15/19 production. FGF15/19 then travels to the liver to repress <italic>CYP7A1</italic> and hepatic BA synthesis, resulting in improved glucose homeostasis and reduced lipogenesis (<xref ref-type="bibr" rid="B44">Guo et al., 2016</xref>; <xref ref-type="bibr" rid="B108">Pathak et al., 2018</xref>). The resulting systemic anti-inflammatory and metabolic improvements resonate in the brain. Berberine has demonstrated efficacy in animal models of depression and AD, improving cognitive function, reducing depressive-like behaviors, and attenuating neuroinflammation, effects that are likely mediated by this microbiome-BA-FXR/TRG5 axis (<xref ref-type="bibr" rid="B169">Zhu et al., 2011</xref>).</p>
<p><bold>Quercetin (a flavonoid abundant in onions, apples, and capers):</bold> This flavonoid can alter BAs composition by modulating the gut bacterial community and has been identified as a TGR5 activator, promoting GLP-1 secretion from intestinal L-cells (<xref ref-type="bibr" rid="B166">Zhang et al., 2016</xref>; <xref ref-type="bibr" rid="B78">Les et al., 2018</xref>). Its potent anti-inflammatory and antioxidant properties, combined with its ability to modulate BAs signaling and the gut-brain axis, contribute to its observed neuroprotective benefits in models of AD, cerebral ischemia, and aging-related cognitive decline (<xref ref-type="bibr" rid="B22">Costa et al., 2016</xref>; <xref ref-type="bibr" rid="B25">Dajas et al., 2003</xref>).</p>
</sec>
<sec>
<label>5.2</label>
<title>Bioactive compounds in tea</title>
<p>Tea, one of the most widely consumed beverages globally, is not only a cultural symbol but also a treasure trove of diverse bioactive compounds. Its primary active constituents include catechins (particularly epigallocatechin gallate, EGCG), theanine, caffeine, theaflavins, and tea polysaccharides. The various bioactive compounds in tea constitute a complex &#x0201C;multi-component, multi-target&#x0201D; regulatory network that collectively acts on multiple aspects of BAs synthesis, metabolism, signaling, and gut microecology. By modulating FXR/TGR5 signaling, reshaping the gut microbiota to optimize the BAs pool composition, and exerting direct neuroprotective and anti-inflammatory effects, these compounds hold promise for positively influencing the prevention and adjunctive treatment of neuropsychiatric disorders such as Alzheimer&#x00027;s disease, Parkinson&#x00027;s disease, and depression (<xref ref-type="bibr" rid="B159">Xu et al., 2023</xref>; <xref ref-type="bibr" rid="B139">Tang et al., 2019</xref>; <xref ref-type="bibr" rid="B160">Yan et al., 2020</xref>).</p>
<sec>
<label>5.2.1</label>
<title>Modulation of bile acid receptors and synthases by tea polyphenols</title>
<p>Tea polyphenols, especially EGCG, are the most extensively studied active substances in tea. Researches show that EGCG can function as a modulator of the FXR. Although its direct binding affinity for FXR is relatively weak, EGCG can indirectly regulate FXR transcriptional activity by influencing FXR co-activators or through other upstream signaling pathways, such as the MAPK pathway (<xref ref-type="bibr" rid="B80">Li and Chiang, 2012</xref>; <xref ref-type="bibr" rid="B158">Xu et al., 2016</xref>). In animal models, EGCG intervention has been shown to downregulate the expression of the rate-limiting BAs synthesis enzyme CYP7A1 in the liver, thereby reducing total BAs synthesis and altering the BAs composition profile&#x02014;for instance, decreasing the proportion of DCA (<xref ref-type="bibr" rid="B58">Huang et al., 2018</xref>). Furthermore, EGCG is an effective agonist of Takeda G protein-coupled receptor 5 (TGR5). By activating TGR5, EGCG promotes the secretion of glucagon-like peptide-1 (GLP-1) from intestinal L-cells. This not only aids in improving glucose homeostasis but also contributes to brain health through the neuroprotective and anti-inflammatory effects of GLP-1 (<xref ref-type="bibr" rid="B23">Cremonini et al., 2021</xref>). The anti-inflammatory signaling mediated by TGR5 synergizes with the inherent antioxidant and anti-inflammatory properties of EGCG. Together, they collectively maintain the integrity of BBB and neuronal function (<xref ref-type="bibr" rid="B100">Mokra et al., 2022</xref>).</p>
</sec>
<sec>
<label>5.2.2</label>
<title>Reshaping the gut microbiota and secondary BAs metabolism by tea components</title>
<p>Tea components significantly shape the gut microbial ecosystem. EGCG and theaflavins possess antimicrobial activity, selectively inhibiting the growth of potential pathogens (e.g., certain Clostridium species) while promoting the proliferation of beneficial bacteria such as Bifidobacterium and Lactobacillus (<xref ref-type="bibr" rid="B109">Patra, 2024</xref>). This alteration in microbial community structure directly impacts secondary BAs production. Specifically, EGCG can inhibit bacterial bile salt hydrolase (BSH) activity, leading to an increased proportion of conjugated BAs in the gut, which may potentiate intestinal FXR signaling. Concurrently, it can suppress 7&#x003B1;-dehydroxylase activity, reducing the conversion of CA to DCA and thereby lowering the concentration of potentially cytotoxic secondary BAs like DCA in serum and feces (<xref ref-type="bibr" rid="B156">Wen et al., 2023</xref>). This ability to shift the bile acid pool toward a more hydrophilic and less toxic profile is a key mechanism through which tea components alleviate systemic inflammation and protect hepatic and neurological function.</p>
</sec>
<sec>
<label>5.2.3</label>
<title>Synergistic and balancing effects of theanine and caffeine</title>
<p>Theanine is a unique non-protein amino acid found almost exclusively in tea, known for its notable neuroregulatory and relaxant effects. It can cross BBB, influencing neurotransmitter levels in the brain&#x02014;such as increasing GABA, dopamine, and serotonin&#x02014;while antagonizing the excitotoxic effects of glutamate (<xref ref-type="bibr" rid="B75">Lardner, 2014</xref>). In the context of BAs metabolism, theanine exerts anti-stress and hypothalamic-pituitary-adrenal (HPA) axis modulating effects, which may indirectly stabilize the enterohepatic circulation of BAs against disruptions caused by psychological stress (<xref ref-type="bibr" rid="B126">Rothenberg and Zhang, 2019</xref>). Caffeine, a central nervous system stimulant, has less direct research linking it to BAs metabolism, but it is known to exert neuroprotective effects by antagonizing adenosine A2A receptors. Importantly, in tea, theanine effectively mitigates the potential tension and anxiety sometimes induced by caffeine. This unique &#x0201C;slow-release&#x0201D; and &#x0201C;balancing&#x0201D; effect makes tea a gentle and sustainable neuromodulator, potentially providing an ideal medium for maintaining a stable bile acid-gut-brain axis function over the long term (<xref ref-type="bibr" rid="B143">Unno et al., 2011</xref>).</p>
</sec>
<sec>
<label>5.2.4</label>
<title>Prebiotic-like effects of tea polysaccharides</title>
<p>Tea polysaccharides are a class of complex macromolecules in tea that are not easily absorbed directly by the human digestive tract but can serve as fermentation substrates for gut microbiota, exerting prebiotic-like effects. Studies have found that tea polysaccharides significantly increase the abundance of short-chain fatty acid (SCFA)-producing bacteria, such as certain genera within the Bacteroidetes and Firmicutes phyla (<xref ref-type="bibr" rid="B153">Wang et al., 2022b</xref>). The resultant increase in SCFA production (particularly butyrate) lowers colonic pH, further inhibiting the activity of 7&#x003B1;-dehydroxylating bacteria, thereby creating an intestinal environment less conducive to the generation of secondary bile acids like lithocholic acid (LCA) and DCA. Furthermore, SCFAs themselves possess potent anti-inflammatory and immunomodulatory functions and can enhance the intestinal barrier, preventing systemic inflammation triggered by endotoxin translocation (<xref ref-type="bibr" rid="B162">Yang et al., 2025</xref>). Through this pathway, tea polysaccharides indirectly but powerfully optimize the intestinal microenvironment for bile acid metabolism, laying a solid foundation for upstream bile acid signaling regulation (<xref ref-type="bibr" rid="B16">Chen et al., 2024</xref>).</p>
</sec>
</sec>
<sec>
<label>5.3</label>
<title>Dietary fibers</title>
<p><bold>Soluble Fiber (e.g., inulin, pectin, found in oats, legumes, and fruits):</bold> This represents an indirect, prebiotic mechanism. Fermentable fibers are not digested in the small intestine and serve as substrates for colonic bacteria. Their fermentation produces Short-Chain Fatty Acids (SCFAs) like acetate, propionate, and butyrate (<xref ref-type="bibr" rid="B15">Cani et al., 2009</xref>). SCFAs, particularly butyrate, lower the intestinal pH, creating an environment that inhibits the growth and activity of 7&#x003B1;-dehydroxylating bacteria (e.g., <italic>Clostridium scindens</italic>), thereby reducing the production of secondary BAs like DCA and LCA (<xref ref-type="bibr" rid="B119">Ridlon et al., 2016b</xref>; <xref ref-type="bibr" rid="B9">Berding et al., 2021</xref>). A shift toward a less hydrophobic BAs pool, with relatively higher levels of primary BAs, may be beneficial for reducing systemic and neuro-inflammation. Epidemiological studies consistently link diets high in soluble fiber with improved cognitive function and a reduced risk of AD and vascular dementia, potentially mediated in part through this BA-modulating mechanism (<xref ref-type="bibr" rid="B145">van de Wouw et al., 2018</xref>).</p>
</sec>
<sec>
<label>5.4</label>
<title>Probiotics</title>
<p>Probiotics can regulate BAs metabolism through various mechanisms. Probiotics such as <italic>Lactobacillus</italic> and <italic>Bifidobacterium</italic> can express BAs hydrolases, which affect the process of BAs dissociation (<xref ref-type="bibr" rid="B8">Begley et al., 2006</xref>). At the same time, probiotics can also reduce the number of 7&#x003B1;-dehydrogenating bacteria and lower the production of secondary BAs through competitive inhibition (<xref ref-type="bibr" rid="B105">O&#x00027;Toole and Cooney, 2008</xref>). Probiotics such as oligofructose and oligogalactose can selectively promote beneficial bacterial growth and indirectly regulate BAs metabolism (<xref ref-type="bibr" rid="B121">Roberfroid et al., 2010</xref>). Research has shown that prebiotic intervention can alter the structure of gut microbiota, optimize BAs composition, and improve metabolic health (<xref ref-type="bibr" rid="B39">Gibson et al., 2017</xref>). Synbiotics (a combination of probiotics and prebiotics) may have a synergistic effect in regulating BAs metabolism. Clinical studies have shown that specific synbiotics can significantly alter BAs profiles, improve insulin sensitivity, and metabolic parameters (<xref ref-type="bibr" rid="B167">Zhang et al., 2021</xref>). These findings provide new ideas for regulating BAs metabolism through microbial intervention.</p>
</sec>
<sec>
<label>5.5</label>
<title>Resistant starch (found in cooked and cooled potatoes, green bananas, legumes)</title>
<p>Similar to other prebiotics, resistant starch promotes the growth of specific beneficial bacteria, such as <italic>Bifidobacterium, Lactobacillus</italic>, and <italic>Ruminococcus bromii</italic>, which generally lack 7&#x003B1;-dehydroxylase activity (<xref ref-type="bibr" rid="B93">Martinez et al., 2010</xref>; <xref ref-type="bibr" rid="B144">Upadhyaya et al., 2016</xref>). This selective enrichment shapes a BA profile characterized by higher levels of primary BAs and lower levels of cytotoxic secondary BAs like LCA. This modulation has been mechanistically linked to improved glycemic control, enhanced gut barrier integrity, and reduced systemic inflammation&#x02014;all factors that are beneficial for brain health and cognitive function (<xref ref-type="bibr" rid="B15">Cani et al., 2009</xref>; <xref ref-type="bibr" rid="B12">Bindels et al., 2015</xref>).</p>
</sec>
<sec>
<label>5.6</label>
<title>Taurine and glycine</title>
<p>Since the hepatic conjugation process is a major determinant of BAs physicochemical and signaling properties, dietary intake of the precursor amino acids taurine (abundant in seafood and meat) and glycine can influence the conjugation pattern of the BAs pool (<xref ref-type="bibr" rid="B52">Hofmann and Hagey, 2008</xref>). Taurine-conjugated BAs, in particular, have been specifically associated with the neuroprotective effects of TUDCA. Ensuring adequate dietary taurine may therefore be beneficial to the endogenous production of taurine-conjugated BAs, potentially enhancing the brain&#x00027;s resilience to stress and injury (<xref ref-type="bibr" rid="B13">Boatright et al., 2009</xref>; <xref ref-type="bibr" rid="B120">Ripps and Shen, 2012</xref>). Taurine supplementation itself has shown independent neuroprotective effects in various models of stroke, epilepsy, and neurodegeneration, which may be partly attributed to its role in supporting the conjugation and thus the function of the BAs pool (<xref ref-type="bibr" rid="B120">Ripps and Shen, 2012</xref>; <xref ref-type="bibr" rid="B98">Menzie et al., 2014</xref>).</p>
</sec>
</sec>
<sec id="s6">
<label>6</label>
<title>Conclusions and perspectives</title>
<p>This comprehensive review has charted the remarkable scientific journey of BAs, from their classical role as simple digestive detergents to their contemporary status as central regulators of systemic metabolism and neurological health. We have outlined their complex, multi-pathway biosynthesis in the liver and their intricate enterohepatic circulation, emphasizing the indispensable role of the gut microbiome as a &#x0201C;bio-transformer&#x0201D; that generates a diverse BAs metabolome with distinct signaling properties. The activation of FXR and TGR5 receptors by specific BAs forms a pervasive signaling network. This network extends far beyond the liver and gut. It directly and indirectly influences key brain processes, including neuroinflammation, cellular stress, neurotransmitter function, synaptic plasticity, and BBB integrity. The expression, regulation, and relative importance of FXR and TGR5 signaling within the CNS vs. via peripheral pathways (e.g., vagal, immune) need further clarification.</p>
<p>A growing, though largely correlative, body of evidence associates dysregulation of the BA signaling system with a spectrum of brain disorders. From Alzheimer&#x00027;s and Parkinson&#x00027;s diseases to major depression and hepatic encephalopathy, a common observation is the alteration of BAs profiles&#x02014;frequently manifesting as a reduction in beneficial secondary BAs and a concomitant increase in toxic hydrophobic species. This recurrent &#x0201C;dysbiotic&#x0201D; signature points to a core disruption of the gut-liver-brain axis across diverse neuropathologies, suggesting that BAs metabolism may represent a convergent pathway linking peripheral metabolic and inflammatory states to brain health.</p>
<p>The emerging field of nutritional neuroscience offers a compelling and pragmatic strategy which is the targeted modulation of the BAs system through diet. As detailed, specific phytochemicals like resveratrol, curcumin, and berberine, along with prebiotic fibers and specific amino acids, demonstrate a significant capacity to reshape the BAs pool and fine-tune receptor signaling. These dietary components act as natural &#x0201C;BAs modulators,&#x0201D; presenting a viable, non-pharmacological path for prevention and adjunct therapy by harnessing the body&#x00027;s own endogenous signaling systems to promote a neuroprotective environment. However, several challenges and exciting frontiers must be addressed to translate this knowledge into effective clinical applications.</p>
<p><bold>Establishing Causality:</bold> While strong associations between BAs alterations and neurological diseases are evident, more sophisticated research is still needed to establish definitive causality. The use of germ-free animals, targeted bacterial interventions (e.g., precise probiotic cocktails or fecal microbiota transplantation from characterized donors), and BAs receptor knockout models will be crucial to determine whether BA changes are primary drivers of neuropathology or secondary consequences of the disease state.</p>
<p><bold>BBB Dynamics and Brain Delivery:</bold> A deeper, more nuanced understanding of how different BAs traverse the BBB under healthy and diseased conditions is essential. The expression, regulation, and function of specific BAs transporters (e.g., ASBT, OST&#x003B1;/OST&#x003B2;, MRPs) at the BBB remain an active area of investigation. Developing strategies to enhance the brain delivery of neuroprotective BAs or BAs-based drugs, perhaps through nano-formulations or prodrug approaches, could significantly improve their therapeutic efficacy.</p>
<p><bold>Personalized Nutrition and Medicine:</bold> The effects of any dietary intervention on BAs metabolism are highly dependent on an individual&#x00027;s baseline gut microbiota composition, their genetic background (e.g., polymorphisms in BA receptors and transporters), and their overall metabolic health. Future therapeutic strategies will likely need to be highly personalized. This entails deep phenotyping through microbiome sequencing, BAs metabolomic profiling, and host genetics.</p>
<p><bold>Robust Clinical Translation:</bold> While preclinical data, particularly for compounds like TUDCA, are exceptionally strong and promising, there is a pressing need for larger, well-designed, randomized, placebo-controlled human clinical trials to confirm their efficacy and safety in specific neurological diseases. Defining optimal dosing regimens, treatment durations, and identifying the patient subpopulations most likely to benefit are critical next steps.</p>
<p><bold>Novel Therapeutic Agonists/Antagonists:</bold> The pharmaceutical development of highly specific, brain-penetrant FXR and TGR5 agonists, antagonists, or modulators that can target neurological pathways with minimal peripheral side effects is a highly active and promising area of research. Such compounds could offer more precise control over BA signaling than broad dietary interventions.</p>
<p><bold>Microbiome Engineering:</bold> Beyond diet, more direct strategies aimed at manipulating the gut microbiome to correct BA dysregulation represent a futuristic but plausible frontier. This could include next-generation probiotics (e.g., engineered consortia containing <italic>Clostridium scindens</italic> to boost secondary BA production) or defined microbial ecosystem therapeutics tailored to restore a healthy BAs-metabolizing community.</p>
<p>In conclusion, the BAs system represents a fundamental biological pathway that intricately links our diet, our gut microbial symbionts, and our brain health. Harnessing this system through the sophisticated application of nutritional science holds immense promise for tackling the growing global burden of neurological and psychiatric diseases in the twenty-first century. It is critical to note that these promising results are primarily derived from cell and rodent models. Translating these findings to human pathophysiology requires caution due to significant species differences in BAs composition, receptor biology, and disease etiology. A deeper understanding of &#x0201C;bile-acid-mediated nutrition&#x0201D; could pave the way for a new class of evidence-based nutraceuticals and refined dietary guidelines specifically designed to optimize brain function and resilience across the human lifespan.</p>
</sec>
</body>
<back>
<sec sec-type="author-contributions" id="s7">
<title>Author contributions</title>
<p>JW: Conceptualization, Visualization, Writing &#x02013; original draft, Investigation. YZha: Writing &#x02013; original draft, Investigation. QW: Conceptualization, Writing &#x02013; original draft. YZho: Conceptualization, Writing &#x02013; original draft. ZX: Writing &#x02013; review &#x00026; editing. JY: Writing &#x02013; review &#x00026; editing, Supervision.</p>
</sec>
<sec sec-type="COI-statement" id="conf1">
<title>Conflict of interest</title>
<p>The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec sec-type="ai-statement" id="s9">
<title>Generative AI statement</title>
<p>The author(s) declared that generative AI was not used in the creation of this manuscript.</p>
<p>Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.</p>
</sec>
<sec sec-type="disclaimer" id="s10">
<title>Publisher&#x00027;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ackerman</surname> <given-names>H. D.</given-names></name> <name><surname>Gerhard</surname> <given-names>G. S.</given-names></name></person-group> (<year>2016</year>). <article-title>Bile acids in neurodegenerative disorders</article-title>. <source>Front. Aging Neurosci.</source> <volume>8</volume>:<fpage>263</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fnagi.2016.00263</pub-id><pub-id pub-id-type="pmid">27920719</pub-id></mixed-citation>
</ref>
<ref id="B2">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahboucha</surname> <given-names>S.</given-names></name> <name><surname>Butterworth</surname> <given-names>R. F.</given-names></name></person-group> (<year>2008</year>). <article-title>The neurosteroid system: implication in the pathophysiology of hepatic encephalopathy</article-title>. <source>Neurochem. Int.</source> <volume>52</volume>, <fpage>575</fpage>&#x02013;<lpage>587</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.neuint.2007.05.004</pub-id><pub-id pub-id-type="pmid">17610999</pub-id></mixed-citation>
</ref>
<ref id="B3">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahluwalia</surname> <given-names>V.</given-names></name> <name><surname>Betrapally</surname> <given-names>N. S.</given-names></name> <name><surname>Hylemon</surname> <given-names>P. B.</given-names></name> <name><surname>White</surname> <given-names>M. B.</given-names></name> <name><surname>Gillevet</surname> <given-names>P. M.</given-names></name> <name><surname>Unser</surname> <given-names>A. B.</given-names></name> <etal/></person-group>. (<year>2016</year>). <article-title>Impaired gut-liver-brain axis in patients with cirrhosis</article-title>. <source>Sci. Rep.</source> <volume>6</volume>, <fpage>1</fpage>&#x02013;<lpage>11</lpage>. doi: <pub-id pub-id-type="doi">10.1038/srep26800</pub-id><pub-id pub-id-type="pmid">27225869</pub-id></mixed-citation>
</ref>
<ref id="B4">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Athauda</surname> <given-names>D.</given-names></name> <name><surname>Foltynie</surname> <given-names>T.</given-names></name></person-group> (<year>2016</year>). <article-title>The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson&#x00027;s disease: mechanisms of action</article-title>. <source>Drug Discov. Today</source> <volume>21</volume>, <fpage>802</fpage>&#x02013;<lpage>818</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.drudis.2016.01.013</pub-id><pub-id pub-id-type="pmid">26851597</pub-id></mixed-citation>
</ref>
<ref id="B5">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baloni</surname> <given-names>P.</given-names></name> <name><surname>Funk</surname> <given-names>C. C.</given-names></name> <name><surname>Yan</surname> <given-names>J.</given-names></name> <name><surname>Yurkovich</surname> <given-names>J. T.</given-names></name> <name><surname>Kueider-Paisley</surname> <given-names>A.</given-names></name> <name><surname>Nho</surname> <given-names>K.</given-names></name> <etal/></person-group>. (<year>2020</year>). <article-title>Metabolic network analysis reveals altered bile acid synthesis and metabolism in Alzheimer&#x00027;s disease</article-title>. <source>Cell Rep. Med.</source> <volume>1</volume>:<fpage>100138</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.xcrm.2020.100138</pub-id><pub-id pub-id-type="pmid">33294859</pub-id></mixed-citation>
</ref>
<ref id="B6">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bastianetto</surname> <given-names>S.</given-names></name> <name><surname>M&#x000E9;nard</surname> <given-names>C.</given-names></name> <name><surname>Quirion</surname> <given-names>R.</given-names></name></person-group> (<year>2015</year>). <article-title>Neuroprotective action of resveratrol</article-title>. <source>Biochim. Biophys. Acta Mol. Basis Dis.</source> <volume>1852</volume>, <fpage>1195</fpage>&#x02013;<lpage>1201</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.bbadis.2014.09.011</pub-id><pub-id pub-id-type="pmid">25281824</pub-id></mixed-citation>
</ref>
<ref id="B7">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Batta</surname> <given-names>A. K.</given-names></name> <name><surname>Salen</surname> <given-names>G.</given-names></name> <name><surname>Arora</surname> <given-names>R.</given-names></name> <name><surname>Shefer</surname> <given-names>S.</given-names></name> <name><surname>Batta</surname> <given-names>M.</given-names></name> <name><surname>Person</surname> <given-names>A.</given-names></name></person-group> (<year>1990</year>). <article-title>Side chain conjugation prevents bacterial 7-dehydroxylation of bile acids</article-title>. <source>J. Biol. Chem.</source> <volume>265</volume>, <fpage>10925</fpage>&#x02013;<lpage>10928</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0021-9258(19)38535-7</pub-id><pub-id pub-id-type="pmid">2358447</pub-id></mixed-citation>
</ref>
<ref id="B8">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Begley</surname> <given-names>M.</given-names></name> <name><surname>Hill</surname> <given-names>C.</given-names></name> <name><surname>Gahan</surname> <given-names>C. G.</given-names></name></person-group> (<year>2006</year>). <article-title>Bile salt hydrolase activity in probiotics</article-title>. <source>Appl. Environ. Microbiol.</source> <volume>72</volume>, <fpage>1729</fpage>&#x02013;<lpage>1738</lpage>. doi: <pub-id pub-id-type="doi">10.1128/AEM.72.3.1729-1738.2006</pub-id><pub-id pub-id-type="pmid">16517616</pub-id></mixed-citation>
</ref>
<ref id="B9">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berding</surname> <given-names>K.</given-names></name> <name><surname>Vlckova</surname> <given-names>K.</given-names></name> <name><surname>Marx</surname> <given-names>W.</given-names></name> <name><surname>Schellekens</surname> <given-names>H.</given-names></name> <name><surname>Stanton</surname> <given-names>C.</given-names></name> <name><surname>Clarke</surname> <given-names>G.</given-names></name> <etal/></person-group>. (<year>2021</year>). <article-title>Diet and the microbiota&#x02013;gut&#x02013;brain axis: sowing the seeds of good mental health</article-title>. <source>Adv. Nutr.</source> <volume>12</volume>, <fpage>1239</fpage>&#x02013;<lpage>1285</lpage>. doi: <pub-id pub-id-type="doi">10.1093/advances/nmaa181</pub-id><pub-id pub-id-type="pmid">33693453</pub-id></mixed-citation>
</ref>
<ref id="B10">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beuers</surname> <given-names>U.</given-names></name> <name><surname>Trauner</surname> <given-names>M.</given-names></name> <name><surname>Jansen</surname> <given-names>P.</given-names></name> <name><surname>Poupon</surname> <given-names>R.</given-names></name></person-group> (<year>2015</year>). <article-title>New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond</article-title>. <source>J. Hepatol.</source> <volume>62</volume>, <fpage>S25</fpage>&#x02013;<lpage>S37</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jhep.2015.02.023</pub-id><pub-id pub-id-type="pmid">25920087</pub-id></mixed-citation>
</ref>
<ref id="B11">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhargava</surname> <given-names>P.</given-names></name> <name><surname>Smith</surname> <given-names>M. D.</given-names></name> <name><surname>Mische</surname> <given-names>L.</given-names></name> <name><surname>Harrington</surname> <given-names>E.</given-names></name> <name><surname>Fitzgerald</surname> <given-names>K. C.</given-names></name> <name><surname>Martin</surname> <given-names>K.</given-names></name> <etal/></person-group>. (<year>2020</year>). <article-title>Bile acid metabolism is altered in multiple sclerosis and supplementation ameliorates neuroinflammation</article-title>. <source>J. Clin. Invest.</source> <volume>130</volume>, <fpage>3467</fpage>&#x02013;<lpage>3482</lpage>. doi: <pub-id pub-id-type="doi">10.1172/JCI129401</pub-id><pub-id pub-id-type="pmid">32182223</pub-id></mixed-citation>
</ref>
<ref id="B12">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bindels</surname> <given-names>L. B.</given-names></name> <name><surname>Delzenne</surname> <given-names>N. M.</given-names></name> <name><surname>Cani</surname> <given-names>P. D.</given-names></name> <name><surname>Walter</surname> <given-names>J.</given-names></name></person-group> (<year>2015</year>). <article-title>Towards a more comprehensive concept for prebiotics</article-title>. <source>Nat. Rev. Gastroenterol. Hepatol.</source> <volume>12</volume>, <fpage>303</fpage>&#x02013;<lpage>310</lpage>. doi: <pub-id pub-id-type="doi">10.1038/nrgastro.2015.47</pub-id><pub-id pub-id-type="pmid">25824997</pub-id></mixed-citation>
</ref>
<ref id="B13">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boatright</surname> <given-names>J. H.</given-names></name> <name><surname>Nickerson</surname> <given-names>J. M.</given-names></name> <name><surname>Moring</surname> <given-names>A. G.</given-names></name> <name><surname>Pardue</surname> <given-names>M. T.</given-names></name></person-group> (<year>2009</year>). <article-title>Bile acids in treatment of ocular disease</article-title>. <source>J. Ocul. Biol. Dis. Infor.</source> <volume>2</volume>, <fpage>149</fpage>&#x02013;<lpage>157</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s12177-009-9030-x</pub-id><pub-id pub-id-type="pmid">20046852</pub-id></mixed-citation>
</ref>
<ref id="B14">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buzzetti</surname> <given-names>E.</given-names></name> <name><surname>Pinzani</surname> <given-names>M.</given-names></name> <name><surname>Tsochatzis</surname> <given-names>E. A.</given-names></name></person-group> (<year>2016</year>). <article-title>The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)</article-title>. <source>Metab. Clin. Exp.</source> <volume>65</volume>, <fpage>1038</fpage>&#x02013;<lpage>1048</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.metabol.2015.12.012</pub-id><pub-id pub-id-type="pmid">26823198</pub-id></mixed-citation>
</ref>
<ref id="B15">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cani</surname> <given-names>P. D.</given-names></name> <name><surname>Lecourt</surname> <given-names>E.</given-names></name> <name><surname>Dewulf</surname> <given-names>E. M.</given-names></name> <name><surname>Sohet</surname> <given-names>F. M.</given-names></name> <name><surname>Pachikian</surname> <given-names>B. D.</given-names></name> <name><surname>Naslain</surname> <given-names>D.</given-names></name> <etal/></person-group>. (<year>2009</year>). <article-title>Gut microbiota fermentation of prebiotics increases satietogenic and incretin gut peptide production with consequences for appetite sensation and glucose response after a meal</article-title>. <source>Am. J. Clin. Nutr.</source> <volume>90</volume>, <fpage>1236</fpage>&#x02013;<lpage>1243</lpage>. doi: <pub-id pub-id-type="doi">10.3945/ajcn.2009.28095</pub-id><pub-id pub-id-type="pmid">19776140</pub-id></mixed-citation>
</ref>
<ref id="B16">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname> <given-names>Y.</given-names></name> <name><surname>Li</surname> <given-names>H.</given-names></name> <name><surname>Lai</surname> <given-names>F.</given-names></name> <name><surname>Min</surname> <given-names>T.</given-names></name> <name><surname>Wu</surname> <given-names>H.</given-names></name> <name><surname>Zhan</surname> <given-names>Q.</given-names></name></person-group> (<year>2024</year>). <article-title>The influence and mechanisms of natural plant polysaccharides on intestinal microbiota-mediated metabolic disorders</article-title>. <source>Foods</source> <volume>13</volume>:<fpage>3882</fpage>. doi: <pub-id pub-id-type="doi">10.3390/foods13233882</pub-id><pub-id pub-id-type="pmid">39682954</pub-id></mixed-citation>
</ref>
<ref id="B17">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chiang</surname> <given-names>J. Y.</given-names></name></person-group> (<year>2002</year>). <article-title>Bile acid regulation of gene expression: roles of nuclear hormone receptors</article-title>. <source>Endocr. Rev.</source> <volume>23</volume>, <fpage>443</fpage>&#x02013;<lpage>463</lpage>. doi: <pub-id pub-id-type="doi">10.1210/er.2000-0035</pub-id><pub-id pub-id-type="pmid">12202460</pub-id></mixed-citation>
</ref>
<ref id="B18">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chiang</surname> <given-names>J. Y.</given-names></name></person-group> (<year>2009</year>). Bile acids: regulation of synthesis: thematic review series: bile acids <source>J. Lipid Res.</source> <volume>50</volume>, <fpage>1955</fpage>&#x02013;<lpage>1966</lpage>. doi: <pub-id pub-id-type="doi">10.1194/jlr.R900010-JLR200</pub-id></mixed-citation>
</ref>
<ref id="B19">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chiang</surname> <given-names>J. Y.</given-names></name></person-group> (<year>2013</year>). <article-title>Bile acid metabolism and signaling</article-title>. <source>Compr. Physiol.</source> <volume>3</volume>, <fpage>1191</fpage>&#x02013;<lpage>1212</lpage>. doi: <pub-id pub-id-type="doi">10.1002/j.2040-4603.2013.tb00517.x</pub-id><pub-id pub-id-type="pmid">23897684</pub-id></mixed-citation>
</ref>
<ref id="B20">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chiang</surname> <given-names>J. Y.</given-names></name></person-group> (<year>2017</year>). <article-title>Bile acid metabolism and signaling in liver disease and therapy</article-title>. <source>Liver Res.</source> <volume>1</volume>, <fpage>3</fpage>&#x02013;<lpage>9</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.livres.2017.05.001</pub-id><pub-id pub-id-type="pmid">29104811</pub-id></mixed-citation>
</ref>
<ref id="B21">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Collins</surname> <given-names>S. L.</given-names></name> <name><surname>Stine</surname> <given-names>J. G.</given-names></name> <name><surname>Bisanz</surname> <given-names>J. E.</given-names></name> <name><surname>Okafor</surname> <given-names>C. D.</given-names></name> <name><surname>Patterson</surname> <given-names>A. D.</given-names></name></person-group> (<year>2023</year>). <article-title>Bile acids and the gut microbiota: metabolic interactions and impacts on disease</article-title>. <source>Nat. Rev. Microbiol.</source> 236&#x02013;247. doi: <pub-id pub-id-type="doi">10.1038/s41579-022-00805-x</pub-id><pub-id pub-id-type="pmid">36253479</pub-id></mixed-citation>
</ref>
<ref id="B22">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Costa</surname> <given-names>L. G.</given-names></name> <name><surname>Garrick</surname> <given-names>J. M.</given-names></name> <name><surname>Roqu&#x000E8;</surname> <given-names>P. J.</given-names></name> <name><surname>Pellacani</surname> <given-names>C.</given-names></name></person-group> (<year>2016</year>). <article-title>Mechanisms of neuroprotection by quercetin: counteracting oxidative stress and more</article-title>. <source>Oxid. Med. Cell. Longev.</source> 2986796. doi: <pub-id pub-id-type="doi">10.1155/2016/2986796</pub-id><pub-id pub-id-type="pmid">26904161</pub-id></mixed-citation>
</ref>
<ref id="B23">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cremonini</surname> <given-names>E.</given-names></name> <name><surname>Daveri</surname> <given-names>E.</given-names></name> <name><surname>Mastaloudis</surname> <given-names>A.</given-names></name> <name><surname>Oteiza</surname> <given-names>P. I.</given-names></name></person-group> (<year>2021</year>). <article-title>(&#x02013;)-Epicatechin and anthocyanins modulate GLP-1 metabolism: evidence from C57BL/6J mice and GLUTag cells</article-title>. <source>J. Nutr.</source> <volume>151</volume>, <fpage>1497</fpage>&#x02013;<lpage>1506</lpage>. doi: <pub-id pub-id-type="doi">10.1093/jn/nxab029</pub-id><pub-id pub-id-type="pmid">33693759</pub-id></mixed-citation>
</ref>
<ref id="B24">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cryan</surname> <given-names>J. F.</given-names></name> <name><surname>O&#x00027;Riordan</surname> <given-names>K. J.</given-names></name> <name><surname>Cowan</surname> <given-names>C. S.</given-names></name> <name><surname>Sandhu</surname> <given-names>K. V.</given-names></name> <name><surname>Bastiaanssen</surname> <given-names>T. F.</given-names></name> <name><surname>Boehme</surname> <given-names>M.</given-names></name> <etal/></person-group>. (<year>2019</year>). <article-title>The microbiota-gut-brain axis</article-title>. <source>Physiol. Rev.</source> <volume>99</volume>, <fpage>1877</fpage>&#x02013;<lpage>2013</lpage>. doi: <pub-id pub-id-type="doi">10.1152/physrev.00018.2018</pub-id></mixed-citation>
</ref>
<ref id="B25">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dajas</surname> <given-names>F.</given-names></name> <name><surname>Rivera-Megret</surname> <given-names>F.</given-names></name> <name><surname>Blasina</surname> <given-names>F.</given-names></name> <name><surname>Arredondo</surname> <given-names>F.</given-names></name> <name><surname>Abin-Carriquiry</surname> <given-names>J. A.</given-names></name> <name><surname>Costa</surname> <given-names>G.</given-names></name> <etal/></person-group>. (<year>2003</year>). <article-title>Neuroprotection by flavonoids</article-title>. <source>Brazil. J. Med. Biol. Res.</source> <volume>36</volume>, <fpage>1613</fpage>&#x02013;<lpage>1620</lpage>. doi: <pub-id pub-id-type="doi">10.1590/S0100-879X2003001200002</pub-id><pub-id pub-id-type="pmid">14666245</pub-id></mixed-citation>
</ref>
<ref id="B26">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dawson</surname> <given-names>P. A.</given-names></name> <name><surname>Karpen</surname> <given-names>S. J.</given-names></name></person-group> (<year>2015</year>). <article-title>Intestinal transport and metabolism of bile acids</article-title>. <source>J. Lipid Res.</source> <volume>56</volume>, <fpage>1085</fpage>&#x02013;<lpage>1099</lpage>. doi: <pub-id pub-id-type="doi">10.1194/jlr.R054114</pub-id><pub-id pub-id-type="pmid">25210150</pub-id></mixed-citation>
</ref>
<ref id="B27">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dawson</surname> <given-names>P. A.</given-names></name> <name><surname>Lan</surname> <given-names>T.</given-names></name> <name><surname>Rao</surname> <given-names>A.</given-names></name></person-group> (<year>2009</year>). <article-title>Bile acid transporters</article-title>. <source>J. Lipid Res.</source> <volume>50</volume>, <fpage>2340</fpage>&#x02013;<lpage>2357</lpage>. doi: <pub-id pub-id-type="doi">10.1194/jlr.R900012-JLR200</pub-id></mixed-citation>
</ref>
<ref id="B28">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Aguiar Vallim</surname> <given-names>T. Q.</given-names></name> <name><surname>Tarling</surname> <given-names>E. J.</given-names></name> <name><surname>Edwards</surname> <given-names>P. A.</given-names></name></person-group> (<year>2013</year>). <article-title>Pleiotropic roles of bile acids in metabolism</article-title>. <source>Cell Metab.</source> <volume>17</volume>, <fpage>657</fpage>&#x02013;<lpage>669</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.cmet.2013.03.013</pub-id><pub-id pub-id-type="pmid">23602448</pub-id></mixed-citation>
</ref>
<ref id="B29">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dean</surname> <given-names>G.</given-names></name> <name><surname>Hanauer</surname> <given-names>S.</given-names></name> <name><surname>Levitsky</surname> <given-names>J.</given-names></name></person-group> (<year>2020</year>). <article-title>The role of the intestine in the pathogenesis of primary sclerosing cholangitis: evidence and therapeutic implications</article-title>. <source>Hepatology</source> <volume>72</volume>, <fpage>1127</fpage>&#x02013;<lpage>1138</lpage>. doi: <pub-id pub-id-type="doi">10.1002/hep.31311</pub-id><pub-id pub-id-type="pmid">32394535</pub-id></mixed-citation>
</ref>
<ref id="B30">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Devkota</surname> <given-names>S.</given-names></name> <name><surname>Wang</surname> <given-names>Y.</given-names></name> <name><surname>Musch</surname> <given-names>M. W.</given-names></name> <name><surname>Leone</surname> <given-names>V.</given-names></name> <name><surname>Fehlner-Peach</surname> <given-names>H.</given-names></name> <name><surname>Nadimpalli</surname> <given-names>A.</given-names></name> <etal/></person-group>. (<year>2012</year>). <article-title>Dietary-fat-induced taurocholic acid promotes pathobiont expansion and colitis in Il10<sup>&#x02212;/&#x02212;</sup> mice</article-title>. <source>Nature</source> <volume>487</volume>, <fpage>104</fpage>&#x02013;<lpage>108</lpage>. doi: <pub-id pub-id-type="doi">10.1038/nature11225</pub-id><pub-id pub-id-type="pmid">22722865</pub-id></mixed-citation>
</ref>
<ref id="B31">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Devos</surname> <given-names>D.</given-names></name> <name><surname>Lebouvier</surname> <given-names>T.</given-names></name> <name><surname>Lardeux</surname> <given-names>B.</given-names></name> <name><surname>Biraud</surname> <given-names>M.</given-names></name> <name><surname>Rouaud</surname> <given-names>T.</given-names></name> <name><surname>Pouclet</surname> <given-names>H.</given-names></name> <etal/></person-group>. (<year>2013</year>). <article-title>Colonic inflammation in Parkinson&#x00027;s disease</article-title>. <source>Neurobiol. Dis.</source> <volume>50</volume>, <fpage>42</fpage>&#x02013;<lpage>48</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.nbd.2012.09.007</pub-id><pub-id pub-id-type="pmid">23017648</pub-id></mixed-citation>
</ref>
<ref id="B32">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Meo</surname> <given-names>F.</given-names></name> <name><surname>Margarucci</surname> <given-names>S.</given-names></name> <name><surname>Galderisi</surname> <given-names>U.</given-names></name> <name><surname>Crispi</surname> <given-names>S.</given-names></name> <name><surname>Peluso</surname> <given-names>G.</given-names></name></person-group> (<year>2019</year>). <article-title>Curcumin, gut microbiota, and neuroprotection</article-title>. <source>Nutrients</source> <volume>11</volume>:<fpage>2426</fpage>. doi: <pub-id pub-id-type="doi">10.3390/nu11102426</pub-id><pub-id pub-id-type="pmid">31614630</pub-id></mixed-citation>
</ref>
<ref id="B33">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elia</surname> <given-names>A. E.</given-names></name> <name><surname>Lalli</surname> <given-names>S.</given-names></name> <name><surname>Monsurr&#x000F2;</surname> <given-names>M. R.</given-names></name> <name><surname>Sagnelli</surname> <given-names>A.</given-names></name> <name><surname>Taiello</surname> <given-names>A. C.</given-names></name> <name><surname>Reggiori</surname> <given-names>B.</given-names></name> <etal/></person-group>. (<year>2016</year>). <article-title>Tauroursodeoxycholic acid in the treatment of patients with amyotrophic lateral sclerosis</article-title>. <source>Euro. J. Neurol.</source> <volume>23</volume>, <fpage>45</fpage>&#x02013;<lpage>52</lpage>. doi: <pub-id pub-id-type="doi">10.1111/ene.12664</pub-id><pub-id pub-id-type="pmid">25664595</pub-id></mixed-citation>
</ref>
<ref id="B34">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferslew</surname> <given-names>B. C.</given-names></name> <name><surname>Xie</surname> <given-names>G.</given-names></name> <name><surname>Johnston</surname> <given-names>C. K.</given-names></name> <name><surname>Su</surname> <given-names>M.</given-names></name> <name><surname>Stewart</surname> <given-names>P. W.</given-names></name> <name><surname>Jia</surname> <given-names>W.</given-names></name> <etal/></person-group>. (<year>2015</year>). <article-title>Altered bile acid metabolome in patients with nonalcoholic steatohepatitis</article-title>. <source>Dig. Dis. Sci.</source> <volume>60</volume>, <fpage>3318</fpage>&#x02013;<lpage>3328</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s10620-015-3776-8</pub-id><pub-id pub-id-type="pmid">26138654</pub-id></mixed-citation>
</ref>
<ref id="B35">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fiorucci</surname> <given-names>S.</given-names></name> <name><surname>Biagioli</surname> <given-names>M.</given-names></name> <name><surname>Zampella</surname> <given-names>A.</given-names></name> <name><surname>Distrutti</surname> <given-names>E.</given-names></name></person-group> (<year>2018</year>). <article-title>Bile acids activated receptors regulate innate immunity</article-title>. <source>Front. Immunol.</source> <volume>9</volume>:<fpage>1853</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fimmu.2018.01853</pub-id><pub-id pub-id-type="pmid">30150987</pub-id></mixed-citation>
</ref>
<ref id="B36">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Foley</surname> <given-names>M. H.</given-names></name> <name><surname>O&#x00027;Flaherty</surname> <given-names>S.</given-names></name> <name><surname>Barrangou</surname> <given-names>R.</given-names></name> <name><surname>Theriot</surname> <given-names>C. M.</given-names></name></person-group> (<year>2019</year>). <article-title>Bile salt hydrolases: gatekeepers of bile acid metabolism and host-microbiome crosstalk in the gastrointestinal tract</article-title>. <source>PLoS Pathog.</source> <volume>15</volume>:<fpage>e1007581</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.ppat.1007581</pub-id><pub-id pub-id-type="pmid">30845232</pub-id></mixed-citation>
</ref>
<ref id="B37">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Foster</surname> <given-names>J. A.</given-names></name> <name><surname>Rinaman</surname> <given-names>L.</given-names></name> <name><surname>Cryan</surname> <given-names>J. F.</given-names></name></person-group> (<year>2017</year>). <article-title>Stress &#x00026; the gut-brain axis: regulation by the microbiome</article-title>. <source>Neurobiol. Stress</source> <volume>19</volume>, <fpage>124</fpage>&#x02013;<lpage>136</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ynstr.2017.03.001</pub-id></mixed-citation>
</ref>
<ref id="B38">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghosal</surname> <given-names>S.</given-names></name> <name><surname>Myers</surname> <given-names>B.</given-names></name> <name><surname>Herman</surname> <given-names>J. P.</given-names></name></person-group> (<year>2013</year>). <article-title>Role of central glucagon-like peptide-1 in stress regulation</article-title>. <source>Physiol. Behav.</source> <volume>122</volume>, <fpage>201</fpage>&#x02013;<lpage>207</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.physbeh.2013.04.003</pub-id><pub-id pub-id-type="pmid">23623992</pub-id></mixed-citation>
</ref>
<ref id="B39">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gibson</surname> <given-names>G. R.</given-names></name> <name><surname>Hutkins</surname> <given-names>R.</given-names></name> <name><surname>Sanders</surname> <given-names>M. E.</given-names></name> <name><surname>Prescott</surname> <given-names>S. L.</given-names></name> <name><surname>Reimer</surname> <given-names>R. A.</given-names></name> <name><surname>Salminen</surname> <given-names>S. J.</given-names></name> <etal/></person-group>. (<year>2017</year>). <article-title>Expert consensus document: the International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics</article-title>. <source>Nat. Rev. Gastroenterol. Hepatol.</source> <volume>14</volume>, <fpage>491</fpage>&#x02013;<lpage>502</lpage>. doi: <pub-id pub-id-type="doi">10.1038/nrgastro.2017.75</pub-id><pub-id pub-id-type="pmid">28611480</pub-id></mixed-citation>
</ref>
<ref id="B40">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goodwin</surname> <given-names>B.</given-names></name> <name><surname>Jones</surname> <given-names>S. A.</given-names></name> <name><surname>Price</surname> <given-names>R. R.</given-names></name> <name><surname>Watson</surname> <given-names>M. A.</given-names></name> <name><surname>McKee</surname> <given-names>D. D.</given-names></name> <name><surname>Moore</surname> <given-names>L. B.</given-names></name> <etal/></person-group>. (<year>2000</year>). <article-title>A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis</article-title>. <source>Mol. Cell</source> <volume>6</volume>, <fpage>517</fpage>&#x02013;<lpage>526</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S1097-2765(00)00051-4</pub-id><pub-id pub-id-type="pmid">11030332</pub-id></mixed-citation>
</ref>
<ref id="B41">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>G&#x000F6;rg</surname> <given-names>B.</given-names></name> <name><surname>Karababa</surname> <given-names>A.</given-names></name> <name><surname>Shafigullina</surname> <given-names>A.</given-names></name> <name><surname>Bidmon</surname> <given-names>H. J.</given-names></name> <name><surname>H&#x000E4;ussinger</surname> <given-names>D.</given-names></name></person-group> (<year>2015</year>). <article-title>Ammonia-induced senescence in cultured rat astrocytes and in human cerebral cortex in hepatic encephalopathy</article-title>. <source>Glia</source> <volume>63</volume>, <fpage>37</fpage>&#x02013;<lpage>50</lpage>. doi: <pub-id pub-id-type="doi">10.1002/glia.22731</pub-id><pub-id pub-id-type="pmid">25092802</pub-id></mixed-citation>
</ref>
<ref id="B42">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grant</surname> <given-names>S. M.</given-names></name> <name><surname>DeMorrow</surname> <given-names>S.</given-names></name></person-group> (<year>2020</year>). <article-title>Bile acid signaling in neurodegenerative and neurological disorders</article-title>. <source>Int. J. Mol. Sci.</source> <volume>21</volume>:<fpage>5982</fpage>. doi: <pub-id pub-id-type="doi">10.3390/ijms21175982</pub-id><pub-id pub-id-type="pmid">32825239</pub-id></mixed-citation>
</ref>
<ref id="B43">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gu</surname> <given-names>S.</given-names></name> <name><surname>Cao</surname> <given-names>B.</given-names></name> <name><surname>Sun</surname> <given-names>R.</given-names></name> <name><surname>Tang</surname> <given-names>Y.</given-names></name> <name><surname>Paletta</surname> <given-names>J. L.</given-names></name> <name><surname>Wu</surname> <given-names>X. L.</given-names></name> <etal/></person-group>. (<year>2015</year>). <article-title>A metabolomic and pharmacokinetic study on the mechanism underlying the lipid-lowering effect of orally administered berberine</article-title>. <source>Mol. Biosyst.</source> <volume>11</volume>, <fpage>463</fpage>&#x02013;<lpage>474</lpage>. doi: <pub-id pub-id-type="doi">10.1039/C4MB00500G</pub-id><pub-id pub-id-type="pmid">25411028</pub-id></mixed-citation>
</ref>
<ref id="B44">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname> <given-names>C.</given-names></name> <name><surname>Xie</surname> <given-names>S.</given-names></name> <name><surname>Chi</surname> <given-names>Z.</given-names></name> <name><surname>Zhang</surname> <given-names>J.</given-names></name> <name><surname>Liu</surname> <given-names>Y.</given-names></name> <name><surname>Zhang</surname> <given-names>L.</given-names></name> <etal/></person-group>. (<year>2016</year>). <article-title>Bile acids control inflammation and metabolic disorder through inhibition of NLRP3 inflammasome</article-title>. <source>Immunity</source> <volume>45</volume>, <fpage>802</fpage>&#x02013;<lpage>816</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.immuni.2016.09.008</pub-id><pub-id pub-id-type="pmid">27760343</pub-id></mixed-citation>
</ref>
<ref id="B45">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Halilbasic</surname> <given-names>E.</given-names></name> <name><surname>Fuchs</surname> <given-names>C.</given-names></name> <name><surname>Hofer</surname> <given-names>H.</given-names></name> <name><surname>Paumgartner</surname> <given-names>G.</given-names></name> <name><surname>Trauner</surname> <given-names>M.</given-names></name></person-group> (<year>2015</year>). <article-title>Therapy of primary sclerosing cholangitis&#x02014;today and tomorrow</article-title>. <source>Diges. Dis.</source> <volume>33</volume>, <fpage>149</fpage>&#x02013;<lpage>163</lpage>. doi: <pub-id pub-id-type="doi">10.1159/000440827</pub-id><pub-id pub-id-type="pmid">26641242</pub-id></mixed-citation>
</ref>
<ref id="B46">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamilton</surname> <given-names>J. P.</given-names></name> <name><surname>Xie</surname> <given-names>G.</given-names></name> <name><surname>Raufman</surname> <given-names>J. P.</given-names></name> <name><surname>Hogan</surname> <given-names>S.</given-names></name> <name><surname>Griffin</surname> <given-names>T. L.</given-names></name> <name><surname>Packard</surname> <given-names>C. A.</given-names></name> <etal/></person-group>. (<year>2007</year>). <article-title>Human cecal bile acids: concentration and spectrum</article-title>. <source>Am. J. Physiol. Gastrointestinal Liver Physiol.</source> <volume>293</volume>, <fpage>G256</fpage>&#x02013;<lpage>G263</lpage>. doi: <pub-id pub-id-type="doi">10.1152/ajpgi.00027.2007</pub-id><pub-id pub-id-type="pmid">17412828</pub-id></mixed-citation>
</ref>
<ref id="B47">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harach</surname> <given-names>T.</given-names></name> <name><surname>Pols</surname> <given-names>T. W.</given-names></name> <name><surname>Nomura</surname> <given-names>M.</given-names></name> <name><surname>Maida</surname> <given-names>A.</given-names></name> <name><surname>Watanabe</surname> <given-names>M.</given-names></name> <name><surname>Auwerx</surname> <given-names>J.</given-names></name> <etal/></person-group>. (<year>2012</year>). <article-title>TGR5 potentiates GLP-1 secretion in response to anionic exchange resins</article-title>. <source>Sci. Rep.</source> <volume>2</volume>:<fpage>430</fpage>. doi: <pub-id pub-id-type="doi">10.1038/srep00430</pub-id><pub-id pub-id-type="pmid">22666533</pub-id></mixed-citation>
</ref>
<ref id="B48">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hasegawa</surname> <given-names>S.</given-names></name> <name><surname>Goto</surname> <given-names>S.</given-names></name> <name><surname>Tsuji</surname> <given-names>H.</given-names></name> <name><surname>Okuno</surname> <given-names>T.</given-names></name> <name><surname>Asahara</surname> <given-names>T.</given-names></name> <name><surname>Nomoto</surname> <given-names>K.</given-names></name> <etal/></person-group>. (<year>2015</year>). <article-title>Intestinal dysbiosis and lowered serum lipopolysaccharide-binding protein in Parkinson&#x00027;s disease</article-title>. <source>PLoS ONE</source> <volume>10</volume>:<fpage>e0142164</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0142164</pub-id><pub-id pub-id-type="pmid">26539989</pub-id></mixed-citation>
</ref>
<ref id="B49">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname> <given-names>X.</given-names></name> <name><surname>Ji</surname> <given-names>G.</given-names></name> <name><surname>Jia</surname> <given-names>W.</given-names></name> <name><surname>Li</surname> <given-names>H.</given-names></name></person-group> (<year>2016</year>). <article-title>Gut microbiota and nonalcoholic fatty liver disease: insights on mechanism and application of metabolomics</article-title>. <source>Int. J. Mol. Sci.</source> <volume>17</volume>:<fpage>300</fpage>. doi: <pub-id pub-id-type="doi">10.3390/ijms17030300</pub-id><pub-id pub-id-type="pmid">26999104</pub-id></mixed-citation>
</ref>
<ref id="B50">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hill-Burns</surname> <given-names>E. M.</given-names></name> <name><surname>Debelius</surname> <given-names>J. W.</given-names></name> <name><surname>Morton</surname> <given-names>J. T.</given-names></name> <name><surname>Wissemann</surname> <given-names>W. T.</given-names></name> <name><surname>Lewis</surname> <given-names>M. R.</given-names></name> <name><surname>Wallen</surname> <given-names>Z. D.</given-names></name> <etal/></person-group>. (<year>2017</year>). <article-title>Parkinson&#x00027;s disease and Parkinson&#x00027;s disease medications have distinct signatures of the gut microbiome</article-title>. <source>Mov. Disord.</source> <volume>32</volume>, <fpage>739</fpage>&#x02013;<lpage>749</lpage>. doi: <pub-id pub-id-type="doi">10.1002/mds.26942</pub-id><pub-id pub-id-type="pmid">28195358</pub-id></mixed-citation>
</ref>
<ref id="B51">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hofmann</surname> <given-names>A. F.</given-names></name></person-group> (<year>1999</year>). <article-title>The continuing importance of bile acids in liver and intestinal disease</article-title>. <source>Arch. Intern. Med.</source> <volume>159</volume>, <fpage>2647</fpage>&#x02013;<lpage>2658</lpage>. doi: <pub-id pub-id-type="doi">10.1001/archinte.159.22.2647</pub-id><pub-id pub-id-type="pmid">10597755</pub-id></mixed-citation>
</ref>
<ref id="B52">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hofmann</surname> <given-names>A. F.</given-names></name> <name><surname>Hagey</surname> <given-names>L. R.</given-names></name></person-group> (<year>2008</year>). <article-title>Bile acids: chemistry, pathochemistry, biology, pathobiology, and therapeutics</article-title>. <source>Cell. Mol. Life Sci.</source> <volume>65</volume>, <fpage>2461</fpage>&#x02013;<lpage>2483</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s00018-008-7568-6</pub-id><pub-id pub-id-type="pmid">18488143</pub-id></mixed-citation>
</ref>
<ref id="B53">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>H&#x000F6;lscher</surname> <given-names>C.</given-names></name></person-group> (<year>2018</year>). <article-title>Novel dual GLP-1/GIP receptor agonists show neuroprotective effects in Alzheimer&#x00027;s and Parkinson&#x00027;s disease models</article-title>. <source>Neuropharmacology</source> <volume>136</volume>, <fpage>251</fpage>&#x02013;<lpage>259</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.neuropharm.2018.01.040</pub-id><pub-id pub-id-type="pmid">29402504</pub-id></mixed-citation>
</ref>
<ref id="B54">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Houten</surname> <given-names>S. M.</given-names></name> <name><surname>Watanabe</surname> <given-names>M.</given-names></name> <name><surname>Auwerx</surname> <given-names>J.</given-names></name></person-group> (<year>2006</year>). <article-title>Endocrine functions of bile acids</article-title>. <source>EMBO J.</source> <volume>25</volume>, <fpage>1419</fpage>&#x02013;<lpage>1425</lpage>. doi: <pub-id pub-id-type="doi">10.1038/sj.emboj.7601049</pub-id><pub-id pub-id-type="pmid">16541101</pub-id></mixed-citation>
</ref>
<ref id="B55">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname> <given-names>W.</given-names></name> <name><surname>Wu</surname> <given-names>J.</given-names></name> <name><surname>Ye</surname> <given-names>T.</given-names></name> <name><surname>Chen</surname> <given-names>Z.</given-names></name> <name><surname>Tao</surname> <given-names>J.</given-names></name> <name><surname>Tong</surname> <given-names>L.</given-names></name> <etal/></person-group>. (<year>2020</year>). <article-title>Farnesoid X receptor-mediated cytoplasmic translocation of CRTC2 disrupts CREB-BDNF signaling in hippocampal CA1 and leads to the development of depression-like behaviors in mice</article-title>. <source>Int. J. Neuropsychopharmacol.</source> <volume>23</volume>, <fpage>673</fpage>&#x02013;<lpage>686</lpage>. doi: <pub-id pub-id-type="doi">10.1093/ijnp/pyaa039</pub-id><pub-id pub-id-type="pmid">32453814</pub-id></mixed-citation>
</ref>
<ref id="B56">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname> <given-names>C.</given-names></name> <name><surname>Wang</surname> <given-names>J.</given-names></name> <name><surname>Hu</surname> <given-names>W.</given-names></name> <name><surname>Wang</surname> <given-names>C.</given-names></name> <name><surname>Lu</surname> <given-names>X.</given-names></name> <name><surname>Tong</surname> <given-names>L.</given-names></name></person-group> (<year>2016</year>). <article-title>Identification of functional farnesoid X receptors in brain neurons</article-title>. <source>FEBS Lett.</source> <volume>590</volume>, <fpage>3233</fpage>&#x02013;<lpage>3242</lpage>. doi: <pub-id pub-id-type="doi">10.1002/1873-3468.12373</pub-id><pub-id pub-id-type="pmid">27545319</pub-id></mixed-citation>
</ref>
<ref id="B57">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname> <given-names>F.</given-names></name> <name><surname>Wang</surname> <given-names>T.</given-names></name> <name><surname>Lan</surname> <given-names>Y.</given-names></name> <name><surname>Yang</surname> <given-names>L.</given-names></name> <name><surname>Pan</surname> <given-names>W.</given-names></name> <name><surname>Zhu</surname> <given-names>Y.</given-names></name> <etal/></person-group>. (<year>2015</year>). <article-title>Deletion of mouse FXR gene disturbs multiple neurotransmitter systems and alters neurobehavior</article-title>. <source>Front. Behav. Neurosci.</source> <volume>9</volume>:<fpage>70</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fnbeh.2015.00070</pub-id><pub-id pub-id-type="pmid">25870546</pub-id></mixed-citation>
</ref>
<ref id="B58">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname> <given-names>J.</given-names></name> <name><surname>Feng</surname> <given-names>S.</given-names></name> <name><surname>Liu</surname> <given-names>A.</given-names></name> <name><surname>Dai</surname> <given-names>Z.</given-names></name> <name><surname>Wang</surname> <given-names>H.</given-names></name> <name><surname>Reuhl</surname> <given-names>K.</given-names></name> <etal/></person-group>. (<year>2018</year>). <article-title>Green tea polyphenol EGCG alleviates metabolic abnormality and fatty liver by decreasing bile acid and lipid absorption in mice</article-title>. <source>Mol. Nutr. Food Res</source>. <volume>62</volume>:<fpage>1700696</fpage>. doi: <pub-id pub-id-type="doi">10.1002/mnfr.201700696</pub-id><pub-id pub-id-type="pmid">29278293</pub-id></mixed-citation>
</ref>
<ref id="B59">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Inagaki</surname> <given-names>T.</given-names></name> <name><surname>Choi</surname> <given-names>M.</given-names></name> <name><surname>Moschetta</surname> <given-names>A.</given-names></name> <name><surname>Peng</surname> <given-names>L.</given-names></name> <name><surname>Cummins</surname> <given-names>C. L.</given-names></name> <name><surname>McDonald</surname> <given-names>J. G.</given-names></name> <etal/></person-group>. (<year>2005</year>). <article-title>Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis</article-title>. <source>Cell Metab.</source> <volume>2</volume>, <fpage>217</fpage>&#x02013;<lpage>225</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.cmet.2005.09.001</pub-id><pub-id pub-id-type="pmid">16213224</pub-id></mixed-citation>
</ref>
<ref id="B60">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Inagaki</surname> <given-names>T.</given-names></name> <name><surname>Moschetta</surname> <given-names>A.</given-names></name> <name><surname>Lee</surname> <given-names>Y. K.</given-names></name> <name><surname>Peng</surname> <given-names>L.</given-names></name> <name><surname>Zhao</surname> <given-names>G.</given-names></name> <name><surname>Downes</surname> <given-names>M.</given-names></name> <etal/></person-group>. (<year>2006</year>). <article-title>Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor</article-title>. <source>Proc. Nat. Acad. Sci. U.S.A.</source> <volume>103</volume>, <fpage>3920</fpage>&#x02013;<lpage>3925</lpage>. doi: <pub-id pub-id-type="doi">10.1073/pnas.0509592103</pub-id><pub-id pub-id-type="pmid">16473946</pub-id></mixed-citation>
</ref>
<ref id="B61">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Islam</surname> <given-names>K. B.</given-names></name> <name><surname>Fukiya</surname> <given-names>S.</given-names></name> <name><surname>Hagio</surname> <given-names>M.</given-names></name> <name><surname>Fujii</surname> <given-names>N.</given-names></name> <name><surname>Ishizuka</surname> <given-names>S.</given-names></name> <name><surname>Ooka</surname> <given-names>T.</given-names></name> <etal/></person-group>. (<year>2011</year>). <article-title>Bile acid is a host factor that regulates the composition of the cecal microbiota in rats</article-title>. <source>Gastroenterology</source> <volume>141</volume>, <fpage>1773</fpage>&#x02013;<lpage>1781</lpage>. doi: <pub-id pub-id-type="doi">10.1053/j.gastro.2011.07.046</pub-id><pub-id pub-id-type="pmid">21839040</pub-id></mixed-citation>
</ref>
<ref id="B62">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jansen</surname> <given-names>P. L.</given-names></name> <name><surname>Ghallab</surname> <given-names>A.</given-names></name> <name><surname>Vartak</surname> <given-names>N.</given-names></name> <name><surname>Reif</surname> <given-names>R.</given-names></name> <name><surname>Schaap</surname> <given-names>F. G.</given-names></name> <name><surname>Hampe</surname> <given-names>J.</given-names></name> <etal/></person-group>. (<year>2017</year>). <article-title>The ascending pathophysiology of cholestatic liver disease</article-title>. <source>Hepatology</source> <volume>65</volume>, <fpage>722</fpage>&#x02013;<lpage>738</lpage>. doi: <pub-id pub-id-type="doi">10.1002/hep.28965</pub-id><pub-id pub-id-type="pmid">27981592</pub-id></mixed-citation>
</ref>
<ref id="B63">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Janssen</surname> <given-names>A. W.</given-names></name> <name><surname>Houben</surname> <given-names>T.</given-names></name> <name><surname>Katiraei</surname> <given-names>S.</given-names></name> <name><surname>Dijk</surname> <given-names>W.</given-names></name> <name><surname>Boutens</surname> <given-names>L.</given-names></name> <name><surname>van Der Bolt</surname> <given-names>N.</given-names></name> <etal/></person-group>. (<year>2017</year>). <article-title>Modulation of the gut microbiota impacts nonalcoholic fatty liver disease: a potential role for bile acids</article-title>. <source>J. Lipid Res.</source> <volume>58</volume>, <fpage>1399</fpage>&#x02013;<lpage>1416</lpage>. doi: <pub-id pub-id-type="doi">10.1194/jlr.M075713</pub-id><pub-id pub-id-type="pmid">28533304</pub-id></mixed-citation>
</ref>
<ref id="B64">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jia</surname> <given-names>M.</given-names></name> <name><surname>Fan</surname> <given-names>Y.</given-names></name> <name><surname>Ma</surname> <given-names>Q.</given-names></name> <name><surname>Yang</surname> <given-names>D.</given-names></name> <name><surname>Wang</surname> <given-names>Y.</given-names></name> <name><surname>He</surname> <given-names>X.</given-names></name> <etal/></person-group>. (<year>2024</year>). <article-title>Gut microbiota dysbiosis promotes cognitive impairment via bile acid metabolism in major depressive disorder</article-title>. <source>Transl. Psychiatry</source> <volume>14</volume>:<fpage>503</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41398-024-03211-4</pub-id><pub-id pub-id-type="pmid">39719433</pub-id></mixed-citation>
</ref>
<ref id="B65">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jia</surname> <given-names>W.</given-names></name> <name><surname>Xie</surname> <given-names>G.</given-names></name> <name><surname>Jia</surname> <given-names>W.</given-names></name></person-group> (<year>2018</year>). <article-title>Bile acid&#x02013;microbiota crosstalk in gastrointestinal inflammation and carcinogenesis</article-title>. <source>Nat. Rev. Gastroenterol. Hepatol.</source> <volume>15</volume>, <fpage>111</fpage>&#x02013;<lpage>128</lpage>. doi: <pub-id pub-id-type="doi">10.1038/nrgastro.2017.119</pub-id><pub-id pub-id-type="pmid">29018272</pub-id></mixed-citation>
</ref>
<ref id="B66">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname> <given-names>C.</given-names></name> <name><surname>Shen</surname> <given-names>D.</given-names></name> <name><surname>Li</surname> <given-names>K.</given-names></name> <name><surname>Wang</surname> <given-names>H.</given-names></name> <name><surname>Sang</surname> <given-names>W.</given-names></name> <name><surname>Qi</surname> <given-names>H.</given-names></name></person-group> (<year>2022</year>). <article-title>Protective effects of ursodeoxycholic acid against oxidative stress and neuroinflammation through mitogen-activated protein kinases pathway in MPTP-induced Parkinson disease</article-title>. <source>Clin. Neuropharmacol.</source> <volume>45</volume>, <fpage>168</fpage>&#x02013;<lpage>174</lpage>. doi: <pub-id pub-id-type="doi">10.1097/WNF.0000000000000528</pub-id><pub-id pub-id-type="pmid">36383915</pub-id></mixed-citation>
</ref>
<ref id="B67">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiao</surname> <given-names>N.</given-names></name> <name><surname>Baker</surname> <given-names>S. S.</given-names></name> <name><surname>Chapa-Rodriguez</surname> <given-names>A.</given-names></name> <name><surname>Liu</surname> <given-names>W.</given-names></name> <name><surname>Nugent</surname> <given-names>C. A.</given-names></name> <name><surname>Tsompana</surname> <given-names>M.</given-names></name> <etal/></person-group>. (<year>2018</year>). <article-title>Suppressed hepatic bile acid signalling despite elevated production of primary and secondary bile acids in NAFLD</article-title>. <source>Gut</source> <volume>67</volume>, <fpage>1881</fpage>&#x02013;<lpage>1891</lpage>. doi: <pub-id pub-id-type="doi">10.1136/gutjnl-2017-314307</pub-id><pub-id pub-id-type="pmid">28774887</pub-id></mixed-citation>
</ref>
<ref id="B68">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname> <given-names>B. V.</given-names></name> <name><surname>Begley</surname> <given-names>M.</given-names></name> <name><surname>Hill</surname> <given-names>C.</given-names></name> <name><surname>Gahan</surname> <given-names>C. G.</given-names></name> <name><surname>Marchesi</surname> <given-names>J. R.</given-names></name></person-group> (<year>2008</year>). <article-title>Functional and comparative metagenomic analysis of bile salt hydrolase activity in the human gut microbiome</article-title>. <source>Proc. Nat. Acad. Sci. U.S.A.</source> <volume>105</volume>, <fpage>13580</fpage>&#x02013;<lpage>13585</lpage>. doi: <pub-id pub-id-type="doi">10.1073/pnas.0804437105</pub-id><pub-id pub-id-type="pmid">18757757</pub-id></mixed-citation>
</ref>
<ref id="B69">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Joyce</surname> <given-names>S. A.</given-names></name> <name><surname>Gahan</surname> <given-names>C. G.</given-names></name></person-group> (<year>2014</year>). <article-title>The gut microbiota and the metabolic health of the host</article-title>. <source>Curr. Opin. Gastroenterol.</source> <volume>30</volume>, <fpage>120</fpage>&#x02013;<lpage>127</lpage>. doi: <pub-id pub-id-type="doi">10.1097/MOG.0000000000000039</pub-id><pub-id pub-id-type="pmid">24468803</pub-id></mixed-citation>
</ref>
<ref id="B70">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kakiyama</surname> <given-names>G.</given-names></name> <name><surname>Pandak</surname> <given-names>W. M.</given-names></name> <name><surname>Gillevet</surname> <given-names>P. M.</given-names></name> <name><surname>Hylemon</surname> <given-names>P. B.</given-names></name> <name><surname>Heuman</surname> <given-names>D. M.</given-names></name> <name><surname>Daita</surname> <given-names>K.</given-names></name> <etal/></person-group>. (<year>2013</year>). <article-title>Modulation of the fecal bile acid profile by gut microbiota in cirrhosis</article-title>. <source>J. Hepatol.</source> <volume>58</volume>, <fpage>949</fpage>&#x02013;<lpage>955</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jhep.2013.01.003</pub-id><pub-id pub-id-type="pmid">23333527</pub-id></mixed-citation>
</ref>
<ref id="B71">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keene</surname> <given-names>C. D.</given-names></name> <name><surname>Rodrigues</surname> <given-names>C. M.</given-names></name> <name><surname>Eich</surname> <given-names>T.</given-names></name> <name><surname>Linehan-Stieers</surname> <given-names>C.</given-names></name> <name><surname>Abt</surname> <given-names>A.</given-names></name> <name><surname>Kren</surname> <given-names>B. T.</given-names></name> <etal/></person-group>. (<year>2001</year>). <article-title>A bile acid protects against motor and cognitive deficits and reduces striatal degeneration in the 3-nitropropionic acid model of Huntington&#x00027;s disease</article-title>. <source>Exp. Neurol.</source> <volume>171</volume>, <fpage>351</fpage>&#x02013;<lpage>360</lpage>. doi: <pub-id pub-id-type="doi">10.1006/exnr.2001.7755</pub-id><pub-id pub-id-type="pmid">11573988</pub-id></mixed-citation>
</ref>
<ref id="B72">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keitel</surname> <given-names>V.</given-names></name> <name><surname>G&#x000F6;rg</surname> <given-names>B.</given-names></name> <name><surname>Bidmon</surname> <given-names>H. J.</given-names></name> <name><surname>Zemtsova</surname> <given-names>I.</given-names></name> <name><surname>Spomer</surname> <given-names>L.</given-names></name> <name><surname>Zilles</surname> <given-names>K.</given-names></name> <etal/></person-group>. (<year>2010</year>). <article-title>The bile acid receptor TGR5 (Gpbar-1) acts as a neurosteroid receptor in brain</article-title>. <source>Glia</source> <volume>58</volume>, <fpage>1794</fpage>&#x02013;<lpage>1805</lpage>. doi: <pub-id pub-id-type="doi">10.1002/glia.21049</pub-id><pub-id pub-id-type="pmid">20665558</pub-id></mixed-citation>
</ref>
<ref id="B73">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keitel</surname> <given-names>V.</given-names></name> <name><surname>H&#x000E4;ussinger</surname> <given-names>D.</given-names></name></person-group> (<year>2011</year>). <article-title>TGR5 in the biliary tree</article-title>. <source>Digest. Dis.</source> <volume>29</volume>, <fpage>45</fpage>&#x02013;<lpage>47</lpage>. doi: <pub-id pub-id-type="doi">10.1159/000324127</pub-id><pub-id pub-id-type="pmid">21691103</pub-id></mixed-citation>
</ref>
<ref id="B74">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kiriyama</surname> <given-names>Y.</given-names></name> <name><surname>Nochi</surname> <given-names>H.</given-names></name></person-group> (<year>2019</year>). <article-title>The biosynthesis, signaling, and neurological functions of bile acids</article-title>. <source>Biomolecules</source> <volume>9</volume>:<fpage>232</fpage>. doi: <pub-id pub-id-type="doi">10.3390/biom9060232</pub-id><pub-id pub-id-type="pmid">31208099</pub-id></mixed-citation>
</ref>
<ref id="B75">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lardner</surname> <given-names>A. L.</given-names></name></person-group> (<year>2014</year>). <article-title>Neurobiological effects of the green tea constituent theanine and its potential role in the treatment of psychiatric and neurodegenerative disorders</article-title>. <source>Nutr. Neurosci.</source> <volume>17</volume>, <fpage>145</fpage>&#x02013;<lpage>155</lpage>. doi: <pub-id pub-id-type="doi">10.1179/1476830513Y.0000000079</pub-id><pub-id pub-id-type="pmid">23883567</pub-id></mixed-citation>
</ref>
<ref id="B76">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Larrosa</surname> <given-names>M.</given-names></name> <name><surname>Ya&#x000F1;&#x000E9;z-Gasc&#x000F3;n</surname> <given-names>M. J.</given-names></name> <name><surname>Selma</surname> <given-names>M. V.</given-names></name> <name><surname>Gonz&#x000E1;lez-Sarr&#x000ED;as</surname> <given-names>A.</given-names></name> <name><surname>Toti</surname> <given-names>S.</given-names></name> <name><surname>Cer&#x000F3;n</surname> <given-names>J. J.</given-names></name> <etal/></person-group>. (<year>2009</year>). <article-title>Effect of a low dose of dietary resveratrol on colon microbiota, inflammation and tissue damage in a DSS-induced colitis rat model</article-title>. <source>J. Agric. Food Chem.</source> <volume>57</volume>, <fpage>2211</fpage>&#x02013;<lpage>2220</lpage>. doi: <pub-id pub-id-type="doi">10.1021/jf803638d</pub-id><pub-id pub-id-type="pmid">19228061</pub-id></mixed-citation>
</ref>
<ref id="B77">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lefebvre</surname> <given-names>P.</given-names></name> <name><surname>Cariou</surname> <given-names>B.</given-names></name> <name><surname>Lien</surname> <given-names>F.</given-names></name> <name><surname>Kuipers</surname> <given-names>F.</given-names></name> <name><surname>Staels</surname> <given-names>B.</given-names></name></person-group> (<year>2009</year>). <article-title>Role of bile acids and bile acid receptors in metabolic regulation</article-title>. <source>Physiol. Rev.</source> <volume>89</volume>, <fpage>147</fpage>&#x02013;<lpage>191</lpage>. doi: <pub-id pub-id-type="doi">10.1152/physrev.00010.2008</pub-id><pub-id pub-id-type="pmid">19126757</pub-id></mixed-citation>
</ref>
<ref id="B78">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Les</surname> <given-names>F.</given-names></name> <name><surname>Arbon&#x000E9;s-Mainar</surname> <given-names>J. M.</given-names></name> <name><surname>Valero</surname> <given-names>M. S.</given-names></name> <name><surname>L&#x000F3;pez</surname> <given-names>V.</given-names></name></person-group> (<year>2018</year>). <article-title>Pomegranate polyphenols and urolithin A inhibit &#x003B1;-glucosidase, dipeptidyl peptidase-4, lipase, triglyceride accumulation and adipogenesis related genes in 3T3-L1 adipocyte-like cells</article-title>. <source>J. Ethnopharmacol.</source> <volume>220</volume>, <fpage>67</fpage>&#x02013;<lpage>74</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jep.2018.03.029</pub-id><pub-id pub-id-type="pmid">29604377</pub-id></mixed-citation>
</ref>
<ref id="B79">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>P.</given-names></name> <name><surname>Killinger</surname> <given-names>B. A.</given-names></name> <name><surname>Ensink</surname> <given-names>E.</given-names></name> <name><surname>Beddows</surname> <given-names>I.</given-names></name> <name><surname>Yilmaz</surname> <given-names>A.</given-names></name> <name><surname>Lubben</surname> <given-names>N.</given-names></name> <etal/></person-group>. (<year>2021</year>). <article-title>Gut microbiota dysbiosis is associated with elevated bile acids in Parkinson&#x00027;s disease</article-title>. <source>Metabolites</source> <volume>11</volume>:<fpage>29</fpage>. doi: <pub-id pub-id-type="doi">10.3390/metabo11010029</pub-id><pub-id pub-id-type="pmid">33406628</pub-id></mixed-citation>
</ref>
<ref id="B80">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>T.</given-names></name> <name><surname>Chiang</surname> <given-names>J. Y.</given-names></name></person-group> (<year>2012</year>). <article-title>Bile acid signaling in liver metabolism and diseases</article-title>. <source>J. Lipids</source> <volume>2012</volume>:<fpage>75406</fpage>. doi: <pub-id pub-id-type="doi">10.1155/2012/754067</pub-id><pub-id pub-id-type="pmid">21991404</pub-id></mixed-citation>
</ref>
<ref id="B81">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li-Hawkins</surname> <given-names>J.</given-names></name> <name><surname>G&#x000E5;fvels</surname> <given-names>M.</given-names></name> <name><surname>Olin</surname> <given-names>M.</given-names></name> <name><surname>Lund</surname> <given-names>E. G.</given-names></name> <name><surname>Andersson</surname> <given-names>U.</given-names></name> <name><surname>Schuster</surname> <given-names>G.</given-names></name> <etal/></person-group>. (<year>2002</year>). <article-title>Cholic acid mediates negative feedback regulation of bile acid synthesis in mice</article-title>. <source>J. Clin. Investig.</source> <volume>110</volume>, <fpage>1191</fpage>&#x02013;<lpage>1200</lpage>. doi: <pub-id pub-id-type="doi">10.1172/JCI0216309</pub-id><pub-id pub-id-type="pmid">12393855</pub-id></mixed-citation>
</ref>
<ref id="B82">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Little</surname> <given-names>R.</given-names></name> <name><surname>Wine</surname> <given-names>E.</given-names></name> <name><surname>Kamath</surname> <given-names>B. M.</given-names></name> <name><surname>Griffiths</surname> <given-names>A. M.</given-names></name> <name><surname>Ricciuto</surname> <given-names>A.</given-names></name></person-group> (<year>2020</year>). <article-title>Gut microbiome in primary sclerosing cholangitis: a review</article-title>. <source>World J. Gastroenterol.</source> <volume>26</volume>:<fpage>2768</fpage>. doi: <pub-id pub-id-type="doi">10.3748/wjg.v26.i21.2768</pub-id><pub-id pub-id-type="pmid">32550753</pub-id></mixed-citation>
</ref>
<ref id="B83">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname> <given-names>Y.</given-names></name> <name><surname>Wang</surname> <given-names>Z.</given-names></name> <name><surname>Zhang</surname> <given-names>Y.</given-names></name> <name><surname>Zhao</surname> <given-names>T.</given-names></name> <name><surname>Zhang</surname> <given-names>Q.</given-names></name> <name><surname>Huang</surname> <given-names>W.</given-names></name> <etal/></person-group>. (<year>2025</year>). <article-title>Dietary cholesterol impairs cognition via gut microbiota-derived deoxycholic acid in obese mice</article-title>. <source>Gut Microbes</source> <volume>17</volume>:<fpage>2537753</fpage>. doi: <pub-id pub-id-type="doi">10.1080/19490976.2025.2537753</pub-id><pub-id pub-id-type="pmid">40717663</pub-id></mixed-citation>
</ref>
<ref id="B84">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lombardo</surname> <given-names>F. L.</given-names></name> <name><surname>Spila Alegiani</surname> <given-names>S.</given-names></name> <name><surname>Mayer</surname> <given-names>F.</given-names></name> <name><surname>Cipriani</surname> <given-names>M.</given-names></name> <name><surname>Lo Giudice</surname> <given-names>M.</given-names></name> <name><surname>Ludolph</surname> <given-names>A. C.</given-names></name> <etal/></person-group>. (<year>2023</year>). <article-title>A randomized double-blind clinical trial on safety and efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment in patients affected by amyotrophic lateral sclerosis (ALS): the statistical analysis plan of TUDCA-ALS trial</article-title>. <source>Trials</source> <volume>24</volume>:<fpage>792</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s13063-023-07638-w</pub-id><pub-id pub-id-type="pmid">38053196</pub-id></mixed-citation>
</ref>
<ref id="B85">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lopresti</surname> <given-names>A. L.</given-names></name></person-group> (<year>2017</year>). <article-title>Curcumin for neuropsychiatric disorders: a review of <italic>in vitro</italic>, animal and human studies</article-title>. <source>J. Psychopharmacol.</source> <volume>31</volume>, <fpage>287</fpage>&#x02013;<lpage>302</lpage>. doi: <pub-id pub-id-type="doi">10.1177/0269881116686883</pub-id><pub-id pub-id-type="pmid">28135888</pub-id></mixed-citation>
</ref>
<ref id="B86">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname> <given-names>T. T.</given-names></name> <name><surname>Makishima</surname> <given-names>M.</given-names></name> <name><surname>Repa</surname> <given-names>J. J.</given-names></name> <name><surname>Schoonjans</surname> <given-names>K.</given-names></name> <name><surname>Kerr</surname> <given-names>T. A.</given-names></name> <name><surname>Auwerx</surname> <given-names>J.</given-names></name> <etal/></person-group>. (<year>2000</year>). <article-title>Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors</article-title>. <source>Mol. Cell</source> <volume>6</volume>, <fpage>507</fpage>&#x02013;<lpage>515</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S1097-2765(00)00050-2</pub-id><pub-id pub-id-type="pmid">11030331</pub-id></mixed-citation>
</ref>
<ref id="B87">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lucidi</surname> <given-names>L.</given-names></name> <name><surname>Pettorruso</surname> <given-names>M.</given-names></name> <name><surname>Vellante</surname> <given-names>F.</given-names></name> <name><surname>Di Carlo</surname> <given-names>F.</given-names></name> <name><surname>Ceci</surname> <given-names>F.</given-names></name> <name><surname>Santovito</surname> <given-names>M. C.</given-names></name> <etal/></person-group>. (<year>2021</year>). <article-title>Gut microbiota and bipolar disorder: an overview on a novel biomarker for diagnosis and treatment</article-title>. <source>Int. J. Mol. Sci.</source> <volume>22</volume>:<fpage>3723</fpage>. doi: <pub-id pub-id-type="doi">10.3390/ijms22073723</pub-id><pub-id pub-id-type="pmid">33918462</pub-id></mixed-citation>
</ref>
<ref id="B88">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>MahmoudianDehkordi</surname> <given-names>S.</given-names></name> <name><surname>Arnold</surname> <given-names>M.</given-names></name> <name><surname>Nho</surname> <given-names>K.</given-names></name> <name><surname>Ahmad</surname> <given-names>S.</given-names></name> <name><surname>Jia</surname> <given-names>W.</given-names></name> <name><surname>Xie</surname> <given-names>G.</given-names></name> <etal/></person-group>. (<year>2019</year>). <article-title>Altered bile acid profile associates with cognitive impairment in Alzheimer&#x00027;s disease&#x02014;An emerging role for gut microbiome</article-title>. <source>Alzheimer. Dement.</source> <volume>15</volume>, <fpage>76</fpage>&#x02013;<lpage>92</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jalz.2018.07.217</pub-id><pub-id pub-id-type="pmid">30337151</pub-id></mixed-citation>
</ref>
<ref id="B89">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Makishima</surname> <given-names>M.</given-names></name> <name><surname>Lu</surname> <given-names>T. T.</given-names></name> <name><surname>Xie</surname> <given-names>W.</given-names></name> <name><surname>Whitfield</surname> <given-names>G. K.</given-names></name> <name><surname>Domoto</surname> <given-names>H.</given-names></name> <name><surname>Evans</surname> <given-names>R. M.</given-names></name> <etal/></person-group>. (<year>2002</year>). <article-title>Vitamin D receptor as an intestinal bile acid sensor</article-title>. <source>Science</source> <volume>296</volume>, <fpage>1313</fpage>&#x02013;<lpage>1316</lpage>. doi: <pub-id pub-id-type="doi">10.1126/science.1070477</pub-id><pub-id pub-id-type="pmid">12016314</pub-id></mixed-citation>
</ref>
<ref id="B90">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Makishima</surname> <given-names>M.</given-names></name> <name><surname>Okamoto</surname> <given-names>A. Y.</given-names></name> <name><surname>Repa</surname> <given-names>J. J.</given-names></name> <name><surname>Tu</surname> <given-names>H.</given-names></name> <name><surname>Learned</surname> <given-names>R. M.</given-names></name> <name><surname>Luk</surname> <given-names>A.</given-names></name> <etal/></person-group>. (<year>1999</year>). <article-title>Identification of a nuclear receptor for bile acids</article-title>. <source>Science</source> <volume>284</volume>, <fpage>1362</fpage>&#x02013;<lpage>1365</lpage>. doi: <pub-id pub-id-type="doi">10.1126/science.284.5418.1362</pub-id><pub-id pub-id-type="pmid">10334992</pub-id></mixed-citation>
</ref>
<ref id="B91">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malhi</surname> <given-names>H.</given-names></name> <name><surname>Camilleri</surname> <given-names>M.</given-names></name></person-group> (<year>2017</year>). <article-title>Modulating bile acid pathways and TGR5 receptors for treating liver and GI diseases</article-title>. <source>Curr. Opin. Pharmacol.</source> <volume>37</volume>, <fpage>80</fpage>&#x02013;<lpage>86</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.coph.2017.09.008</pub-id><pub-id pub-id-type="pmid">29102744</pub-id></mixed-citation>
</ref>
<ref id="B92">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marksteiner</surname> <given-names>J.</given-names></name> <name><surname>Blasko</surname> <given-names>I.</given-names></name> <name><surname>Kemmler</surname> <given-names>G.</given-names></name> <name><surname>Koal</surname> <given-names>T.</given-names></name> <name><surname>Humpel</surname> <given-names>C.</given-names></name></person-group> (<year>2018</year>). <article-title>Bile acid quantification of 20 plasma metabolites identifies lithocholic acid as a putative biomarker in Alzheimer&#x00027;s disease</article-title>. <source>Metabolomics</source> <volume>14</volume>, <fpage>1</fpage>&#x02013;<lpage>10</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s11306-017-1297-5</pub-id><pub-id pub-id-type="pmid">29249916</pub-id></mixed-citation>
</ref>
<ref id="B93">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martinez</surname> <given-names>I.</given-names></name> <name><surname>Kim</surname> <given-names>J.</given-names></name> <name><surname>Duffy</surname> <given-names>P. R.</given-names></name> <name><surname>Schlegel</surname> <given-names>V. L.</given-names></name> <name><surname>Walter</surname> <given-names>J.</given-names></name></person-group> (<year>2010</year>). <article-title>Resistant starches types 2 and 4 have differential effects on the composition of the fecal microbiota in human subjects</article-title>. <source>PLoS ONE</source> <volume>5</volume>:<fpage>e15046</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0015046</pub-id><pub-id pub-id-type="pmid">21151493</pub-id></mixed-citation>
</ref>
<ref id="B94">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maruyama</surname> <given-names>T.</given-names></name> <name><surname>Miyamoto</surname> <given-names>Y.</given-names></name> <name><surname>Nakamura</surname> <given-names>T.</given-names></name> <name><surname>Tamai</surname> <given-names>Y.</given-names></name> <name><surname>Okada</surname> <given-names>H.</given-names></name> <name><surname>Sugiyama</surname> <given-names>E.</given-names></name> <etal/></person-group>. (<year>2002</year>). <article-title>Identification of membrane-type receptor for bile acids (M-BAR)</article-title>. <source>Biochem. Biophys. Res. Commun.</source> <volume>298</volume>, <fpage>714</fpage>&#x02013;<lpage>719</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0006-291X(02)02550-0</pub-id><pub-id pub-id-type="pmid">12419312</pub-id></mixed-citation>
</ref>
<ref id="B95">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McMillin</surname> <given-names>M.</given-names></name> <name><surname>DeMorrow</surname> <given-names>S.</given-names></name></person-group> (<year>2016</year>). <article-title>Effects of bile acids on neurological function and disease</article-title>. <source>FASEB J.</source> <volume>30</volume>, <fpage>3658</fpage>&#x02013;<lpage>3668</lpage>. doi: <pub-id pub-id-type="doi">10.1096/fj.201600275R</pub-id><pub-id pub-id-type="pmid">27468758</pub-id></mixed-citation>
</ref>
<ref id="B96">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McMillin</surname> <given-names>M.</given-names></name> <name><surname>Frampton</surname> <given-names>G.</given-names></name> <name><surname>Tobin</surname> <given-names>R.</given-names></name> <name><surname>Dusio</surname> <given-names>G.</given-names></name> <name><surname>Smith</surname> <given-names>J.</given-names></name> <name><surname>Shin</surname> <given-names>H.</given-names></name> <etal/></person-group>. (<year>2015</year>). <article-title>TGR5 signaling reduces neuroinflammation during hepatic encephalopathy</article-title>. <source>J. Neurochem.</source> <volume>135</volume>, <fpage>565</fpage>&#x02013;<lpage>576</lpage>. doi: <pub-id pub-id-type="doi">10.1111/jnc.13243</pub-id><pub-id pub-id-type="pmid">26179031</pub-id></mixed-citation>
</ref>
<ref id="B97">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mencarelli</surname> <given-names>A.</given-names></name> <name><surname>Renga</surname> <given-names>B.</given-names></name> <name><surname>Migliorati</surname> <given-names>M.</given-names></name> <name><surname>Cipriani</surname> <given-names>S.</given-names></name> <name><surname>Distrutti</surname> <given-names>E.</given-names></name> <name><surname>Santucci</surname> <given-names>L.</given-names></name> <etal/></person-group>. (<year>2009</year>). <article-title>The bile acid sensor farnesoid X receptor is a modulator of liver immunity in a rodent model of acute hepatitis</article-title>. <source>J. Immunol.</source> <volume>183</volume>, <fpage>6657</fpage>&#x02013;<lpage>6666</lpage>. doi: <pub-id pub-id-type="doi">10.4049/jimmunol.0901347</pub-id><pub-id pub-id-type="pmid">19880446</pub-id></mixed-citation>
</ref>
<ref id="B98">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Menzie</surname> <given-names>J.</given-names></name> <name><surname>Pan</surname> <given-names>C.</given-names></name> <name><surname>Prentice</surname> <given-names>H.</given-names></name> <name><surname>Wu</surname> <given-names>J. Y.</given-names></name></person-group> (<year>2014</year>). <article-title>Taurine and central nervous system disorders</article-title>. <source>Amino Acids</source> <volume>46</volume>, <fpage>31</fpage>&#x02013;<lpage>46</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s00726-012-1382-z</pub-id><pub-id pub-id-type="pmid">22903433</pub-id></mixed-citation>
</ref>
<ref id="B99">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname> <given-names>A. H.</given-names></name> <name><surname>Raison</surname> <given-names>C. L.</given-names></name></person-group> (<year>2016</year>). <article-title>The role of inflammation in depression: from evolutionary imperative to modern treatment target</article-title>. <source>Nat. Rev. Immunol.</source> <volume>16</volume>, <fpage>22</fpage>&#x02013;<lpage>23</lpage> doi: <pub-id pub-id-type="doi">10.1038/nri.2015.5</pub-id><pub-id pub-id-type="pmid">26711676</pub-id></mixed-citation>
</ref>
<ref id="B100">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mokra</surname> <given-names>D.</given-names></name> <name><surname>Joskova</surname> <given-names>M.</given-names></name> <name><surname>Mokry</surname> <given-names>J.</given-names></name></person-group> (<year>2022</year>). <article-title>Therapeutic effects of green tea polyphenol (&#x02013;)-Epigallocatechin-3-Gallate (EGCG) in relation to molecular pathways controlling inflammation, oxidative stress, and apoptosis</article-title>. <source>Int. J. Mol. Sci.</source> <volume>24</volume>:<fpage>340</fpage>. doi: <pub-id pub-id-type="doi">10.3390/ijms24010340</pub-id><pub-id pub-id-type="pmid">36613784</pub-id></mixed-citation>
</ref>
<ref id="B101">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mouzaki</surname> <given-names>M.</given-names></name> <name><surname>Wang</surname> <given-names>A. Y.</given-names></name> <name><surname>Bandsma</surname> <given-names>R.</given-names></name> <name><surname>Comelli</surname> <given-names>E. M.</given-names></name> <name><surname>Arendt</surname> <given-names>B. M.</given-names></name> <name><surname>Zhang</surname> <given-names>L.</given-names></name> <etal/></person-group>. (<year>2016</year>). <article-title>Bile acids and dysbiosis in non-alcoholic fatty liver disease</article-title>. <source>PLoS ONE</source> <volume>11</volume>:<fpage>e0151829</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0151829</pub-id><pub-id pub-id-type="pmid">27203081</pub-id></mixed-citation>
</ref>
<ref id="B102">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mulak</surname> <given-names>A.</given-names></name></person-group> (<year>2021</year>). <article-title>Bile acids as key modulators of the brain-gut-microbiota axis in Alzheimer&#x00027;s disease</article-title>. <source>J. Alzheimer. Dis.</source> <volume>84</volume>, <fpage>461</fpage>&#x02013;<lpage>477</lpage>. doi: <pub-id pub-id-type="doi">10.3233/JAD-210608</pub-id><pub-id pub-id-type="pmid">34569953</pub-id></mixed-citation>
</ref>
<ref id="B103">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nho</surname> <given-names>K.</given-names></name> <name><surname>Kueider-Paisley</surname> <given-names>A.</given-names></name> <name><surname>MahmoudianDehkordi</surname> <given-names>S.</given-names></name> <name><surname>Arnold</surname> <given-names>M.</given-names></name> <name><surname>Risacher</surname> <given-names>S. L.</given-names></name> <name><surname>Louie</surname> <given-names>G.</given-names></name> <etal/></person-group>. (<year>2019</year>). <article-title>Altered bile acid profile in mild cognitive impairment and Alzheimer&#x00027;s disease: relationship to neuroimaging and CSF biomarkers</article-title>. <source>Alzheimer. Dement.</source> <volume>15</volume>, <fpage>232</fpage>&#x02013;<lpage>244</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jalz.2018.08.012</pub-id><pub-id pub-id-type="pmid">30337152</pub-id></mixed-citation>
</ref>
<ref id="B104">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nunes</surname> <given-names>A. F.</given-names></name> <name><surname>Amaral</surname> <given-names>J. D.</given-names></name> <name><surname>Lo</surname> <given-names>A. C.</given-names></name> <name><surname>Fonseca</surname> <given-names>M. B.</given-names></name> <name><surname>Viana</surname> <given-names>R. J.</given-names></name> <name><surname>Callaerts-Vegh</surname> <given-names>Z.</given-names></name> <etal/></person-group>. (<year>2012</year>). <article-title>TUDCA, a bile acid, attenuates amyloid precursor protein processing and amyloid-&#x003B2; deposition in APP/PS1 mice</article-title>. <source>Mol. Neurobiol</source>. <volume>45</volume>, <fpage>440</fpage>&#x02013;<lpage>454</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s12035-012-8256-y</pub-id><pub-id pub-id-type="pmid">22438081</pub-id></mixed-citation>
</ref>
<ref id="B105">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O&#x00027;Toole</surname> <given-names>P. W.</given-names></name> <name><surname>Cooney</surname> <given-names>J. C.</given-names></name></person-group> (<year>2008</year>). <article-title>Probiotic bacteria influence the composition and function of the intestinal microbiota</article-title>. <source>Interdiscip. Perspect. Infect. Dis.</source> <volume>2008</volume>:<fpage>175285</fpage>. doi: <pub-id pub-id-type="doi">10.1155/2008/175285</pub-id><pub-id pub-id-type="pmid">19277099</pub-id></mixed-citation>
</ref>
<ref id="B106">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paganoni</surname> <given-names>S.</given-names></name> <name><surname>Macklin</surname> <given-names>E. A.</given-names></name> <name><surname>Hendrix</surname> <given-names>S.</given-names></name> <name><surname>Berry</surname> <given-names>J. D.</given-names></name> <name><surname>Elliott</surname> <given-names>M. A.</given-names></name> <name><surname>Maiser</surname> <given-names>S.</given-names></name> <etal/></person-group>. (<year>2020</year>). <article-title>Trial of sodium phenylbutyrate&#x02013;taurursodiol for amyotrophic lateral sclerosis</article-title>. <source>N. Engl. J. Med.</source> <volume>383</volume>, <fpage>919</fpage>&#x02013;<lpage>930</lpage>. doi: <pub-id pub-id-type="doi">10.1056/NEJMoa1916945</pub-id><pub-id pub-id-type="pmid">32877582</pub-id></mixed-citation>
</ref>
<ref id="B107">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pandak</surname> <given-names>W. M.</given-names></name> <name><surname>Kakiyama</surname> <given-names>G.</given-names></name></person-group> (<year>2019</year>). <article-title>The acidic pathway of bile acid synthesis: not just an alternative pathway</article-title>. <source>Liver Res.</source> <volume>3</volume>, <fpage>88</fpage>&#x02013;<lpage>98</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.livres.2019.05.001</pub-id><pub-id pub-id-type="pmid">32015930</pub-id></mixed-citation>
</ref>
<ref id="B108">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pathak</surname> <given-names>P.</given-names></name> <name><surname>Xie</surname> <given-names>C.</given-names></name> <name><surname>Nichols</surname> <given-names>R. G.</given-names></name> <name><surname>Ferrell</surname> <given-names>J. M.</given-names></name> <name><surname>Boehme</surname> <given-names>S.</given-names></name> <name><surname>Krausz</surname> <given-names>K. W.</given-names></name> <etal/></person-group>. (<year>2018</year>). <article-title>Intestine farnesoid X receptor agonist and the gut microbiota activate G-protein bile acid receptor-1 signaling to improve metabolism</article-title>. <source>Hepatology</source> <volume>68</volume>, <fpage>1574</fpage>&#x02013;<lpage>1588</lpage>. doi: <pub-id pub-id-type="doi">10.1002/hep.29857</pub-id><pub-id pub-id-type="pmid">29486523</pub-id></mixed-citation>
</ref>
<ref id="B109">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patra</surname> <given-names>D.</given-names></name></person-group> (<year>2024</year>). <article-title>Synthetic biology-enabled engineering of probiotics for precision and targeted therapeutic delivery applications</article-title>. <source>Exon</source> <volume>1</volume>, <fpage>54</fpage>&#x02013;<lpage>66</lpage>. doi: <pub-id pub-id-type="doi">10.69936/en11y0024</pub-id></mixed-citation>
</ref>
<ref id="B110">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paumgartner</surname> <given-names>G.</given-names></name> <name><surname>Beuers</surname> <given-names>U.</given-names></name></person-group> (<year>2002</year>). <article-title>Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited</article-title>. <source>Hepatology</source> <volume>36</volume>, <fpage>525</fpage>&#x02013;<lpage>531</lpage>. doi: <pub-id pub-id-type="doi">10.1053/jhep.2002.36088</pub-id><pub-id pub-id-type="pmid">12198643</pub-id></mixed-citation>
</ref>
<ref id="B111">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pols</surname> <given-names>T. W.</given-names></name> <name><surname>Noriega</surname> <given-names>L. G.</given-names></name> <name><surname>Nomura</surname> <given-names>M.</given-names></name> <name><surname>Auwerx</surname> <given-names>J.</given-names></name> <name><surname>Schoonjans</surname> <given-names>K.</given-names></name></person-group> (<year>2011</year>). <article-title>The bile acid membrane receptor TGR5: a valuable metabolic target</article-title>. <source>Digest. Dis.</source> <volume>29</volume>, <fpage>37</fpage>&#x02013;<lpage>44</lpage>. doi: <pub-id pub-id-type="doi">10.1159/000324126</pub-id><pub-id pub-id-type="pmid">21691102</pub-id></mixed-citation>
</ref>
<ref id="B112">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Potthoff</surname> <given-names>M. J.</given-names></name> <name><surname>Potts</surname> <given-names>A.</given-names></name> <name><surname>He</surname> <given-names>T.</given-names></name> <name><surname>Duarte</surname> <given-names>J. A.</given-names></name> <name><surname>Taussig</surname> <given-names>R.</given-names></name> <name><surname>Mangelsdorf</surname> <given-names>D. J.</given-names></name> <etal/></person-group>. (<year>2013</year>). <article-title>Colesevelam suppresses hepatic glycogenolysis by TGR5-mediated induction of GLP-1 action in DIO mice</article-title>. <source>Am. J. Physiol. Gastrointestinal Liver Physiol.</source> <volume>304</volume>, <fpage>G371</fpage>&#x02013;<lpage>G380</lpage>. doi: <pub-id pub-id-type="doi">10.1152/ajpgi.00400.2012</pub-id><pub-id pub-id-type="pmid">23257920</pub-id></mixed-citation>
</ref>
<ref id="B113">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qiao</surname> <given-names>Y.</given-names></name> <name><surname>Sun</surname> <given-names>J.</given-names></name> <name><surname>Xia</surname> <given-names>S.</given-names></name> <name><surname>Tang</surname> <given-names>X.</given-names></name> <name><surname>Shi</surname> <given-names>Y.</given-names></name> <name><surname>Le</surname> <given-names>G.</given-names></name></person-group> (<year>2014</year>). <article-title>Effects of resveratrol on gut microbiota and fat storage in a mouse model with high-fat-induced obesity</article-title>. <source>Food Funct.</source> <volume>5</volume>, <fpage>1241</fpage>&#x02013;<lpage>1249</lpage>. doi: <pub-id pub-id-type="doi">10.1039/c3fo60630a</pub-id><pub-id pub-id-type="pmid">24722352</pub-id></mixed-citation>
</ref>
<ref id="B114">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quinn</surname> <given-names>M.</given-names></name> <name><surname>McMillin</surname> <given-names>M.</given-names></name> <name><surname>Galindo</surname> <given-names>C.</given-names></name> <name><surname>Frampton</surname> <given-names>G.</given-names></name> <name><surname>Pae</surname> <given-names>H. Y.</given-names></name> <name><surname>DeMorrow</surname> <given-names>S.</given-names></name></person-group> (<year>2014</year>). <article-title>Bile acids permeabilize the blood brain barrier after bile duct ligation in rats via Rac1-dependent mechanisms</article-title>. <source>Digest. Liver Dis.</source> <volume>46</volume>, <fpage>527</fpage>&#x02013;<lpage>534</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.dld.2014.01.159</pub-id><pub-id pub-id-type="pmid">24629820</pub-id></mixed-citation>
</ref>
<ref id="B115">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramalho</surname> <given-names>R. M.</given-names></name> <name><surname>Viana</surname> <given-names>R. J.</given-names></name> <name><surname>Low</surname> <given-names>W. C.</given-names></name> <name><surname>Steer</surname> <given-names>C. J.</given-names></name> <name><surname>Rodrigues</surname> <given-names>C. M.</given-names></name></person-group> (<year>2008</year>). <article-title>Bile acids and apoptosis modulation: an emerging role in experimental Alzheimer&#x00027;s disease</article-title>. <source>Trends Mol. Med.</source> <volume>14</volume>, <fpage>54</fpage>&#x02013;<lpage>62</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.molmed.2007.12.001</pub-id><pub-id pub-id-type="pmid">18218342</pub-id></mixed-citation>
</ref>
<ref id="B116">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ridlon</surname> <given-names>J. M.</given-names></name> <name><surname>Harris</surname> <given-names>S. C.</given-names></name> <name><surname>Bhowmik</surname> <given-names>S.</given-names></name> <name><surname>Kang</surname> <given-names>D. J.</given-names></name> <name><surname>Hylemon</surname> <given-names>P. B.</given-names></name></person-group> (<year>2016a</year>). <article-title>Consequences of bile salt biotransformations by intestinal bacteria</article-title>. <source>Gut Microbes</source> <volume>7</volume>, <fpage>22</fpage>&#x02013;<lpage>39</lpage>. doi: <pub-id pub-id-type="doi">10.1080/19490976.2015.1127483</pub-id><pub-id pub-id-type="pmid">26939849</pub-id></mixed-citation>
</ref>
<ref id="B117">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ridlon</surname> <given-names>J. M.</given-names></name> <name><surname>Kang</surname> <given-names>D. J.</given-names></name> <name><surname>Hylemon</surname> <given-names>P. B.</given-names></name></person-group> (<year>2006</year>). <article-title>Bile salt biotransformations by human intestinal bacteria</article-title>. <source>J. Lipid Res.</source> <volume>47</volume>, <fpage>241</fpage>&#x02013;<lpage>259</lpage>. doi: <pub-id pub-id-type="doi">10.1194/jlr.R500013-JLR200</pub-id><pub-id pub-id-type="pmid">16299351</pub-id></mixed-citation>
</ref>
<ref id="B118">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ridlon</surname> <given-names>J. M.</given-names></name> <name><surname>Kang</surname> <given-names>D. J.</given-names></name> <name><surname>Hylemon</surname> <given-names>P. B.</given-names></name> <name><surname>Bajaj</surname> <given-names>J. S.</given-names></name></person-group> (<year>2014</year>). <article-title>Bile acids and the gut microbiome</article-title>. <source>Curr. Opin. Gastroenterol.</source> <volume>30</volume>, <fpage>332</fpage>&#x02013;<lpage>338</lpage>. doi: <pub-id pub-id-type="doi">10.1097/MOG.0000000000000057</pub-id></mixed-citation>
</ref>
<ref id="B119">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ridlon</surname> <given-names>J. M.</given-names></name> <name><surname>Wolf</surname> <given-names>P. G.</given-names></name> <name><surname>Gaskins</surname> <given-names>H. R.</given-names></name></person-group> (<year>2016b</year>). <article-title>Taurocholic acid metabolism by gut microbes and colon cancer</article-title>. <source>Gut Microbes</source> <volume>7</volume>, <fpage>201</fpage>&#x02013;<lpage>215</lpage>. doi: <pub-id pub-id-type="doi">10.1080/19490976.2016.1150414</pub-id><pub-id pub-id-type="pmid">27003186</pub-id></mixed-citation>
</ref>
<ref id="B120">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ripps</surname> <given-names>H.</given-names></name> <name><surname>Shen</surname> <given-names>W.</given-names></name></person-group> (<year>2012</year>). <article-title>Review: taurine: a &#x0201C;very essential&#x0201D; amino acid</article-title>. <source>Mol. Vis.</source> <volume>18</volume>:<fpage>2673</fpage>. <pub-id pub-id-type="pmid">23170060</pub-id></mixed-citation>
</ref>
<ref id="B121">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roberfroid</surname> <given-names>M.</given-names></name> <name><surname>Gibson</surname> <given-names>G. R.</given-names></name> <name><surname>Hoyles</surname> <given-names>L.</given-names></name> <name><surname>McCartney</surname> <given-names>A. L.</given-names></name> <name><surname>Rastall</surname> <given-names>R.</given-names></name> <name><surname>Rowland</surname> <given-names>I.</given-names></name> <etal/></person-group>. (<year>2010</year>). <article-title>Prebiotic effects: metabolic and health benefits</article-title>. <source>Br. J. Nutr.</source> <volume>104</volume>, <fpage>S1</fpage>&#x02013;<lpage>S63</lpage>. doi: <pub-id pub-id-type="doi">10.1017/S0007114510003363</pub-id><pub-id pub-id-type="pmid">20920376</pub-id></mixed-citation>
</ref>
<ref id="B122">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodrigues</surname> <given-names>C. M.</given-names></name> <name><surname>Sol&#x000E1;</surname> <given-names>S.</given-names></name> <name><surname>Nan</surname> <given-names>Z.</given-names></name> <name><surname>Castro</surname> <given-names>R. E.</given-names></name> <name><surname>Ribeiro</surname> <given-names>P. S.</given-names></name> <name><surname>Low</surname> <given-names>W. C.</given-names></name> <etal/></person-group>. (<year>2003</year>). <article-title>Tauroursodeoxycholic acid reduces apoptosis and protects against neurological injury after acute hemorrhagic stroke in rats</article-title>. <source>Proc. Nat. Acad. Sci. U.S.A.</source> <volume>100</volume>, <fpage>6087</fpage>&#x02013;<lpage>6092</lpage>. doi: <pub-id pub-id-type="doi">10.1073/pnas.1031632100</pub-id><pub-id pub-id-type="pmid">12721362</pub-id></mixed-citation>
</ref>
<ref id="B123">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodrigues</surname> <given-names>C. M.</given-names></name> <name><surname>Spellman</surname> <given-names>S. R.</given-names></name> <name><surname>Sol&#x000E1;</surname> <given-names>S.</given-names></name> <name><surname>Grande</surname> <given-names>A. W.</given-names></name> <name><surname>Linehan-Stieers</surname> <given-names>C.</given-names></name> <name><surname>Low</surname> <given-names>W. C.</given-names></name> <etal/></person-group>. (<year>2002</year>). <article-title>Neuroprotection by a bile acid in an acute stroke model in the rat</article-title>. <source>J. Cereb. Blood Flow Metab.</source> <volume>22</volume>, <fpage>463</fpage>&#x02013;<lpage>471</lpage>. doi: <pub-id pub-id-type="doi">10.1097/00004647-200204000-00010</pub-id><pub-id pub-id-type="pmid">11919517</pub-id></mixed-citation>
</ref>
<ref id="B124">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodrigues</surname> <given-names>C. M.</given-names></name> <name><surname>Steer</surname> <given-names>C. J.</given-names></name></person-group> (<year>2001</year>). <article-title>The therapeutic effects of ursodeoxycholic acid in hepatobiliary disease</article-title>. <source>J. Clin. Gastroenterol.</source> <volume>33</volume>, <fpage>1</fpage>&#x02013;<lpage>8</lpage>.</mixed-citation>
</ref>
<ref id="B125">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodrigues</surname> <given-names>M. H.</given-names></name> <name><surname>Bruno</surname> <given-names>A. S.</given-names></name> <name><surname>Nahas-Neto</surname> <given-names>J.</given-names></name> <name><surname>Santos</surname> <given-names>M. E. S.</given-names></name> <name><surname>Nahas</surname> <given-names>E. A.</given-names></name></person-group> (<year>2014</year>). <article-title>Nonalcoholic fatty liver disease and metabolic syndrome in postmenopausal women</article-title>. <source>Gynecological Endocrinology</source> <volume>30</volume>, <fpage>325</fpage>&#x02013;<lpage>329</lpage>. doi: <pub-id pub-id-type="doi">10.3109/09513590.2013.875992</pub-id><pub-id pub-id-type="pmid">24460502</pub-id></mixed-citation>
</ref>
<ref id="B126">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rothenberg</surname> <given-names>D. O. N.</given-names></name> <name><surname>Zhang</surname> <given-names>L.</given-names></name></person-group> (<year>2019</year>). <article-title>Mechanisms underlying the anti-depressive effects of regular tea consumption</article-title>. <source>Nutrients</source> <volume>11</volume>:<fpage>1361</fpage>. doi: <pub-id pub-id-type="doi">10.3390/nu11061361</pub-id><pub-id pub-id-type="pmid">31212946</pub-id></mixed-citation>
</ref>
<ref id="B127">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Russell</surname> <given-names>D. W.</given-names></name> <name><surname>Setchell</surname> <given-names>K. D.</given-names></name></person-group> (<year>1992</year>). <article-title>Bile acid biosynthesis</article-title>. <source>Biochemistry</source> <volume>31</volume>, <fpage>4737</fpage>&#x02013;<lpage>4749</lpage>. doi: <pub-id pub-id-type="doi">10.1021/bi00135a001</pub-id></mixed-citation>
</ref>
<ref id="B128">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sampson</surname> <given-names>T. R.</given-names></name> <name><surname>Debelius</surname> <given-names>J. W.</given-names></name> <name><surname>Thron</surname> <given-names>T.</given-names></name> <name><surname>Janssen</surname> <given-names>S.</given-names></name> <name><surname>Shastri</surname> <given-names>G. G.</given-names></name> <name><surname>Ilhan</surname> <given-names>Z. E.</given-names></name> <etal/></person-group>. (<year>2016</year>). <article-title>Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson&#x00027;s disease</article-title>. <source>Cell</source> <volume>167</volume>, <fpage>1469</fpage>&#x02013;<lpage>1480</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.cell.2016.11.018</pub-id><pub-id pub-id-type="pmid">27912057</pub-id></mixed-citation>
</ref>
<ref id="B129">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sayin</surname> <given-names>S. I.</given-names></name> <name><surname>Wahlstr&#x000F6;m</surname> <given-names>A.</given-names></name> <name><surname>Felin</surname> <given-names>J.</given-names></name> <name><surname>J&#x000E4;ntti</surname> <given-names>S.</given-names></name> <name><surname>Marschall</surname> <given-names>H. U.</given-names></name> <name><surname>Bamberg</surname> <given-names>K.</given-names></name> <etal/></person-group>. (<year>2013</year>). <article-title>Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist</article-title>. <source>Cell Metab.</source> <volume>17</volume>, <fpage>225</fpage>&#x02013;<lpage>235</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.cmet.2013.01.003</pub-id><pub-id pub-id-type="pmid">23395169</pub-id></mixed-citation>
</ref>
<ref id="B130">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schaap</surname> <given-names>F. G.</given-names></name> <name><surname>Trauner</surname> <given-names>M.</given-names></name> <name><surname>Jansen</surname> <given-names>P. L.</given-names></name></person-group> (<year>2014</year>). <article-title>Bile acid receptors as targets for drug development</article-title>. <source>Nat. Rev. Gastroenterol. Hepatol.</source> <volume>11</volume>, <fpage>55</fpage>&#x02013;<lpage>67</lpage>. doi: <pub-id pub-id-type="doi">10.1038/nrgastro.2013.151</pub-id><pub-id pub-id-type="pmid">23982684</pub-id></mixed-citation>
</ref>
<ref id="B131">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scheperjans</surname> <given-names>F.</given-names></name> <name><surname>Aho</surname> <given-names>V.</given-names></name> <name><surname>Pereira</surname> <given-names>P. A.</given-names></name> <name><surname>Koskinen</surname> <given-names>K.</given-names></name> <name><surname>Paulin</surname> <given-names>L.</given-names></name> <name><surname>Pekkonen</surname> <given-names>E.</given-names></name> <etal/></person-group>. (<year>2015</year>). <article-title>Gut microbiota are related to Parkinson&#x00027;s disease and clinical phenotype</article-title>. <source>Mov. Disord.</source> <volume>30</volume>, <fpage>350</fpage>&#x02013;<lpage>358</lpage>. doi: <pub-id pub-id-type="doi">10.1002/mds.26069</pub-id><pub-id pub-id-type="pmid">25476529</pub-id></mixed-citation>
</ref>
<ref id="B132">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schneider</surname> <given-names>K. M.</given-names></name> <name><surname>Albers</surname> <given-names>S.</given-names></name> <name><surname>Trautwein</surname> <given-names>C.</given-names></name></person-group> (<year>2018</year>). <article-title>Role of bile acids in the gut-liver axis</article-title>. <source>J. Hepatol.</source> <volume>68</volume>, <fpage>1083</fpage>&#x02013;<lpage>1085</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jhep.2017.11.025</pub-id><pub-id pub-id-type="pmid">29519549</pub-id></mixed-citation>
</ref>
<ref id="B133">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharon</surname> <given-names>G.</given-names></name> <name><surname>Sampson</surname> <given-names>T. R.</given-names></name> <name><surname>Geschwind</surname> <given-names>D. H.</given-names></name> <name><surname>Mazmanian</surname> <given-names>S. K.</given-names></name></person-group> (<year>2016</year>). <article-title>The central nervous system and the gut microbiome</article-title>. <source>Cell</source> <volume>167</volume>, <fpage>915</fpage>&#x02013;<lpage>932</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.cell.2016.10.027</pub-id><pub-id pub-id-type="pmid">27814521</pub-id></mixed-citation>
</ref>
<ref id="B134">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname> <given-names>L.</given-names></name> <name><surname>Liu</surname> <given-names>L.</given-names></name> <name><surname>Ji</surname> <given-names>H. F.</given-names></name></person-group> (<year>2017</year>). <article-title>Regulative effects of curcumin spice administration on gut microbiota and its pharmacological implications</article-title>. <source>Food Nutr. Res.</source> <volume>61</volume>:<fpage>1361780</fpage>. doi: <pub-id pub-id-type="doi">10.1080/16546628.2017.1361780</pub-id><pub-id pub-id-type="pmid">28814952</pub-id></mixed-citation>
</ref>
<ref id="B135">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname> <given-names>K. H.</given-names></name> <name><surname>Chiang</surname> <given-names>J. Y.</given-names></name></person-group> (<year>2006</year>). <article-title>Glucagon and cAMP inhibit cholesterol 7&#x003B1;-hydroxylase (CYP7A1) gene expression in human hepatocytes: discordant regulation of bile acid synthesis and gluconeogenesis</article-title>. <source>Hepatology</source> <volume>43</volume>, <fpage>117</fpage>&#x02013;<lpage>125</lpage>. doi: <pub-id pub-id-type="doi">10.1002/hep.20919</pub-id></mixed-citation>
</ref>
<ref id="B136">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Staudinger</surname> <given-names>J. L.</given-names></name> <name><surname>Goodwin</surname> <given-names>B.</given-names></name> <name><surname>Jones</surname> <given-names>S. A.</given-names></name> <name><surname>Hawkins-Brown</surname> <given-names>D.</given-names></name> <name><surname>MacKenzie</surname> <given-names>K. I.</given-names></name> <name><surname>LaTour</surname> <given-names>A.</given-names></name> <etal/></person-group>. (<year>2001</year>). <article-title>The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity</article-title>. <source>Proc. Nat. Acad. Sci. U.S.A.</source> <volume>98</volume>, <fpage>3369</fpage>&#x02013;<lpage>3374</lpage>. doi: <pub-id pub-id-type="doi">10.1073/pnas.051551698</pub-id><pub-id pub-id-type="pmid">11248085</pub-id></mixed-citation>
</ref>
<ref id="B137">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stieger</surname> <given-names>B.</given-names></name></person-group> (<year>2010</year>). <article-title>The role of the sodium-taurocholate cotransporting polypeptide (NTCP) and of the bile salt export pump (BSEP) in physiology and pathophysiology of bile formation</article-title>. <source>Drug Transport.</source> <volume>201</volume>, <fpage>205</fpage>&#x02013;<lpage>259</lpage>. doi: <pub-id pub-id-type="doi">10.1007/978-3-642-14541-4_5</pub-id><pub-id pub-id-type="pmid">21103971</pub-id></mixed-citation>
</ref>
<ref id="B138">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stiehl</surname> <given-names>A.</given-names></name> <name><surname>Becker</surname> <given-names>M.</given-names></name> <name><surname>Czygan</surname> <given-names>P.</given-names></name> <name><surname>Frohling</surname> <given-names>W.</given-names></name> <name><surname>Kommerell</surname> <given-names>B.</given-names></name> <name><surname>Rotthauwe</surname> <given-names>H. W.</given-names></name></person-group> (<year>1980</year>). <article-title>Bile acids and their sulphated and glucuronidated derivatives in bile, plasma, and urine of children with intrahepatic cholestasis: effects of phenobarbital treatment</article-title>. <source>Eur. J. Clin. Invest.</source> <volume>10</volume>, <fpage>307</fpage>&#x02013;<lpage>316</lpage>. doi: <pub-id pub-id-type="doi">10.1111/j.1365-2362.1980.tb00038.x</pub-id><pub-id pub-id-type="pmid">6775958</pub-id></mixed-citation>
</ref>
<ref id="B139">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname> <given-names>G. Y.</given-names></name> <name><surname>Meng</surname> <given-names>X.</given-names></name> <name><surname>Gan</surname> <given-names>R. Y.</given-names></name></person-group> (<year>2019</year>). <article-title>Health functions and related molecular mechanisms of tea components: an update review</article-title>. <source>Int. J. Mol. Sci.</source> <volume>20</volume>:<fpage>6196</fpage>. doi: <pub-id pub-id-type="doi">10.3390/ijms20246196</pub-id><pub-id pub-id-type="pmid">31817990</pub-id></mixed-citation>
</ref>
<ref id="B140">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tellone</surname> <given-names>E.</given-names></name> <name><surname>Galtieri</surname> <given-names>A.</given-names></name> <name><surname>Russo</surname> <given-names>A.</given-names></name> <name><surname>Giardina</surname> <given-names>B.</given-names></name> <name><surname>Ficarra</surname> <given-names>S.</given-names></name></person-group> (<year>2015</year>). <article-title>Resveratrol: a focus on several neurodegenerative diseases</article-title>. <source>Oxid. Med. Cell. Longev.</source> <volume>2015</volume>:<fpage>392169</fpage>. doi: <pub-id pub-id-type="doi">10.1155/2015/392169</pub-id><pub-id pub-id-type="pmid">26180587</pub-id></mixed-citation>
</ref>
<ref id="B141">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Theriot</surname> <given-names>C. M.</given-names></name> <name><surname>Young</surname> <given-names>V. B.</given-names></name></person-group> (<year>2015</year>). <article-title>Interactions between the gastrointestinal microbiome and <italic>Clostridium difficile</italic></article-title>. <source>Annu. Rev. Microbiol.</source> <volume>69</volume>, <fpage>445</fpage>&#x02013;<lpage>461</lpage>. doi: <pub-id pub-id-type="doi">10.1146/annurev-micro-091014-104115</pub-id><pub-id pub-id-type="pmid">26488281</pub-id></mixed-citation>
</ref>
<ref id="B142">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thomas</surname> <given-names>C.</given-names></name> <name><surname>Pellicciari</surname> <given-names>R.</given-names></name> <name><surname>Pruzanski</surname> <given-names>M.</given-names></name> <name><surname>Auwerx</surname> <given-names>J.</given-names></name> <name><surname>Schoonjans</surname> <given-names>K.</given-names></name></person-group> (<year>2008</year>). <article-title>Targeting bile-acid signalling for metabolic diseases</article-title>. <source>Nat. Rev. Drug Discov.</source> <volume>7</volume>, <fpage>678</fpage>&#x02013;<lpage>693</lpage>. doi: <pub-id pub-id-type="doi">10.1038/nrd2619</pub-id><pub-id pub-id-type="pmid">18670431</pub-id></mixed-citation>
</ref>
<ref id="B143">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Unno</surname> <given-names>K.</given-names></name> <name><surname>Fujitani</surname> <given-names>K.</given-names></name> <name><surname>Takamori</surname> <given-names>N.</given-names></name> <name><surname>Takabayashi</surname> <given-names>F.</given-names></name> <name><surname>Maeda</surname> <given-names>K. I.</given-names></name> <name><surname>Miyazaki</surname> <given-names>H.</given-names></name> <etal/></person-group>. (<year>2011</year>). <article-title>Theanine intake improves the shortened lifespan, cognitive dysfunction and behavioural depression that are induced by chronic psychosocial stress in mice</article-title>. <source>Free Radic. Res.</source> <volume>45</volume>, <fpage>966</fpage>&#x02013;<lpage>974</lpage>. doi: <pub-id pub-id-type="doi">10.3109/10715762.2011.566869</pub-id><pub-id pub-id-type="pmid">21425911</pub-id></mixed-citation>
</ref>
<ref id="B144">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Upadhyaya</surname> <given-names>B.</given-names></name> <name><surname>McCormack</surname> <given-names>L.</given-names></name> <name><surname>Fardin-Kia</surname> <given-names>A. R.</given-names></name> <name><surname>Juenemann</surname> <given-names>R.</given-names></name> <name><surname>Nichenametla</surname> <given-names>S.</given-names></name> <name><surname>Clapper</surname> <given-names>J.</given-names></name> <etal/></person-group>. (<year>2016</year>). <article-title>Impact of dietary resistant starch type 4 on human gut microbiota and immunometabolic functions</article-title>. <source>Sci. Rep.</source> <volume>6</volume>, <fpage>1</fpage>&#x02013;<lpage>14</lpage>. doi: <pub-id pub-id-type="doi">10.1038/srep28797</pub-id><pub-id pub-id-type="pmid">27356770</pub-id></mixed-citation>
</ref>
<ref id="B145">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van de Wouw</surname> <given-names>M.</given-names></name> <name><surname>Boehme</surname> <given-names>M.</given-names></name> <name><surname>Lyte</surname> <given-names>J. M.</given-names></name> <name><surname>Wiley</surname> <given-names>N.</given-names></name> <name><surname>Strain</surname> <given-names>C.</given-names></name> <name><surname>O&#x00027;Sullivan</surname> <given-names>O.</given-names></name> <etal/></person-group>. (<year>2018</year>). <article-title>Short-chain fatty acids: microbial metabolites that alleviate stress-induced brain&#x02013;gut axis alterations</article-title>. <source>J. Physiol.</source> <volume>596</volume>, <fpage>4923</fpage>&#x02013;<lpage>4944</lpage>. doi: <pub-id pub-id-type="doi">10.1113/JP276431</pub-id><pub-id pub-id-type="pmid">30066368</pub-id></mixed-citation>
</ref>
<ref id="B146">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vang</surname> <given-names>S.</given-names></name> <name><surname>Longley</surname> <given-names>K.</given-names></name> <name><surname>Steer</surname> <given-names>C. J.</given-names></name> <name><surname>Low</surname> <given-names>W. C.</given-names></name></person-group> (<year>2014</year>). <article-title>The unexpected uses of urso-and tauroursodeoxycholic acid in the treatment of non-liver diseases</article-title>. <source>Global Adv. Health Med.</source> <volume>3</volume>, <fpage>58</fpage>&#x02013;<lpage>69</lpage>. doi: <pub-id pub-id-type="doi">10.7453/gahmj.2014.017</pub-id></mixed-citation>
</ref>
<ref id="B147">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vaz</surname> <given-names>A. R.</given-names></name> <name><surname>Cunha</surname> <given-names>C.</given-names></name> <name><surname>Gomes</surname> <given-names>C.</given-names></name> <name><surname>Schmucki</surname> <given-names>N.</given-names></name> <name><surname>Barbosa</surname> <given-names>M.</given-names></name> <name><surname>Brites</surname> <given-names>D.</given-names></name></person-group> (<year>2015</year>). <article-title>Glycoursodeoxycholic acid reduces matrix metalloproteinase-9 and caspase-9 activation in a cellular model of superoxide dismutase-1 neurodegeneration</article-title>. <source>Mol. Neurobiol.</source> <volume>51</volume>, <fpage>864</fpage>&#x02013;<lpage>877</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s12035-014-8731-8</pub-id><pub-id pub-id-type="pmid">24848512</pub-id></mixed-citation>
</ref>
<ref id="B148">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Viana</surname> <given-names>R. J.</given-names></name> <name><surname>Nunes</surname> <given-names>A. F.</given-names></name> <name><surname>Castro</surname> <given-names>R. E.</given-names></name> <name><surname>Ramalho</surname> <given-names>R. M.</given-names></name> <name><surname>Meyerson</surname> <given-names>J.</given-names></name> <name><surname>Fossati</surname> <given-names>S.</given-names></name> <etal/></person-group>. (<year>2009</year>). <article-title>Tauroursodeoxycholic acid prevents E22Q Alzheimer&#x00027;s A&#x003B2; toxicity in human cerebral endothelial cells</article-title>. <source>Cell. Mol. Life Sci.</source> <volume>66</volume>, <fpage>1094</fpage>&#x02013;<lpage>1104</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s00018-009-8746-x</pub-id></mixed-citation>
</ref>
<ref id="B149">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vidicevic</surname> <given-names>S.</given-names></name> <name><surname>Tasic</surname> <given-names>J.</given-names></name> <name><surname>Stanojevic</surname> <given-names>Z.</given-names></name> <name><surname>Ciric</surname> <given-names>D.</given-names></name> <name><surname>Martinovic</surname> <given-names>T.</given-names></name> <name><surname>Paunovic</surname> <given-names>V.</given-names></name> <etal/></person-group>. (<year>2024</year>). <article-title>Endoplasmic reticulum stress response in immune cells contributes to experimental autoimmune encephalomyelitis pathogenesis in rats</article-title>. <source>Immunol. Lett.</source> <volume>267</volume>:<fpage>106855</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.imlet.2024.106855</pub-id><pub-id pub-id-type="pmid">38537720</pub-id></mixed-citation>
</ref>
<ref id="B150">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wahlstr&#x000F6;m</surname> <given-names>A.</given-names></name> <name><surname>Sayin</surname> <given-names>S. I.</given-names></name> <name><surname>Marschall</surname> <given-names>H. U.</given-names></name> <name><surname>B&#x000E4;ckhed</surname> <given-names>F.</given-names></name></person-group> (<year>2016</year>). <article-title>Intestinal crosstalk between bile acids and microbiota and its impact on host metabolism</article-title>. <source>Cell Metab.</source> <volume>24</volume>, <fpage>41</fpage>&#x02013;<lpage>50</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.cmet.2016.05.005</pub-id><pub-id pub-id-type="pmid">27320064</pub-id></mixed-citation>
</ref>
<ref id="B151">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>L.</given-names></name> <name><surname>Lee</surname> <given-names>Y. K.</given-names></name> <name><surname>Bundman</surname> <given-names>D.</given-names></name> <name><surname>Han</surname> <given-names>Y.</given-names></name> <name><surname>Thevananther</surname> <given-names>S.</given-names></name> <name><surname>Kim</surname> <given-names>C. S.</given-names></name> <etal/></person-group>. (<year>2002</year>). <article-title>Redundant pathways for negative feedback regulation of bile acid production</article-title>. <source>Dev. Cell</source> <volume>2</volume>, <fpage>721</fpage>&#x02013;<lpage>731</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S1534-5807(02)00187-9</pub-id><pub-id pub-id-type="pmid">12062085</pub-id></mixed-citation>
</ref>
<ref id="B152">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>Q.</given-names></name> <name><surname>Sun</surname> <given-names>Y. N.</given-names></name> <name><surname>Zou</surname> <given-names>C. M.</given-names></name> <name><surname>Zhang</surname> <given-names>T. L.</given-names></name> <name><surname>Li</surname> <given-names>Z.</given-names></name> <name><surname>Liu</surname> <given-names>M.</given-names></name> <etal/></person-group>. (<year>2022a</year>). <article-title>Regulation of the kynurenine/serotonin pathway by berberine and the underlying effect in the hippocampus of the chronic unpredictable mild stress mice</article-title>. <source>Behav. Brain Res.</source> <volume>422</volume>:<fpage>113764</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.bbr.2022.113764</pub-id><pub-id pub-id-type="pmid">35051489</pub-id></mixed-citation>
</ref>
<ref id="B153">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>Q.</given-names></name> <name><surname>Yang</surname> <given-names>X.</given-names></name> <name><surname>Zhu</surname> <given-names>C.</given-names></name> <name><surname>Liu</surname> <given-names>G.</given-names></name> <name><surname>Sun</surname> <given-names>Y.</given-names></name> <name><surname>Qian</surname> <given-names>L.</given-names></name></person-group> (<year>2022b</year>). <article-title>Advances in the utilization of tea polysaccharides: preparation, physicochemical properties, and health benefits</article-title>. <source>Polymers</source> <volume>14</volume>:<fpage>2775</fpage>. doi: <pub-id pub-id-type="doi">10.3390/polym14142775</pub-id><pub-id pub-id-type="pmid">35890551</pub-id></mixed-citation>
</ref>
<ref id="B154">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>Y. D.</given-names></name> <name><surname>Chen</surname> <given-names>W. D.</given-names></name> <name><surname>Wang</surname> <given-names>M.</given-names></name> <name><surname>Yu</surname> <given-names>D.</given-names></name> <name><surname>Forman</surname> <given-names>B. M.</given-names></name> <name><surname>Huang</surname> <given-names>W.</given-names></name></person-group> (<year>2008</year>). <article-title>Farnesoid X receptor antagonizes nuclear factor &#x003BA;B in hepatic inflammatory response</article-title>. <source>Hepatology</source> <volume>48</volume>, <fpage>1632</fpage>&#x02013;<lpage>1643</lpage>. doi: <pub-id pub-id-type="doi">10.1002/hep.22519</pub-id></mixed-citation>
</ref>
<ref id="B155">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>Y. D.</given-names></name> <name><surname>Chen</surname> <given-names>W. D.</given-names></name> <name><surname>Yu</surname> <given-names>D.</given-names></name> <name><surname>Forman</surname> <given-names>B. M.</given-names></name> <name><surname>Huang</surname> <given-names>W.</given-names></name></person-group> (<year>2011</year>). <article-title>The G-protein-coupled bile acid receptor, Gpbar1 (TGR5), negatively regulates hepatic inflammatory response through antagonizing nuclear factor &#x003BA; light-chain enhancer of activated B cells (NF-&#x003BA;B) in mice</article-title>. <source>Hepatology</source> <volume>54</volume>, <fpage>1421</fpage>&#x02013;<lpage>1432</lpage>. doi: <pub-id pub-id-type="doi">10.1002/hep.24525</pub-id><pub-id pub-id-type="pmid">21735468</pub-id></mixed-citation>
</ref>
<ref id="B156">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wen</surname> <given-names>J. J.</given-names></name> <name><surname>Li</surname> <given-names>M. Z.</given-names></name> <name><surname>Chen</surname> <given-names>C. H.</given-names></name> <name><surname>Hong</surname> <given-names>T.</given-names></name> <name><surname>Yang</surname> <given-names>J. R.</given-names></name> <name><surname>Huang</surname> <given-names>X. J.</given-names></name> <etal/></person-group>. (<year>2023</year>). <article-title>Tea polyphenol and epigallocatechin gallate ameliorate hyperlipidemia via regulating liver metabolism and remodeling gut microbiota</article-title>. <source>Food Chem.</source> <volume>404</volume>:<fpage>134591</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.foodchem.2022.134591</pub-id><pub-id pub-id-type="pmid">36444016</pub-id></mixed-citation>
</ref>
<ref id="B157">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Winston</surname> <given-names>J. A.</given-names></name> <name><surname>Theriot</surname> <given-names>C. M.</given-names></name></person-group> (<year>2020</year>). <article-title>Diversification of host bile acids by members of the gut microbiota</article-title>. <source>Gut Microbes</source> <volume>11</volume>, <fpage>158</fpage>&#x02013;<lpage>171</lpage>. doi: <pub-id pub-id-type="doi">10.1080/19490976.2019.1674124</pub-id><pub-id pub-id-type="pmid">31595814</pub-id></mixed-citation>
</ref>
<ref id="B158">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname> <given-names>J.</given-names></name> <name><surname>Gu</surname> <given-names>W.</given-names></name> <name><surname>Li</surname> <given-names>C.</given-names></name> <name><surname>Li</surname> <given-names>X.</given-names></name> <name><surname>Xing</surname> <given-names>G.</given-names></name> <name><surname>Li</surname> <given-names>Y.</given-names></name> <etal/></person-group>. (<year>2016</year>). <article-title>Epigallocatechin gallate inhibits hepatitis B virus via farnesoid X receptor alpha</article-title>. <source>J. Nat. Med.</source> <volume>70</volume>, <fpage>584</fpage>&#x02013;<lpage>591</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s11418-016-0980-6</pub-id><pub-id pub-id-type="pmid">26968537</pub-id></mixed-citation>
</ref>
<ref id="B159">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname> <given-names>W.</given-names></name> <name><surname>Kong</surname> <given-names>Y.</given-names></name> <name><surname>Zhang</surname> <given-names>T.</given-names></name> <name><surname>Gong</surname> <given-names>Z.</given-names></name> <name><surname>Xiao</surname> <given-names>W.</given-names></name></person-group> (<year>2023</year>). <article-title>L-theanine regulates lipid metabolism by modulating gut microbiota and bile acid metabolism</article-title>. <source>J. Sci. Food Agric.</source> <volume>103</volume>, <fpage>1283</fpage>&#x02013;<lpage>1293</lpage>. doi: <pub-id pub-id-type="doi">10.1002/jsfa.12222</pub-id><pub-id pub-id-type="pmid">36087337</pub-id></mixed-citation>
</ref>
<ref id="B160">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname> <given-names>R.</given-names></name> <name><surname>Ho</surname> <given-names>C. T.</given-names></name> <name><surname>Zhang</surname> <given-names>X.</given-names></name></person-group> (<year>2020</year>). <article-title>Interaction between tea polyphenols and intestinal microbiota in host metabolic diseases from the perspective of the gut&#x02013;brain axis</article-title>. <source>Mol. Nutr. Food Res.</source> <volume>64</volume>:<fpage>2000187</fpage>. doi: <pub-id pub-id-type="doi">10.1002/mnfr.202000187</pub-id><pub-id pub-id-type="pmid">32506625</pub-id></mixed-citation>
</ref>
<ref id="B161">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname> <given-names>F.</given-names></name> <name><surname>Tang</surname> <given-names>X.</given-names></name> <name><surname>Ding</surname> <given-names>L.</given-names></name> <name><surname>Zhou</surname> <given-names>Y.</given-names></name> <name><surname>Yang</surname> <given-names>Q.</given-names></name> <name><surname>Gong</surname> <given-names>J.</given-names></name> <etal/></person-group>. (<year>2016</year>). <article-title>Curcumin protects ANIT-induced cholestasis through signaling pathway of FXR-regulated bile acid and inflammation</article-title>. <source>Sci. Rep.</source> <volume>6</volume>:<fpage>33052</fpage>. doi: <pub-id pub-id-type="doi">10.1038/srep33052</pub-id><pub-id pub-id-type="pmid">27624003</pub-id></mixed-citation>
</ref>
<ref id="B162">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname> <given-names>J.</given-names></name> <name><surname>Chen</surname> <given-names>W.</given-names></name> <name><surname>Chen</surname> <given-names>J.</given-names></name> <name><surname>Xie</surname> <given-names>D.</given-names></name> <name><surname>Wang</surname> <given-names>Y.</given-names></name> <name><surname>Zhou</surname> <given-names>J.</given-names></name></person-group> (<year>2025</year>). <article-title>Tea polyphenol epigallocatechin gallate and the gut&#x02013;health axis: unraveling structural characteristics, metabolic pathways, and systemic benefits</article-title>. <source>Adv. Nutr.</source> <volume>16</volume>:<fpage>100545</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.advnut.2025.100545</pub-id><pub-id pub-id-type="pmid">41106481</pub-id></mixed-citation>
</ref>
<ref id="B163">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yanguas-Cas&#x000E1;s</surname> <given-names>N.</given-names></name> <name><surname>Barreda-Manso</surname> <given-names>M. A.</given-names></name> <name><surname>P&#x000E9;rez-Rial</surname> <given-names>S.</given-names></name> <name><surname>Nieto&#x02013;Sampedro</surname> <given-names>M.</given-names></name> <name><surname>Romero-Ram&#x000ED;rez</surname> <given-names>L.</given-names></name></person-group> (<year>2017</year>). <article-title>TGF&#x003B2; contributes to the anti-inflammatory effects of tauroursodeoxycholic acid on an animal model of acute neuroinflammation</article-title>. <source>Mol. Neurobiol.</source> <volume>54</volume>, <fpage>6737</fpage>&#x02013;<lpage>6749</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s12035-016-0142-6</pub-id></mixed-citation>
</ref>
<ref id="B164">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoneno</surname> <given-names>K.</given-names></name> <name><surname>Hisamatsu</surname> <given-names>T.</given-names></name> <name><surname>Shimamura</surname> <given-names>K.</given-names></name> <name><surname>Kamada</surname> <given-names>N.</given-names></name> <name><surname>Ichikawa</surname> <given-names>R.</given-names></name> <name><surname>Kitazume</surname> <given-names>M. T.</given-names></name> <etal/></person-group>. (<year>2013</year>). <article-title>TGR5 signalling inhibits the production of pro-inflammatory cytokines by <italic>in vitro</italic> differentiated inflammatory and intestinal macrophages in Crohn&#x00027;s disease</article-title>. <source>Immunology</source> <volume>139</volume>, <fpage>19</fpage>&#x02013;<lpage>29</lpage>. doi: <pub-id pub-id-type="doi">10.1111/imm.12045</pub-id><pub-id pub-id-type="pmid">23566200</pub-id></mixed-citation>
</ref>
<ref id="B165">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname> <given-names>L.</given-names></name> <name><surname>Xu</surname> <given-names>T.</given-names></name> <name><surname>Wang</surname> <given-names>S.</given-names></name> <name><surname>Yu</surname> <given-names>L.</given-names></name> <name><surname>Liu</surname> <given-names>D.</given-names></name> <name><surname>Zhan</surname> <given-names>R.</given-names></name> <etal/></person-group>. (<year>2012</year>). <article-title>Curcumin produces antidepressant effects via activating MAPK/ERK-dependent brain-derived neurotrophic factor expression in the amygdala of mice</article-title>. <source>Behav. Brain Res.</source> <volume>235</volume>, <fpage>67</fpage>&#x02013;<lpage>72</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.bbr.2012.07.019</pub-id><pub-id pub-id-type="pmid">22820234</pub-id></mixed-citation>
</ref>
<ref id="B166">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname> <given-names>M.</given-names></name> <name><surname>Xie</surname> <given-names>Z.</given-names></name> <name><surname>Gao</surname> <given-names>W.</given-names></name> <name><surname>Pu</surname> <given-names>L.</given-names></name> <name><surname>Wei</surname> <given-names>J.</given-names></name> <name><surname>Guo</surname> <given-names>C.</given-names></name></person-group> (<year>2016</year>). <article-title>Quercetin regulates hepatic cholesterol metabolism by promoting cholesterol-to-bile acid conversion and cholesterol efflux in rats</article-title>. <source>Nutr. Res.</source> <volume>36</volume>, <fpage>271</fpage>&#x02013;<lpage>279</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.nutres.2015.11.019</pub-id><pub-id pub-id-type="pmid">26923514</pub-id></mixed-citation>
</ref>
<ref id="B167">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname> <given-names>X. F.</given-names></name> <name><surname>Guan</surname> <given-names>X. X.</given-names></name> <name><surname>Tang</surname> <given-names>Y. J.</given-names></name> <name><surname>Sun</surname> <given-names>J. F.</given-names></name> <name><surname>Wang</surname> <given-names>X. K.</given-names></name> <name><surname>Wang</surname> <given-names>W. D.</given-names></name> <etal/></person-group>. (<year>2021</year>). <article-title>Clinical effects and gut microbiota changes of using probiotics, prebiotics or synbiotics in inflammatory bowel disease: a systematic review and meta-analysis</article-title>. <source>Eur. J. Nutr.</source> <volume>60</volume>, <fpage>2855</fpage>&#x02013;<lpage>2875</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s00394-021-02503-5</pub-id><pub-id pub-id-type="pmid">33555375</pub-id></mixed-citation>
</ref>
<ref id="B168">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname> <given-names>P.</given-names></name> <name><surname>Zeng</surname> <given-names>B.</given-names></name> <name><surname>Zhou</surname> <given-names>C.</given-names></name> <name><surname>Liu</surname> <given-names>M.</given-names></name> <name><surname>Fang</surname> <given-names>Z.</given-names></name> <name><surname>Xu</surname> <given-names>X.</given-names></name> <etal/></person-group>. (<year>2016</year>). <article-title>Gut microbiome remodeling induces depressive-like behaviors through a pathway mediated by the host&#x00027;s metabolism</article-title>. <source>Mol. Psychiatry</source> <volume>21</volume>, <fpage>786</fpage>&#x02013;<lpage>796</lpage>. doi: <pub-id pub-id-type="doi">10.1038/mp.2016.44</pub-id><pub-id pub-id-type="pmid">27067014</pub-id></mixed-citation>
</ref>
<ref id="B169">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname> <given-names>F.</given-names></name> <name><surname>Wu</surname> <given-names>F.</given-names></name> <name><surname>Ma</surname> <given-names>Y.</given-names></name> <name><surname>Liu</surname> <given-names>G.</given-names></name> <name><surname>Li</surname> <given-names>Z.</given-names></name> <name><surname>Sun</surname> <given-names>Y.</given-names></name> <etal/></person-group>. (<year>2011</year>). <article-title>Decrease in the production of &#x003B2;-amyloid by berberine inhibition of the expression of &#x003B2;-secretase in HEK293 cells</article-title>. <source>BMC Neurosci.</source> <volume>12</volume>, <fpage>1</fpage>&#x02013;<lpage>9</lpage>. doi: <pub-id pub-id-type="doi">10.1186/1471-2202-12-125</pub-id><pub-id pub-id-type="pmid">22152059</pub-id></mixed-citation>
</ref>
<ref id="B170">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ziemi&#x00144;ska</surname> <given-names>E.</given-names></name> <name><surname>Lazarewicz</surname> <given-names>J. W.</given-names></name></person-group> (<year>2006</year>). <article-title>Excitotoxic neuronal injury in chronic homocysteine neurotoxicity studied <italic>in vitro</italic>: the role of NMDA and group I metabotropic glutamate receptors</article-title>. <source>Acta Neurobiol. Exp.</source> <volume>66</volume>, <fpage>301</fpage>&#x02013;<lpage>309</lpage>. doi: <pub-id pub-id-type="doi">10.55782/ane-2006-1619</pub-id><pub-id pub-id-type="pmid">17265692</pub-id></mixed-citation>
</ref>
<ref id="B171">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zollner</surname> <given-names>G.</given-names></name> <name><surname>Trauner</surname> <given-names>M.</given-names></name></person-group> (<year>2008</year>). <article-title>Mechanisms of cholestasis</article-title>. <source>Clin. Liver Dis.</source> <volume>12</volume>, <fpage>1</fpage>&#x02013;<lpage>26</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.cld.2007.11.010</pub-id><pub-id pub-id-type="pmid">11232196</pub-id></mixed-citation>
</ref>
</ref-list>
<fn-group>
<fn fn-type="custom" custom-type="edited-by" id="fn0001">
<p>Edited by: <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1379016/overview">Guijie Chen</ext-link>, Nanjing Agricultural University, China</p>
</fn>
<fn fn-type="custom" custom-type="reviewed-by" id="fn0002">
<p>Reviewed by: <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/3093052/overview">Ming Zhang</ext-link>, Zhejiang University, China</p>
<p><ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/3299472/overview">Lorenzo Bini</ext-link>, University of Pisa, Italy</p>
</fn>
</fn-group>
</back>
</article>